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ADENOSINE 
Adenosine is a nucleoside composed of a molecule of adenine attached to a ribose sugar 
molecule (ribofuranose) via a β-N9-glycosidic bond (Figure 1). 
 
 
 
 
 
 
Figure 1 – Chemical structure of Adenosine 
 
Adenosine is an endogenous nucleoside-signalling molecule, which, by acting on 
specific membrane receptors produces a number of physiological and 
pathophysiological effects in both the central nervous system and peripheral organs. 
Under normal conditions, adenosine is continuously formed intracellularly as well as 
extracellularly. The intracellular production is mediated either by an intracellular 5'-
nucleotidase, which dephosphorylates or by hydrolysis of S-adenosyl-homocysteine 
(Fredhoml et al., 2001). Adenosine generated intracellularly is transported into the 
extracellular space mainly via specific bi-directional transporters through facilitated 
diffusion that efficiently evens out the intra- and extracellular levels of adenosine. The 
dephosphorylation of extracellular AMP to adenosine, mediated by ecto-5'-nucleotidase, 
is the last step in the enzymatic chain that catalyzes the breakdown of extracellular 
adenine nucleotides, such as ATP, to adenosine. Ectonucleotidases include 
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ectonucleoside triphosphate diphosphohydrolase which can hydrolyze ATP or ADP, 
ectonucleotide pyrophosphatase/phosphodiesterases, alkaline phosphatases and 5'-
nucleotidases (Zimmermann, 2000). When adenosine levels in the extracellular space 
are high, adenosine is transported into cells by means of transporters. It is then 
phosphorylated to AMP by adenosine kinase or degraded to inosine by adenosine 
deaminase. Adenosine deaminase, but not adenosine kinase, is also present in the 
extracellular space (Fredhoml et al., 2001). Another potential source of extracellular 
adenosine is cAMP, which can be released from neurons and converted by extracellular 
phosphodiesterases into AMP and thereafter by an ecto-5'-nucleotidase to adenosine. 
The transport of adenosine by facilitated diffusion is equilibrative and bidirectional, 
meaning that the net transport of adenosine either into or out of the cell depends upon 
the adenosine concentration gradient in both sides of the membrane. Inhibition of 
adenosine transport can, therefore, inhibit either adenosine release or adenosine uptake, 
depending upon the intra- and extracellular levels of adenosine (Gu et al., 1995). 
However, since the extracellular formation of adenosine from released adenine 
nucleotides constitutes a second source of adenosine, which is not affected by transport 
inhibition, the transport inhibitors usually cause an increase in the extracellular 
adenosine levels. Under hypoxic and ischemic conditions there is a marked increase in 
cytoplasmatic adenosine leading to an intense release of adenosine, which is inhibited 
by adenosine uptake inhibitors (Parkinson et al., 2002).  
Excitatory amino acid-mediated release of adenosine is certainly involved; however, of 
greater importance is probably the fact that whenever intracellular levels of adenine 
nucleotides fall as a result of excessive energy use, the intracellular levels of adenosine 
will rise dramatically (Fredhoml et al., 2001). For example, following hypoxia there is a 
decrease of intracellular ATP, accompanied by an accumulation of 5'-AMP and 
subsequently adenosine. The nucleoside is thereafter transported into the extracellular 
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space via the transporters. Furthermore, when the intracellular level of adenosine is very 
high, adenosine simply diffuses out of cells. Direct release of intracellular adenine 
nucleotides, such as ATP, that is thereafter converted extracellularly by ecto-ATPase 
and ecto-ATP-diphosphohydrolase (ecto-apyrase) to AMP and dephosphorylated by 
ecto-5'-nucleotidase to adenosine, should also be considered (Zimmermann et al., 2000).  
Adenosine is neither stored nor released as a classical neurotransmitter since it does not 
accumulate in synaptic vesicles, being released from the cytoplasm into the extracellular 
space through a nucleoside transporter. The adenosine transporters also mediate 
adenosine reuptake, the direction of the transport being dependant upon the 
concentration gradient at both sides of the membrane (Fredhoml et al., 2001). Since it is 
not exocytotically released, adenosine behaves as an extracellular signal molecule 
influencing synaptic transmission without itself being a neurotransmitter, i.e. modulates 
the activity of the nervous system at cellular level presynaptically by inhibiting or 
facilitating transmitter release, postsynaptically by hyperpolarising or depolarising 
neurones and/or exerting non-synaptic effects. Adenosine, therefore, belongs to the 
group of neuromodulators. 
 
Adenosine receptors 
 
Four adenosine receptor (AR) subtypes (A1, A2A, A2B, and A3) have been cloned and 
pharmacologically characterized, all of which are G protein-coupled receptors (GPCRs). 
Adenosine receptors can be distinguished according to their preferred mechanism of 
signal transduction: A1 and A3 receptors interact with pertussis toxin-sensitive G 
proteins of the Gi and Go family; the canonical signaling mechanism of the A2A and of 
the A2B receptors is stimulation of adenylyl cyclase via Gs proteins. In addition to the 
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coupling to adenylyl cyclase, all four subtypes may positively couple to phospholipase 
C via different G protein subunits (Fredholm et al, 2001). 
Considering the overall protein structure, ARs display the topology typical of GPCRs. 
Sequence comparison between the different GPCRs revealed the existence of different 
receptor families sharing no sequence similarity even if specific fingerprints exist in all 
GPCR classes. However, all these receptors have in common a central core domain 
consisting of seven transmembrane helices (TM1-7), with each TM composed of 20–27 
amino acids, connected by three intracellular (IL1, IL2, and IL3) and three extracellular 
(EL1, EL2, and EL3) loops. Two cysteine residues (one in TM3 and one in EL2), which 
are conserved in most GPCRs, form a disulfide link which is possibly crucial for the 
packing and for the stabilization of a restricted number of conformations of these seven 
TMs. Aside from sequence variations, GPCRs differ in the length and function of their 
N-terminal extracellular domain, their C-terminal intracellular domain, and their 
intracellular loops. Each of these domains provides very specific properties to these 
receptor proteins. Particularly, consensus sites for N-linked glycosylation exist on the 
extracellular regions of ARs, although the precise location of the sites for this post-
translational modification varies amongst the AR subtypes. The carboxyl-terminal tails 
of the A1AR, A2BAR, and A3AR, but not A2AAR, possess a conserved cysteine residue 
that may putatively serve as a site for receptor palmitoylation and permit the formation 
of a fourth intracellular loop (Moro et al., 2005). 
The A1AR, A2BAR, and A3AR are very similar in regard to the number of amino acids 
composing their primary structure, and in general, these AR subtypes are among the 
smaller members of the GPCR family. For example, the human homologs of the A1AR, 
A2BAR, and A3AR consist of 326, 328, and 318 amino acid residues, respectively. 
Conversely, the human A2AAR is composed of 409 amino acids. It should be noted that 
the size of ARs deduced from their primary amino acid structure frequently is not 
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consistent with the mass estimated by polyacrylamide gel electrophoresis of the 
expressed proteins. The post-translational glycosylation of ARs, which may vary in a 
cell type-dependent fashion, likely accounts for these discrepancies. The human A1AR 
and human A3AR display 49% overall sequence identity at the amino acid level, while 
the human A2AAR and human A2BAR are 45% identical (Fredholm et al, 2001).  
 
A1 adenosine receptors 
The A1 receptor is widely expressed throughout the body, having its highest expression 
in the brain, spinal cord, atria and adipose tissue (Baraldi et al., 2000). Via adenosine 
A1ARs, adenosine reduces heart rate, glomerular filtration rate, and renin release in the 
kidney; it induces bronchoconstriction  and inhibits lipolysis (Elzein and Zablocki, 
2008). Adenosine A1Rs can be coupled to different pertussis toxin-sensitive G proteins, 
which mediate inhibition of adenylate cyclase  and regulate calcium and potassium 
channels, as well as inositol phosphate metabolism (Fredholm et al., 2001). A1ARs and 
A2AARs are primarily responsible for the central effects of adenosine (Dunwiddie and 
Masino, 2001). In addition to their postsynaptic locations in different brain regions, 
A1ARs can be found presynaptically and modulate neurotransmitter release. Presynaptic 
A1ARs are the prototype of GPCRs, the stimulation of which decreases the probability 
of neurotransmitter release. The main mechanism of A1AR-mediated inhibition of 
exocytosis is a direct inhibitory effect on voltage-dependent Ca2+ channels (Moore et 
al., 2003). A1AR displays two different affinities for agonist, which have classically 
been attributed to a different coupling to heterotrimeric G proteins. According to this 
two independent site model, coupled receptor–G protein complexes display high affinity 
for agonists and uncoupled receptors display low affinity. The reported cluster-arranged 
cooperative model predicts that the high- and low-affinity sites are a consequence of the 
negative cooperativity of agonist binding and do not seem to be related to the content of 
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G protein-coupled or –uncoupled receptors (Franco et al., 1996). Like other GPCR 
members, A1AR expression is regulated in response to agonist or antagonist stimulation. 
Desensitization of A1ARs has been described in intact animals and in cell cultures. 
Prolonged administration of A1AR agonists to animals leads to functional 
desensitization of A1ARs in guinea pig heart, rat adipocytes, rat atrial muscle, and rat 
brain (Moro et al., 2006). The reduced functional response is attributable to a net loss of 
A1ARs or down-regulation, a decrease in the proportion of A1ARs displaying the high-
affinity state for agonists, and a decrease in the content of Gi proteins. The loss of 
binding sites on the cell membrane owing to internalization of A1ARs is a slower event. 
Ser/Thr phosphorylation seems to be related to short-term clustering and 
desensitization, as well as long-term internalization of A1ARs (Ciruela et al., 1997). 
 
A2A adenosine receptors 
The A2AAR exists in a wide variety of organs including major peripheral tissues (e.g., 
liver, heart, lung, and the immune system) and the central nervous system (CNS) (Lee et 
al., 2003). In the developing rat brain, expression of the A2AAR is transiently regulated 
in various areas (e.g., the striatum, cortex, and hippocampus), perhaps implying a role 
of adenosine in neuronal development. Soon after neurogenesis, the A2AAR is highly 
expressed by striatal neurons and co-localizes with the D2 dopamine receptor in 
GABAergic striatopallidal neurons (Ferrè et al., 2008). In addition to the intense 
expression in the striatum, low levels of A2AAR are found in many brain regions (e.g., 
the cortex and hippocampus) and it has been suggested that adenosine acting at the 
A2AAR regulates important neuronal functions including neuronal protection and 
synaptic transmission (Ferrè et al., 2008). Regulation of A2AAR gene expression is 
therefore likely to play an important role in neuronal development, basal ganglia 
activity, and many other peripheral functions. In the CNS, l-DOPA enhanced the gene 
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expression of the striatal A2AAR in 6-OHDA-lesioned rats (Tomiyama et al., 2004). 
Treatment with an antagonist of the NMDA receptor (memantine) was also reported to 
elevate the transcript level of striatal A2AARs (Marvanova and Wong, 2004). The 
adenosine A2AAR couples primarily to members of the Gs family. Like other GPCRs it 
can also interact with other G proteins if the receptor is very over-expressed, but the 
evidence for such coupling in vivo is not compelling. In striatum the A2AAR interacts 
with Golf proteins (Corvol et al., 2001). It is not known if there are significant 
differences in receptor affinity or in signaling dependent on which of the two partners 
(or which variant of Gs) the receptor interacts with. There are instances where other G 
protein pathways have been implicated, and it will be important to determine if this 
alternate coupling is a regulated process, for example via phosphorylation. There is no 
compelling reason to assume that this GPCR coupling to members of the Gs family 
would signal in anything but a canonical way. Thus, most effects are probably due to 
activation of adenylyl cyclase and generation of cAMP. The A2AAR can recruit β-
arrestin via a GRK-2 dependent mechanism (Khoa et al., 2006). This is influenced by 
activation of cytokine receptors, which cause reduced desensitization of the A2AAR 
(Khoa et al., 2006).  
One key target of PKA is the cAMP responsive element-binding protein (CREB) which 
is critical for many forms of neuronal plasticity as well as other neuronal functions 
(Josselyn and Nguyen, 2005). Phosphorylation of CREB at Ser133 by PKA activates 
CREB and turns on genes with cAMP responsive elements (CRE sites) in their 
promoters. One important feature of CREB is that it is a point of convergence for the 
cAMP/PKA and MAPK pathways. Stimulation of the A2AARs counteracts the 
inhibition of neurite outgrowth due to MAPK blockade (Cheng et al., 2002). 
Stimulation of the A2AAR alone also activates the Ras/Raf-1/MEK/ERK signaling 
through PKA-dependent and PKA-independent pathways via Src- and Sos- mediated 
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mechanisms, respectively (Schulte and Fredholm, 2003). Interestingly, 
phosphorylation/activation of CREB has been shown to compete with nuclear factor-κB 
(NFκB) p65 for an important co-factor, CBP. Phosphorylated CREB was therefore 
proposed to mediate the anti-inflammatory effect of the A2AAR receptor and inhibition 
of NFκB by A2AAR activation during acute inflammation in vivo was demonstrated 
(Fredholm et al., 2007).  
An interesting observation is that activation of A2AAR receptor facilitates activities of 
adenosine transporters via a PKC-dependent pathway in the hippocampus, and thus 
reduces the level of extracellular adenosine available for A1AR activation (Pinto-Duarte 
et al., 2005). In addition, PKC was shown to play a key role in mediating the 
enhancement of noradrenaline release by the A2AAR in rat tail artery (Fresco et al., 
2004). Activation of multiple signaling pathways by the A2AAR appears to contribute to 
its diverse and complex functions in various tissues. 
 
A2B adenosine receptors 
A2BAR mRNA was originally detected in a limited number of rat tissues by Northern 
blot analysis, with the highest levels found in cecum, bowel, and bladder, followed by 
brain, spinal cord, lung, epididymis, vas deferens, and pituitary. The use of more 
sensitive reverse transcriptase-polymerase chain reaction techniques revealed a 
ubiquitous distribution of A2BAR (Spicuzza et al., 2006). mRNA encoding A2BAR was 
detected at various levels in all rat tissues studied, with the highest levels in the 
proximal colon and lowest in the liver. In situ hybridization of A2BARs showed 
widespread and uniform distribution of A2BAR mRNA throughout the brain (Dixon et 
al., 1996).  
Pharmacological identification of A2BARs, based on their low affinity and characteristic 
order of potency for agonists, also indicates a widespread distribution of A2BARs. In 
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brain, functional A2BARs are found in neurons  and glial cells. Although there is no 
evidence that A2BAR are present in microglia, there is ample data that show that they 
are expressed in astrocytes and in different glioma cell lines (Fiebich et al., 1996). The 
expression of A2BARs in glial cells, which represent a majority of the brain cell 
population, can explain the original observation that slices from all brain areas 
examined showed an adenosine-stimulated cAMP response. 
Functional A2BARs have been found in fibroblasts and various vascular beds, 
hematopoietic cells, mast cells, myocardial cells, intestinal epithelial and muscle cells, 
retinal pigment epithelium, endothelium, and neurosecretory (Gessi et al., 2005). 
Although activation of adenyl cyclase is arguably an important signaling mechanism for 
A2AARs, this is not necessarily the case for A2BARs, as other intracellular signaling 
pathways have been found to be functionally coupled to these receptors in addition to 
adenyl cyclase. In fact activation of adenosine A2BARs can increase phospholipase C in 
human mast cells and in mouse bone marrow-derived mast cells. A2BAR activation also 
elevates inositol triphosphate (IP3) levels, indicating this receptor can couple also to 
Gq-proteins. A2BARs have been implicated in the regulation of mast cell secretion  and, 
gene expression, intestinal function, neurosecretion, vascular tone and in particular 
asthma (Varani et al., 2005). 
 
A3 adenosine receptors 
The A3AR has widely distributed its mRNA being expressed in testis, lung, kidneys, 
placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, proximal colon and eye of 
rat, sheep and humans. However, marked differences exist in expression levels within 
and among species. In particular rat testis and mast cells express high concentrations of 
A3AR mRNA, while low levels have been detected in most other rat tissues (Gessi et 
al., 2008). Lung and liver have been found as the organs expressing high levels of 
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A3AR mRNA in human, while low levels have been found in aorta and brain. Lung, 
spleen, pars tuberalis and pineal gland expressed the highest levels of A3AR mRNA in 
sheep. 
The presence of A3AR protein has been evaluated through radioligand binding, 
immunoassay or functional assay in a variety of primary cells, tissues and cell lines 
(Gessi et al., 2008). In the mouse brain a widespread, relatively low level of A3AR 
binding sites was found (Jacobson et al., 1993). Similar data were obtained in the rat 
and in gerbil and rabbit brain. Electrophysiological and biochemical evidence suggested 
the presence of A3ARs in the rat hippocampus and cortex, and functional studies also 
indicated its presence in the brain. In cardiomyocytes, there was no direct evidence of 
the presence of A3ARs  but several studies reported that it was responsible for 
cardioprotection in a variety of species and models, including isolated cardiomyocytes 
and isolated myocardial muscle preparations (Peart and Headrick, 2007). In lung 
parenchyma and in human lung type 2 alveolar-like cells (A549), the A3AR was 
detected through radioligand binding and immunohistochemical assays (Varani et al., 
2006).  
The classical pathways associated with A3AR activation are the inhibition of adenylyl 
cyclase activity, through the coupling with Gi proteins, and the stimulation of 
phospholipase C (PLC), inositol triphosphate (IP3) and intracellular calcium (Ca2+), via 
Gq proteins (Fredholm et al., 2001). However, more recently additional intracellular 
pathways have been described as relevant for A3AR signaling. For example, in the 
heart, A3AR mediates cardioprotective effects through ATP-sensitive potassium 
(KATP) channel activation. Moreover, it is coupled to activation of RhoA and a 
subsequent stimulation of phospholipase D (PLD), which in turn mediates protection of 
cardiac myocytes from ischemia (Mozzicato et al., 2004). In addition, in different 
recombinant and native cell lines, A3AR is involved, like the other adenosine subtypes, 
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in the modulation of mitogen-activated protein kinase (MAPK) activity (Schulte and 
Fredholm, 2003). A3AR signaling in Chinese Hamster Ovary cells transfected with 
human A3AR (CHO-hA3) leads to stimulation of extracellular signal-regulated kinases 
(ERK1/2). In particular, A3AR signaling to ERK1/2 depends on βγ release from 
pertussis toxin (PTX)-sensitive G proteins, phosphoinositide 3-kinase (PI3K), Ras and 
mitogen-activated protein kinase kinase (Schulte and Fredholm, 2003). It has been 
reported that A3AR activation is able to decrease the levels of PKA, a downstream 
effector of cAMP, and of the phosphorylated form of PKB/Akt in melanoma cells. This 
implies the deregulation of the Wnt signaling pathway, generally active during 
embryogenesis and tumorigenesis to increase cell cycle progression and cell 
proliferation (Fishman et al., 2002). Involvement of the PI3K/PKB pathway has been 
linked with preconditioning effects induced by A3AR activation in cardiomyocytes from 
newborn rats (Germack and Dickenson, 2005). An elegant study has recently 
documented a role of A3AR in cell survival signaling in resveratrol preconditioning of 
the heart. This study provides evidence that resveratrol preconditions the heart through 
the activation of adenosine A1 and A3AR, transmitting a survival signal through both 
the PI3K-Akt-Bcl2 and, only in the case of A3AR, cAMP response element-binding 
protein (CREB)-Bcl2 pathways (Das et al., 2005). Subsequently it has been 
demonstrated that CREB phosphorylation occurs through both Akt-dependent and -
independent signaling. Activation of PI3K-Akt-pBAD by A3AR has been observed 
recently in glioblastoma cells leading to cell survival in hypoxic conditions (Merighi et 
al., 2007). Further studies indicate that A3AR activation by interfering with PKB/Akt 
pathways can decrease interleukin-12 (IL-12) production in human monocytes (la Sala 
et al., 2005). Collectively, these findings demonstrate that several intracellular 
mechanisms are involved following A3AR stimulation, the understanding of which may 
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be essential and crucial for explaining the different aspect of its activation.  
 
 
Therapeutic potential 
Cardiovascular system 
A1AR is the most extensively studied and well characterized of the adenosine receptor 
subtypes in relation to cardiac protection. The A1AR is best understood insofar as its 
effects on injury and in terms of receptor-coupled kinase/protein signaling. For the most 
part, transduction cascades induced by A1AR agonism follow those of several other 
protective GPCR systems (Hausenloy and Yellon, 2004). However, there remain some 
controversies regarding both signal cascades and A1AR-mediated responses in the heart. 
Originally, adenosine (via A1AR activation) was thought to induce myocardial 
protection through preservation of ATP (and improved nucleotide repletion on 
reperfusion), stimulation of glycolysis, and normalization of the hearts so-called 
“oxygen supply/demand ratio” (Ely and Berne, 1992). Subsequent investigations have 
identified essential protein kinase signaling cascades together with putative end-
effectors (including the mitochondrial KATP channel), in the protective and 
preconditioning actions of A1ARs. 
Adenosine enhances tolerance to ischemia via metabolic substrate effects (Headrick et 
al., 2003). Adenosinergic cardioprotection in ischemic-reperfused hearts involves 
reductions in oncotic and apoptotic death, and improved functional outcomes (Willems 
et al., 2005). Recent work supports differential effects of acute adenosine vs. transient 
adenosinergic preconditioning, consistent with multiple pathways of protection (Peart 
and Headrick, 2003). In terms of cellular targets, adenosine appears to directly protect 
cardiomyocytes or myocardial tissue (likely via A1 and A3ARs), and additionally 
protects via limiting inflammation and injurious interactions between inflammatory 
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cells and vascular and myocardial tissue. The different cardioprotective effects of AR 
agonism have been verified in animal and human tissue (Willems et al., 2005). 
However, few studies have addressed the possibility that altered AR-mediated 
protection might underlie specific cardiovascular disorders, though there is evidence to 
support this. Hypertrophic hearts, for example, display abnormal adenosinergic 
signaling, and dysregulated adenosine formation. Interestingly, ARs impact on many 
processes implicated in cardiovascular "aging", regulating Ca2+ influx and oxidant 
injury, substrate metabolism, angiogenesis, myocardial fibrosis, and apoptotic processes 
(Willems et al., 2005). Given evidence of a role for ARs in intrinsic cardioprotection, 
mediation of preconditioning, and modifying the above-mentioned processes, 
alterations in AR signalling could contribute both to ischemic intolerance and 
emergence of other features of aged myocardium. All ARs are considered to be 
expressed within cardiovascular cells. Studies in different species verify endogenous 
adenosine contributes to intrinsic ischemic tolerance, and support cardioprotective roles 
for A1ARs in vitro and in vivo, and for A2AARs in vivo (Willems et al., 2005). Anti-
ischemic effects of A1ARs appear direct (at cardiomyocytes), since similar protection is 
observed in isolated hearts, cardiomyocytes, and in vivo (Roscoe et al., 2000). 
Protective A2AAR effects involve modulation of vascular function, platelet adhesion and 
neutrophil activation. There is currently no direct evidence for acute A2BAR mediated 
cardioprotection, partially due to lack of selective A2BAR agonists/antagonists. 
In contrast to A1 and A2AARs, there is little evidence that intrinsically activated A3ARs 
mediate protection. A3AR antagonists have no effect on ischemic outcomes in myocytes 
or hearts (Maddock et al., 2002). 
 
 
 
 20
Airways 
A role for adenosine in pulmonary disease was first suggested when it was found that 
adenosine and related synthetic analogues were potent enhancers of IgE-dependent 
mediator release from isolated rodent mast cells (Holgate et al., 1980). A few years 
later, adenosine administered by inhalation was shown to be a powerful 
bronchoconstrictor of asthmatic but, importantly, not of normal airways (Cushley et al., 
1983). Further work showed that both allergic and non-allergic asthmatics responded in 
a similar way and that the effect was also seen with adenosine 5′-monophosphate 
(AMP), ADP and ATP (Basoglu et al., 2005). Elevated levels of adenosine are present 
in chronically inflamed airways; they have been observed both in the bronchoalveolar 
lavage fluid and the exhaled breath condensate of patients with asthma (Caruso et al., 
2006). Adenosine levels are also increased after allergen exposure and during exercises 
in atopic individuals. The observed increase in tissue levels of adenosine suggests that 
adenosine signaling could regulate important features of chronic inflammatory disorders 
of the airways, including asthma and chronic obstructive pulmonary disease (COPD). 
Consistent with the hypothesis of adenosine playing an important role in the 
pathogenesis of chronic inflammatory disorders of the airways, mice deficient in 
adenosine deaminase (ADA) develop severe pulmonary inflammation and airway 
remodeling in association with elevated adenosine concentrations in the lung 
(Blackburn et al., 2000). The pulmonary phenotype in ADA-deficient mice consists of 
airway accumulation of eosinophils and activated macrophages, mast cell degranulation, 
mucus metaplasia in the bronchial airways, and emphysema-like devastation of the lung 
parenchyma. Although these histological traits do not completely resemble those of 
human asthma, the ADA-deficient mouse model is a useful tool to study the pathogenic 
role of adenosine in chronic airway inflammation.  
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The central role of adenosine in chronic lung inflammation is also supported by studies 
carried out in mice that have increased levels of interleukin IL-13 in the lung. These 
mice develop inflammation, fibrosis and alveolar destruction in association with 
elevated adenosine concentrations in the lung (Caruso et al., 2006). Treatment with 
ADA to prevent the increase in adenosine concentrations resulted in a marked decrease 
in the severity of the pulmonary phenotype, suggesting that adenosine mediates IL-13-
induced inflammation and tissue remodeling. Blockade of adenosine re-uptake by 
administration of dipyridamole has been used in humans to test the hypothesis that the 
accumulation of extracellular adenosine functionally modulates important features of 
the asthmatic response. In addition, it has been shown that a rapid increase in sputum 
eosinophilia occurs when asthmatics are exposed to adenosine by means of a 
provocation test with AMP (van der Berge et al., 2003). Taken together, these 
observations indicate that adenosine is likely to play an important role in asthma and 
COPD through interaction with specific cell-surface receptors. Expression of the four 
identified adenosine receptors has been shown in a large number of proinflammatory 
and structural cells and recently in the peripheral lung parenchyma of patients with 
COPD. The affinity of A1, A2A, and A3ARs, studied by means of saturation binding 
assays, was substantially decreased in patients with COPD, whereas their level of 
expression appears to be increased. Conversely, the affinity of A2BARs was not altered, 
but the density was significantly decreased in patients with COPD (Varani et al., 2006). 
This suggests that adenosine signalling play an important but rather complex role in 
COPD. Hence, adenosine responses are not only dictated by the bioavailability of the 
nucleoside but also by the pattern of adenosine receptor expression, which is known to 
be finely modulated by physiological and/or pathological tissue environments. 
Stimulation of A1ARs promotes activation of human neutrophils and enhances 
neutrophil adhesion to the endothelium in vitro, suggesting a pro-inflammatory role for 
 22
this receptor. However, in ADA/A1ARs double knockout mice, the lack of A1ARs 
results in enhanced pulmonary inflammation, mucus metaplasia, alveolar destruction 
and earlier death from respiratory distress, indicating a protective function. Activation 
of A2AARs on activated immune cells by adenosine appears to largely suppress the 
inflammatory response. In human neutrophils, stimulation of A2AARs reduces 
neutrophil adherence to the endothelium, inhibits formyl-Met-Leu-Phe (fMLP)-induced 
oxidative burst and inhibits superoxide anion generation (Fredholm et al., 1996). In 
monocytes and macrophages, activation of A2AARs inhibits lipopolysaccharide-induced 
tumour necrosis factor-α expression. Therefore, A2AAR agonists might have anti-
inflammatory effects in diseases such as COPD, where neutrophil- and monocyte-
mediated tissue injury is implicated (Caruso et al., 2006).  
Initial evidence for the role of A2BARs in asthma and COPD came from 
pharmacological studies of enprofylline, a methylxanthine structurally related to 
theophylline (Feoktistov and Biaggioni, 1995). It was proposed that the A2BAR might 
be the therapeutic target in the long-term clinical benefit achieved with relatively low 
doses of theophylline and enprofylline. Recently, A2BARs have been shown to mediate 
several pro-inflammatory effects of adenosine in the large majority of inflammatory and 
structural cells of the lung. For example, functional human A2BARs have been identified 
in mast cells, bronchial smooth muscle cells and lung fibroblasts. In these cells, 
adenosine, via activation of A2BARs, increases the release of various inflammatory 
cytokines, which induce IgE synthesis from human B lymphocytes and promote 
differentiation of lung fibroblasts into myofibroblasts. Such findings provide support for 
the view that activation of A2BARs could enhance the inflammatory response associated 
with asthma and that selective blockade of these receptors would be potentially 
beneficial in the treatment of asthma and other pulmonary inflammatory diseases. The 
functional significance of the A3AR in the pathogenesis of chronic inflammatory airway 
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diseases remains controversial largely owing to major species differences (Caruso et al., 
2006).  
 
 
 
Adenosine and cancer 
One of the difficulties in treating most of the common cancers (colon, lung, breast, 
prostate, etc.) is that they form solid tumors. The individual cancer cells, being different 
from normal cells, form a tissue mass that behaves in a radically different way from 
normal tissues in the body. This is because the major cell population (the cancer cells) 
has grown in a way that is out of step with all of the other cells that would normally 
form a supportive network. In particular, the growth of the cancer is not coordinated 
with the development of a proper blood supply. The vascular network of a tumor is 
usually inadequate, the blood vessels are often too few in number, the network is 
improperly branched, and their calibre is not well controlled. This means that the blood 
supply is inadequate. Consequently, most solid tumors do not receive sufficient oxygen 
and the cells are hypoxic. Specifically, hypoxia is conducive to adenine nucleotide 
breakdown, which is responsible for the adenosine release (Vaupel et al., 2001). As a 
consequence, adenosine accumulates to high levels in hypoxic tissues. In particular, it is 
recognized that significant levels of adenosine are found in the extracellular fluid of 
solid tumors, suggesting a role of adenosine in tumor growth (Merighi et al., 2003). 
Adenosine, released from hypoxic tissue, is thought to be an angiogenic factor that links 
altered cellular metabolism, caused by oxygen deprivation, to compensatory 
angiogenesis. Angiogenesis (or neovascularization) begins with the migration of 
endothelial cells, originating from capillaries, into the tissue being vascularized. 
Adenosine has been reported to stimulate or inhibit the release of angiogenic factors 
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depending on the cell type examined (Burnstock, 2006). On one hand, adenosine is 
known to cause the synthesis of vascular endothelial growth factor (VEGF) and increase 
the proliferation of endothelial cells obtained from the aorta, coronary vessels, and 
retina (human retinal endothelial cells, HREC). In particular, adenosine has been shown 
to induce the DNA synthesis in cultures of human umbilical vein endothelial cells 
(HUVEC) (Burnstock, 2006).  
In the human leukemia HL60, human melanoma A375, and human astrocytoma cells, 
adenosine at millimolar concentrations caused apoptosis. It seems likely that apoptosis 
is mediated by the intracellular actions of adenosine rather than through surface 
receptors (Merighi et al., 2002). It has been argued that the effect of high adenosine 
concentration might be subsequent to uptake of adenosine by the cell and intracellular 
accumulation of AMP, leading to caspase activation (Merighi et al., 2003). 
In many cases, tumor-induced immune suppression is mediated by soluble inhibition 
factors or cytokines elaborated by the tumor cells. Extracellular fluid of solid 
carcinomas contains immunosuppressive concentrations of adenosine, suggesting that 
this autacoid constitutes an important local immunosuppressant within the 
microenvironment of solid tumors. 
Antigen-presenting cells such as dendritic cells and macrophages are specialized to 
activate naïve T-lymphocytes and initiate primary immune responses. Adenosine 
inhibits interleukin-12 (IL-12) and tumor necrosis factor-α (TNF-α) production in 
dendritic cells and in macrophages impairing T-cell priming and suppressing the 
anticancer immune response. Furthermore, adenosine impairs the induction and 
expansion of cytotoxic T-lymphocytes and the antitumor activity of natural killer 
(Hoskin et al., 2002). 
Differential effects of adenosine on normal and cancer cells have been previously 
reported, showing that the proliferation of lymphocytes derived from patients with 
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chronic lymphocytic leukemia was inhibited by adenosine, whereas the proliferation of 
lymphocytes from healthy people was inhibited to a lesser extent. 
In vivo studies have shown that adenosine exerts a profound inhibitory effect on the 
induction of mouse cytotoxic T-cells, without substantially affecting T-cell viability 
(Hoskin et al., 2002).  
Adenosine sustains a complex role in the immune system activity, because when given 
to mice pretreated with cyclophosphamide it demonstrated a myeloprotective effect by 
restoring the number of white blood cells and the percentage of neutrophils as compared 
with normal values. Furthermore, it has been demonstrated that the elevation of the 
extracellular adenosine concentrations induced a radioprotective effect in mice by the 
stimulation of hematopoiesis in the bone marrow and the spleen. In support of this 
myelostimulatory role, it has been demonstrated that adenosine enhances cycling of the 
hematopoietic progenitor cells (Pospísil et al., 2001). 
The ability of adenosine to specifically inhibit tumor cell growth in vitro and in vivo 
suggests that the activation and/or blockade of the pathways downstream of adenosine 
receptors may contribute to tumor development. Furthermore, the extracellular 
adenosine concentration may be a crucial factor in determining the cell progression 
pathway, either in the apoptotic or in the cytostatic state (Merighi et al., 2003). 
 
Adenosine and central nervous system 
Adenosine levels in the brain extracellular space increase dramatically during 
metabolically stressful conditions, such as ischemia, seizures, or trauma. Adenosine, 
acting via its receptors, modulates excitability in the central nervous system (CNS) and 
has a role in mechanisms of seizure susceptibility, sleep induction, basal ganglia 
function, pain perception, cerebral blood flow,  and respiration (Benarroch, 2008).  
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Adenosine functions as a natural sleep-promoting agent accumulating during periods of 
sustained wakefulness and decreasing during sleep. It was suggested that adenosine 
participates in resetting of the circadian clock by manipulations of behavioural state. 
Indeed, A1ARs of the suprachiasmatic nucleus regulate the response of the circadian 
clock to light (Elliott et al., 2001). The sleep inducing properties of adenosine is in line 
with its A1AR-mediated inhibitory action and may involve multiple neuronal 
populations in the central nervous system; however, the actions upon the basal forebrain 
nuclei involved in sleep and arousal appear to be particularly important (Ribeiro et al., 
2002). In healthy humans, caffeine inhibits psychomotor vigilance deficits from sleep 
inertia, a ubiquitous phenomenon of cognitive performance impairment, grogginess and 
tendency to return to sleep immediately after abrupt awakening from intermittent and 
short sleep periods (van Dongen et al., 2001). It thus emerges that there exists a 
potential role of adenosine-related compounds and of A1AR agonists as sleep promoters 
and adenosine receptor antagonists as arousal stimulators. Adenosine A1AR agonists 
have anxiolytic activity in rodent models of anxiety, whereas caffeine and the adenosine 
A1AR selective antagonist, cyclopentyltheophylline, have anxiogenic properties. The 
involvement of adenosine A1ARs in anxiety was confirmed by the finding that the mice 
knocked out for this receptor showed increased anxiety-related behaviour. Interestingly, 
patients suffering from panic disorder, a serious form of anxiety disorder, appear to be 
particularly sensitive to small amounts of caffeine (Ribeiro et al., 2002). These 
observations, taken together, suggest that drugs that facilitate adenosine A1AR-mediated 
actions may be effective for the treatment of anxiety. Endogenous adenosine, through 
A1AR activation, modulates long-term synaptic plasticity phenomena, such as long-term 
potentiation (LTP), long-term depression (LTD), and depotentiation. In accordance with 
the notion that synaptic plasticity is the basis for learning and memory in different brain 
areas, adenosine correspondingly modulates behaviour in various learning and memory 
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paradigms, and adenosine A1AR antagonists have been proposed for the treatment of 
memory disorders (Ribeiro et al., 2002). Cognitive effects of caffeine are mostly due to 
its ability to antagonise A1ARs in the hippocampus and cortex, the brain areas mostly 
involved in cognition, positive actions of caffeine on information processing and 
performance might also be attributed to improvement of behavioural routines, arousal 
enhancement and sensorimotor gating (Fredholm et al., 1999).  
One of the first pathophysiological roles proposed for adenosine was as an endogenous 
anti-convulsant (Dragunow et al., 1986). Limitations of the use of adenosine receptor 
agonists as anti-convulsant drugs are due to their pronounced peripheral side effects as 
well as central side effects like sedation. To circumvent this limitation, the possibility of 
using compounds to increase the concentrations of endogenous adenosine was 
proposed, in particular inhibitors of adenosine kinase (McGaraughty et al., 2001). These 
compounds would facilitate the increase in extracellular adenosine caused by the 
seizure, having limited effects in other brain areas where the levels of adenosine are 
low. The anti-epileptic properties of adenosine are mostly due to the well-known 
inhibitory actions of A1ARs upon synaptic transmission in the hippocampus, but not 
only presynaptic actions upon glutamate release are involved (Khan et al., 2000).  
In the spinal cord, adenosine A1 AR activation produces anti-noceptive properties in 
acute nociceptive, inflammatory and neuropathic pain tests. Therefore, there was an 
increasing interest in the development of drugs that, by influencing extracellular 
adenosine levels, could have analgesic actions. Probably due to the anti-inflammatory 
actions of adenosine, adenosine kinase inhibitors administered orally are even more 
effective to reduce inflammatory pain than neuropatic or acute pain (Jarvis et al., 2002). 
By comparing the anti-nociceptive and anti-inflammatory properties of adenosine 
kinase inhibitors administered at the ipsilateral or contralateral side of the injury, it was 
concluded that much of the anti-inflammatory action is locally mediated, whereas the 
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anti-nociceptive action is systemically mediated, exerted predominantly at the spinal 
dorsal horn level. Indeed, adenosine kinase inhibitors are able to reduce the increase in 
c-fos expression in the spinal dorsal horn, induced by peripheral injection of an 
inflammatory (carrageenan) substance (Poon and Sawynok, 1999). Modulation of spinal 
chord-mediated pain by A1ARs is probably related to its ability to presynaptically 
inhibit excitatory transmission to substantia gelatinosa neurones in the spinal cord 
(Ribeiro et al., 2002). 
Anti-depressants are widely used in the treatment of neuropatic pain, but their analgesic 
efficacy seem to occur irrespective of mood altering effects. Recent studies showed that 
increases in extracellular adenosine levels and subsequent receptor activation are 
involved in the peripheral anti-nociceptive effect of amitriptyline in nerve injury-
induced neuropatic pain in rats, since co-administration of modest doses of caffeine 
reduces the action of acutely and chronically administered amitriptyline. Similarly, 
endogenous adenosine seems to be involved in the anti-allodynic action of amitriptyline 
in a rat model of painful diabetic neuropathy. Tricyclic anti-depressants, including the 
active metabolite of amitriptyline, nortriptyline, are potent inhibitors of neuronal uptake 
of adenosine and this is most probably the mechanism by which amitriptyline interacts 
with endogenous adenosine. The manipulation of endogenous adenosine by 
amitriptyline, while important, is unlikely to be the sole mechanism underlying its anti-
hyperalgesic action, but the attenuation by modest doses of caffeine (within those easily 
attained in humans after two cups of strong coffee) raise the possibility that dietary 
caffeine consumption might influence the efficacy of amitriptyline in alleviating 
neuropatic pain in humans (Esser and Sawynok, 2000). 
Morphine induces the release of adenosine and this also contributes to analgesic action 
of opioids. In neuropathic rats the release of adenosine induced by morphine is reduced, 
which might explain a decreased efficacy and potency of opioids in the treatment of 
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neuropathic pain (Sandner-Kiesling et al., 2001). An increase in the expression of kappa 
opioid receptors and a decrease in the expression of delta receptors, together with 
corresponding alterations in delta- and kappa-mediated anti-nociception, were recently 
detected in mice lacking the A2AAR gene, suggestive of a functional interplay between 
A2AAR and opioid receptors in the control of pain pathways (Bailey, 2002). 
Phase I clinical safety studies in healthy volunteers showed that intrathecal adenosine 
administration attenuated several types of experimental pain without causing significant 
side effects. Allosteric modulation of adenosine receptors, namely of A1ARs, has been 
attempted with success with the objective of developing drugs that by sinergising with 
endogenous adenosine action could have minimal side effects in the absence of 
adenosine. A further advantage of allosteric modulators is that they usually possess 
some degree of tissue selectivity. Allosteric modulation of adenosine A1ARs reduces 
allodynia, and, more interesting, the allosteric modulator T62 was effective not only 
after intrathecal injection but also after systemic administration, which reinforces the 
interest of adenosine-related compounds as putative drugs for the treatment of chronic 
pain associated with hyperalgesia and allodynia (Pan et al., 2001).  
A1AR agonists were conclusively shown to attenuate ischemic or excitotoxic neuronal 
damage both in vitro (cell cultures, brain slices) and in vivo in different models of 
ischemia/hypoxia (Wardas, 2002). Using primary cortical or hippocampal cell cultures 
subjected to hypoxia or glucose deprivation, it was demonstrated that both adenosine 
and the selective A1AR agonist CHA reduced the neuronal damage (Lynch et al., 1998). 
It has been demonstrated that local administration of CADO, an adenosine analogue, 
can attenuate cell loss in the CA1 region of the rat hippocampus in a model of global 
forebrain ischemia (temporary occlusion of carotid arteries) (Lynch et al., 1998). 
Moreover, acute systemic or intracerebroventricular injection of CHA attenuates the 
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neuronal loss in the hippocampus and improves neurological deficits in gerbils or rats 
subjected to global forebrain ischemia (Wardas et al., 2002). 
Studies in knockout mice or by using pharmacologic blockade indicate that A2AARs in 
the striatum modulate locomotor activity. The A2AARs are highly expressed in medium 
spiny GABA/enkephalin neurons projecting to the glubus pallidus and may form 
heterodimers with D2 dopamine receptors and functionally antagonize the effects of 
dopamine on striatopallidal neurons (Benarroch 2008). Activation of A2AARs results in 
increased GABA release in the globus pallidus, which would lead to disinhibition of the 
subthalamic nucleus (Ribeiro et al., 2002). The A2AARs are also coexpressed with 
A1ARs in glutamatergic corticostriate terminals and antagonize the presynaptic 
inhibitory effect of the A1ARs on glutamate release in the striatum. It has been proposed 
that increased release of glutamate from the subthalamic nucleus projections to the 
substantia nigra pars compacta would predispose to excitotoxic injury of these 
dopaminergic cells whereas presynaptic A2AAR mediated increase in glutamate release 
from corticostriate synapses may predispose to excitotoxic injury of medium spiny 
neurons (Bara-Jimenez et al., 2003). Epidemiologic and laboratory data suggest that 
caffeine may reduce the risk of Parkinson’s disease by preventing degeneration of 
nigrostriatal dopaminergic neurons. Furthermore, caffeine and selective A2AAR 
antagonists protect against dopaminergic cell loss in several toxin models of 
Parkinson’s disease (Simon et al., 2008). After the first studies demonstrating that the 
administration of methylxanthines, which have been later recognized as adenosine 
receptor antagonists, can exert the same behavioural effects as dopamine receptor 
agonists, the discovery of the colocalization of D2 and A2AARs has provided an 
anatomical basis to the functional antagonism between adenosine and dopamine in the 
basal ganglia. In particular, A2AARs and D2 dopamine receptors colocalize on the 
dendritic spines of the striatopallidal neurons, playing an important modulatory role on 
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the excitatory actions of glutamatergic transmission (Hettinger et al., 2001). The final 
functional result of this interaction is that the activation of the A2AARs induces 
hypolocomotion, whereas the opposite is observed after D2 receptor activation. One 
explanation of the antagonistic interaction between A2AAR and D2 receptor stimulation 
came from the observation that they are both coupled to adenylyl cyclase, but with 
opposite effects, namely stimulation and inhibition, respectively (Kull et al., 1999). 
Subsequent studies have provided more in-depth molecular explanations by 
demonstrating that under physiological conditions, activation of the A2AARs is 
responsible for a tonic increase in basal cAMP levels on which dopamine can exert its 
inhibitory effects (Svenningsson et al., 1999). Furthermore, A2AARs have been also 
demonstrated to regulate the phosphorylation status of dopamine- and cAMP-regulated 
phosphoprotein 32 kDa (DARRP-32), and the PKA/CREB cascade, thereby promoting 
immediate early genes and enkephalin expression (Svenningsson et al., 2000). More 
recently, the existence of a physical protein–protein interaction between the two 
receptor subtypes has been demonstrated, which involves peculiar peptide residues 
(Canals et al., 2003). This interaction leads to the formation of receptor heteromers in 
the plasma membrane, which contributes to explain the early observation of agonist 
affinity loss at the D2 receptor after activation of the A2AARs. The adenosine/dopamine 
interaction could have very important implications for basal ganglia functioning. It has 
provided the molecular and biochemical basis to postulate the possible therapeutic use 
of A2AAR antagonists in Parkinson's disease, and has prompted chemists to synthesize 
more selective and clinically useful molecules (Pinna et al., 2005). Besides caffeine and 
theophylline, which represent the first A2AAR antagonists, the synthetic compounds 
SCH58261 and ZM241385 have proven extremely potent and selective toward A2AARs, 
and have represented useful in vitro and in vivo tools to characterize the 
pathophysiological role of this receptor subtype in the CNS. Other compounds, such as 
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KW-6002 (istradefylline) and V2006, are currently undergoing clinical trials as novel 
approaches in the therapy of Parkinson's disease (Jacobson and Gao, 2006).  
 
 
POLYGLUTAMINE DISEASES 
The group of inherited neurodegenerative diseases designated the polyglutamine 
diseases share many seminal features with the other families of neurodegenerative 
diseases (Zoghbi and Orr, 2000). They typically manifest with a late age of onset and, at 
least during their initial stages, these disorders are characterized by a specific set of 
clinical signs with pathology limited to a distinct subset of neurons. Like many other 
neurodegenerative diseases, the polyglutamine diseases have, as a hallmark of 
pathology, the accumulation of insoluble material within neurons, adding further to the 
concept of a common pathogenic theme, the generation and accumulation of misfolded 
proteins.  
Nine neurodegenerative diseases have as their disease-causing mutation the expansion 
of a polyglutamine tract (Table 1). This involves the unstable expansion of a CAG 
sequence within the coding region of each gene. Thus, these diseases fall within a 
broader class of disorders, i.e. diseases that involve the expansion of an unstable 
repetitive element, usually triplet sequences (Gatchel and Zoghbi, 2005). Interestingly, 
expansions of an unstable nucleotide repeat is a mutational mechanism that appears to 
be unique to the human genome. Furthermore, although genes that are highly 
homologous to the polyglutamine genes are present in the genomes of other mammals, 
the polyglutamine tract is not, suggesting that the polyglutamine stretches are not 
necessary for normal function. 
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The polyglutamine disorders include spinobulbar muscular atrophy, Huntington's 
disease (HD), the spinocerebellar ataxias (SCA1, SCA2, SCA3/MJD, SCA6, SCA7 and 
SCA17), and dentatorubral-pallidoluysian atrophy (DRPLA). All of these disorders are 
progressive, typically striking at midlife and having a course that consists of an 
extended period of neuronal dysfunction followed by neuronal loss and eventually death 
10–20 years after onset. Other features that characterize this group of neurodegenerative 
disorders include a direct relationship between the length of the polyglutamine tract and 
the severity of the disease, and between the number of glutamines and the age of onset 
and the severity of the disease (Gatchel and Zoghbi, 2005). Mutant CAG repeats show 
both germline and somatic instability. Germline instability along with the relationship 
between repeat length and disease course are the basis for the phenomena of genetic 
anticipation. As the repeat grows upon passage from generation to generation, affected 
members in successive generations have an earlier age of onset and more rapidly 
progressing form of the disease. 
The autosomal dominant spinocerebellar ataxias (SCAs) are a complex group of 
neurodegenerative disorders characterized by progressive cerebellar ataxia of gait and 
limbs variably associated with ophthalmoplegia, pyramidal and extrapyramidal signs, 
dementia, pigmentary retinopathy and peripheral neuropathy (Zoghbi et al., 2000). 
Disease onset is usually between 30 and 50 years of age, although early onset in 
childhood and onset in later decades after 60 years have been reported. The prognosis is 
variable depending on the underlying cause of the spinocerebellar ataxia subtype. 
Epidemiological data indicate that SCAs might be more common than that previously 
estimated with prevalences of up to 5–7 in 100 000 in some populations (Craig et al., 
2004).  
The clinical features are caused by a combination of degeneration of the cerebellum, 
basal ganglia, cerebral cortex, optic nerve, pontomedullary systems, spinal tracts or 
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peripheral nerves. Although the aetiology of SCAs is still poorly understood, genetic 
analyses, epidemiological data, neuropathological investigations and new experimental 
models are providing important new insights into the pathogenic mechanisms. At least 
28 distinct loci are responsible for rare Mendelian forms of SCA. Interestingly, a few 
SCA subtypes, including SCAs 1, 2, 3, 6, 7, 17 and dentatorubral pallidoluysian atrophy 
(DRPLA), are caused by the expansion of a CAG (DNA sequence coding for 
glutamine) repeat sequence located within the coding region of specific genes, leading 
to an abnormally long polyglutamine (polyQ) tract in the encoded proteins named 
ataxins 1, 2 and 3, alpha 1A-voltage-dependent calcium channel, ataxin 7, TATA box 
binding protein (TBP) and atrophin 1, respectively. These SCAs show, as common 
features, the progressive neurodegeneration of neuronal subsets in distinct brain areas 
and the formation of polyQ-containing protein aggregates forming characteristic nuclear 
or cytoplasmic inclusions (Zoghbi and Orr, 2000). The age at onset and severity of 
disease symptoms inversely correlate with the length of the glutamine repeat. A second 
group of SCAs, including SCAs 8, 10 and 12, are caused by a repeat expansion located 
outside of the coding region of the disease genes leading to dysregulation of gene 
expression (Zoghbi and Orr, 2000). While the molecular mechanisms underlying SCAs 
8 and 10 are unclear, SCA12 appears to be caused by dysregulation of the activity of the 
crucial enzyme protein phosphatase 2 (PP2, formerly named PP2A) in cerebellar 
Purkinje cells. Different mechanisms cause cerebellar ataxia and neurodegeneration in 
SCAs 5, 13, 14 and 27, where alterations in amino acid composition in beta-III spectrin 
(SPTBN2) (Ikeda et al., 2006), potassium channel KCNC3 (Waters et al., 2006), protein 
kinase C (PRKCG) and fibroblast growth factor 14 (FGF14), respectively, elicit disease 
symptoms in these four SCA subtypes (Ikeda et al., 2006). In the rest of SCAs, the 
genes and, therefore, the mutations remain to be identified and characterized.  
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SCA1 is one of several inherited forms autosomal dominant ataxia. Typical of most 
ataxias, SCA1 consists clinically of gait ataxia dysarthria and bulbar dysfunction, with 
death usually ocurring between 10 and 15 years after the onset of symptoms. Despite 
the protein, ataxin-1, being widely expressed in the CNS, the most frequently seen and 
most severe pathological alterations are restricted to loss of Purkinje cells in the 
cerebellar cortex, as well as loss of neurons in the inferior olivary nuclei, the cerebellar 
dentate nuclei and the red nuclei (Mascalchi, 2008). 
With the identification of an expanded polyglutamine tract as the mutational basis for 
several neurodegenerative disorders, a pathogenic mechanism largely dependent on the 
biochemical property of the polyglutamine tract itself gained quick favor. In contrast, 
two experiments utilizing SCA1 transgenic mice showed that amino acid residues 
outside of the polyglutamine had a crucial role in pathogenesis. In the first example an 
amino acid substitution was made in the nuclear localization signal of ataxin-1, such 
that the protein could no longer be translocated into the nucleus. When this substitution 
was placed into a mutant allele of ataxin-1 with an expanded polyglutamine tract that 
was then used to generate transgenic mice, the mice failed to develop disease (Klement 
et al., 1998). Thus by restricting the subcellular distribution of mutant ataxin-1 to the 
cytoplasm of susceptible neurons the protein was no longer pathogenic. Perhaps a more 
dramatic illustration of the importance of 'host' protein sequence for pathogenesis was 
shown recently when a site of phosphorylation of ataxin-1 was identified, the serine at 
position 776 (Emamian et al., 2003). Replacing this serine with an alanine yielded a 
protein that still was transported to the nucleus, but when transported in a mutant ataxin-
1 with 82 glutamines failed to cause disease. 
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TABLE 1. Characteristics of Polyglutamine diseases 
     
 
 
 
 
 
 
Disease Gene 
name 
Chromosomal 
location 
Pattern of 
inheritance 
Protein Normal 
repeat 
length 
Disease  
repeat  
length 
Spinobulbar 
muscular 
atrophy 
(Kennedy 
disease) 
AR Xq13–21 X-linked 
recessive 
androgen 
receptor  
9–36 38–62 
Huntington 
disease 
HD 4p16.3 autosomal 
dominant 
huntingtin 6–35 36–121 
Dentatorubral-
pallidoluysian 
atrophy (Haw 
River 
syndrome) 
DRPLA 12p13.31 autosomal 
dominant 
atrophin-
1 
6–35 49–88 
Spinocerebellar 
ataxia type 1 
SCA1 6p23 autosomal 
dominant 
ataxin-1 6–44 39–82 
Spinocerebellar 
ataxia type 2 
SCA2 12q24.1 autosomal 
dominant 
ataxin-2 15–31 36–63 
Spinocerebellar 
ataxia type 3 
(Machado-
Joseph disease) 
SCA3 14q32.1 autosomal 
dominant 
ataxin-3 12–40 55–84 
Spinocerebellar 
ataxia type 6 
SCA6 19p13 autosomal 
dominant 
α1A-
voltage-
dependent 
calcium 
channel 
subunit 
4–18 21–33 
Spinocerebellar 
ataxia type 7 
SCA7 3p12–13 autosomal 
dominant 
ataxin-7 4–35 37–306 
Spinocerebellar 
ataxia type 17 
SCA17 6q27 autosomal 
dominant 
TATA 
binding 
protein 
25–42 45–63 
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HUNTINGTON’S DISEASE 
Huntington’s disease (HD) is the most common and well-studied polyglutamine 
neurodegenerative disorder. It has a prevalence of 3–10 affected subjects per 100.000 
individuals in Western Europe and North America (Gil and Rego, 2008). The disorder 
was first described in the 19th century by George Huntington, who identified both its 
clinical features and its pattern of familial transmission. However, it was not until 1993 
that a multicenter consortium, organized by the Hereditary Disease Foundation, 
discovered the actual HD gene mutation. This is an unstable expansion of CAG repeats 
within the coding region of the HD gene, which is located on the short arm of 
chromosome 4 (4p63) and encodes the protein huntingtin. The mutation results in a 
stretch of glutamine residues located in the NH2-terminal of huntingtin (The 
Huntington’s Disease Collaborative Research Group, 1993). Although the abnormal 
protein is ubiquitously expressed throughout the organism, cell degeneration occurs 
mainly in the brain (Vonsattel and DiFiglia, 1998).  
 
CLINICAL MANIFESTATIONS 
Classically described as Huntington's Chorea (the Greek word for dance), the first signs 
of the disease are subtle: clumsiness, difficulties with smooth eye pursuit, and slight 
uncontrolled and awkward movements. These motor disturbances, associated with the 
loss of voluntary movement coordination, progress slowly. The involuntary movements 
of the proximal and distal muscles become more severe and the patients gradually lose 
their capacity to move and eventually communicate. Bradykinesia and rigidity are also 
common symptoms in Huntington's patients, especially in late stages of the disease. 
Death generally occurs as a consequence of heart failure or aspiration pneumonia 
(Sánchez-Pernaute et al., 2000). In juvenile patients the symptomatology is considerably 
different, being characterized by bradykinesia, tremors, rigidity and dystonia, and 
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chorea may be completely absent. Affected children may also suffer epileptic seizures. 
The majority of patients suffer also from inexplicable muscle wasting and weight loss, 
despite constant caloric intake (Aziz et al., 2008). Although the cause of these 
peripheral symptoms is still unclear, a recent study has demonstrated the existence of a 
positive correlation between the levels of branched chain amino acids (valine, leucine 
and isoleucine), weight loss and disease progression in HD patients, reinforcing the 
importance of a systemic metabolic defect in HD pathology (Mochel et al., 2007). A 
number of endocrine abnormalities have also been reported in HD patients, including 
increased levels of corticosteroids and reduced levels of testosterone (Markianos et al., 
2005). Furthermore, 10–25% of HD patients exhibit diabetes mellitus. The cognitive 
capacities are also severely affected during the course of HD. The slowing of 
intellectual processes is the first sign of cognitive impairment in HD patients and 
deficits in some cognitive functions can in some cases be detected decades before the 
onset of motor symptoms. These cognitive impairments get worse over time and late-
stage HD patients show profound dementia. Manic–depressive behavior and personality 
changes (irritability, apathy and sexual disturbances) are often part of the psychiatric 
syndrome. Based on the above features, the criteria used for the diagnosis of HD 
include: (i) a family history of HD; (ii) progressive motor disability with chorea or 
rigidity with no other cause; and (iii) psychiatric disturbances with progressive dementia 
with no other cause (Vonsattel and DiFiglia, 1998). Currently, individuals showing 
these symptoms are submitted to genetic testing in order to screen for the HD mutation 
and confirm the diagnosis. 
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GENETICS 
The mutation responsible for HD constitutes a stretch of uninterrupted CAG 
trinucleotide repeats located near the 5'-end in exon 1 of the HD gene coding sequence, 
which comprises 67 exons. Consequently, mutant huntingtin bears a tract of consecutive 
glutamine residues in its NH2-terminal, 17 amino acids downstream of the initiator 
methionine (The Huntington's Disease Collaborative Research Group, 1993). The 
disease is inherited in an autosomal dominant manner. The normal allele is transmitted 
from generation to generation in a Mendelian fashion. The mutant allele is unstable 
during meiosis, changing in length in the majority of intergenerational transmissions, 
with either slight increases of 1–4 units or decreases of 1–2 units. In rare occasions, 
larger-sized increases occur in parental transmissions, reflecting a particularly high 
mutation rate during spermatogenesis (The Huntington's Disease Collaborative 
Research Group, 1993). The number of CAG repeats (i.e. glutamine residues) is the 
primary and major determinant of disease severity, accounting for 30–60% of the 
variance in the age of onset of the first symptoms. The remaining variance is 
attributable to other genetic features and environmental factors (Arning et al., 2005). 
Interestingly, in a recent study that involved 167 HD patients, the length of the 
polyglutamine tail (which ranged from 41 to 45 units) accounted for only 30.8% of the 
variance in the age of onset, whereas 12.3% additional variance could be attributed to 
genotype variation in the gene coding for the N-methyl-D-aspartate (NMDA) receptor 
subunit NR2B and 4.5% to genotype variation in the gene coding for the NMDA 
receptor subunit NR2A (Arning et al., 2005). Normally, asymptomatic individuals have 
>35 CAG repeats whereas HD is manifested when the number of repeats exceeds this 
threshold. Alleles with 35–39 repeats are associated with later onset of the disease, 
although incomplete penetrance has been observed in some individuals who have shown 
no symptoms or neuropathological signs. Alleles of 40–50 units give rise to the most 
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common adult-onset form of the disease, whereas the longest repeats (normally 
associated with high allele instability during parental transmission) are responsible for 
the severe juvenile and infantile cases (The Huntington's Disease Collaborative 
Research Group, 1993). Importantly, there is a positive correlation between the number 
of CAG repeats and the Vonsattel grades of neuropathological severity, with greater 
CAG repeat lengths being associated with greater degrees of cell death in the striatum 
and higher Vonsattel grades (Vonsattel and DiFiglia, 1998).  
 
PATHOGENESIS 
Huntingtin is a protein composed of >3100 amino acids and with a molecular mass of ca 
349 kDa, depending on the exact number of glutamine residues. A polymorphic proline-
rich segment follows the polyglutamine tail (The Huntington's Disease Collaborative 
Research Group, 1993). Huntingtin does not show structural homology with any other 
known protein. The wild-type protein is widely expressed throughout the body, in both 
neuronal and non-neuronal cells, raising the questions of how and why the disease 
mutation results in a selective neuronal loss. In the HD brain, particularly in the two 
most affected regions, the striatum and cerebral cortex, an altered intracellular 
localization and perinuclear accumulation of mutant huntingtin is observed, with the 
formation of neuronal intranuclear inclusions (NIIs) and aggregates in dystrophic 
neurites. However, the neurons bearing inclusions do not correspond to the most 
vulnerable ones. Indeed, some interneurons that are spared during the course of the 
disease are the ones that display the highest frequency of aggregates, raising the 
question of whether inclusions are toxic, protective, or just an epiphenomenon of the 
disease mechanism. 
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Functions of wild-type huntingtin 
Pioneer studies have suggested that wild-type huntingtin is essential for normal 
embryonic development, as engineered knockout mutations that disrupt exon 4, exon 5, 
or the promoter of the mouse HD gene homolog Hdh, leading to its complete 
inactivation, and result in embryonic lethality (Zeitlin et al., 1995). However, a 
subsequent study has shown that mutant human huntingtin can compensate for the 
absence of endogenous huntingtin, rescuing the embryonic lethality of mice 
homozygous for a targeted disruption of the endogenous Hdh gene (Leavitt et al., 2001). 
Thus, it is reasonable to suggest that huntingtin's function during embryonic 
development is independent of the length of the polyglutamine tail. Moreover, the HD 
mutation does not seem to abrogate the developmental functions of huntingtin, as HD 
patients appear to develop normally and the symptoms only start to manifest several 
years after birth. Furthermore, some evidence suggests that huntingtin might be required 
not only during embryogenesis but also throughout life, as conditional knockout mice in 
which the Hdh gene is inactivated during adulthood are sterile, develop a progressive 
motor phenotype and show a reduced life span (Dragatsis et al., 2000). Nevertheless, 
these studies have not been replicated and, thus, the actual role of normal huntingtin 
during adulthood is still under debate. 
Within the cell, wild-type huntingtin is mainly localized in the cytoplasm associated 
with organelles such as mitochondria, the Golgi apparatus, the endoplasmic reticulum, 
synaptic vesicles and several components of the cytoskeleton. Wild-type huntingtin is 
also present inside the nucleus, although to a lesser extent (Landles and Bates, 2004). 
Yeast two-hybrid screenings, affinity pull-down assays, Western blotting and 
immunoprecipitation studies have shown that wild-type huntingtin binds to numerous 
proteins. Accordingly, a recent study has identified 234 high-confidence huntingtin-
associated proteins (Kaltenbach et al., 2007). Relevant examples include: (i) huntingtin-
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associated protein 1 (HAP1), a novel protein with at least two isoforms (HAP1-A and 
HAP1-B), which is expressed in several tissues including the brain and which interacts 
with the p150 subunit of dynactin, thus being involved in intracellular transport; (ii) 
huntingtin-interacting protein 1 (HIP1), a protein that binds to α–adaptin and clathrin, 
and is thus implicated in cytoskeleton assembly and in endocytosis; (iii) huntingtin-
interacting protein 2 (HIP2), a ubiquitin-conjugating enzyme that catalyzes the covalent 
attachment of ubiquitin units to intracellular proteins, tagging them for degradation by 
the proteasome; (iv) glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a glycolytic 
enzyme; and (v) microtubules and β-tubulin, which are components of the cytoskeleton 
(Li and Li, 2004). As expected, the presence of an expanded polyglutamine tail can 
disrupt and/or modify the nature of the interactions between huntingtin and these 
interacting proteins, ultimately inhibiting and/or modifying the normal function of these 
proteins. 
Wild-type huntingtin promotes the expression of brain-derived neurotrophic factor 
(BDNF) by interacting with the transcriptional factor complex repressor-element-1 
transcription factor (REST)–neuron-restrictive silencer factor (NRSF) in the cytoplasm 
and preventing this complex from translocating into the nucleus and binding to the 
neuron-restrictive silencer element (NRSE) present in the promoter of the BDNF gene 
(Zuccato et al., 2003). Wild-type huntingtin also promotes the vesicular transport of 
BDNF along the microtubules through a mechanism that involves HAP1 and the p150 
subunit of dynactin. The interaction of wild-type huntingtin with both HAP1 and mixed-
lineage kinase 2 (MLK2) has been shown to promote the expression of NeuroD, a 
helix–loop–helix transcription factor that is crucial for the development of the dentate 
gyrus of the hippocampus and for the morphogenesis of pancreatic islets (Huang et al., 
2002). Wild-type huntingtin prevents the activation of caspase-8 by interacting with 
HIP1 and preventing the formation of the caspase-activating complex HIP1–HIP1-
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protein interactor. Furthermore, neurons from HIP1-knockout mice were recently shown 
to be less sensitive to NMDA-induced cell death than wild-type neurons, suggesting that 
HIP1 may play an important role during excitotoxicity (Metzler et al., 2007). 
Importantly, wild-type huntingtin is believed to have a pro-survival role in the cell. The 
antiapoptotic function of wild-type huntingtin has been corroborated in several in vitro 
studies. These have demonstrated that expression of the full-length protein protected 
conditionally immortalized striatal-derived cells from a variety of apoptotic stimuli. 
Wild-type huntingtin appeared to act downstream of mitochondrial cytochrome c 
release, preventing the formation of a functional apoptosome complex and the 
consequent activation of caspase-9 and caspase-3 (Rigamonti et al., 2001). Moreover, it 
was recently shown that wild-type huntingtin physically interacts with active caspase-3 
inhibiting its proteolytic activity (Zhang et al., 2006). On the other hand, in vivo 
overexpression of full-length wild-type huntingtin bearing 18 glutamine residues in 
yeast artificial chromosome (YAC)18 transgenic mice conferred significant protection 
against apoptosis triggered by NMDA receptor-induced excitotoxicity. 
Interestingly, the huntingtin sequence contains several HEAT (huntingtin, elongation 
factor 3, protein phosphatase 2A, target of rapamycin 1) repeats, which are conserved 
repeating segments of 40 amino acids that form two hydrophobic α-helices. According 
to a model proposed on a recent study, full-length wild-type human huntingtin may be 
entirely composed of HEAT repeats stacking on top of each other to form an elongated 
superhelix (Li et al., 2006). The function of these motifs is still unclear, although they 
are found in a variety of proteins that are involved in intracellular transport and 
chromosomal segregation. Furthermore, the 18 amino acids of the huntingtin N-
terminus constitute an amphipathic α-helical membrane-binding domain that can 
reversibly target the protein to the endoplasmic reticulum. As this association is affected 
by endoplasmic reticulum stress, it was recently suggested that wild-type huntingtin 
 44
may function as an endoplasmic reticulum-associated protein that can translocate to the 
nucleus and back out in response to endoplasmic reticulum stress (Gil and Rego, 2008). 
Overall, these studies indicate that wild-type huntingtin may exert a variety of 
intracellular functions such as: (i) protein trafficking; (ii) vesicle transport and 
anchoring to the cytoskeleton; (iii) clathrin-mediated endocytosis; (iv) postsynaptic 
signaling; (v) transcriptional regulation; and (vi) anti-apoptotic function. 
 
Aggregation of mutant huntingtin 
The normal tertiary protein conformation is destabilized by the presence of the 
expanded polyglutamine tract, leading to the establishment of abnormal protein–protein 
interactions with other polyglutamine-bearing proteins (including other molecules of 
mutant and wild-type huntingtin). This results in the formation of insoluble β-pleated 
sheets that form polar zipper structures via hydrogen bonding (Stott et al., 1995).  
Transglutaminases are enzymes that are involved in the cross-linking of glutamine 
residues and thus may also participate in the formation of aggregates. Indeed, in vitro 
studies have shown that huntingtin is a transglutaminase substrate and that the 
transglutaminase-mediated crosslinking increases with the length of the polyglutamine 
stretch. Hence, the expanded polyglutamine tract caused by the disease mutation could 
result in an increased transglutaminase-mediated crosslinking with other molecules of 
mutant and wild-type huntingtin, as well as other polyglutamine-containing proteins, 
leading to the precipitation and intraneuronal accumulation of protein complexes. In 
support of this model, transglutaminase activity has been shown to be increased in HD 
brains (Gil and Rego, 2008). 
Some evidence suggests that, once formed, these aggregates of mutant huntingtin may 
be transported by the microtubule organization center, or centrosome, to a perinuclear 
localization. However, these results have not been recently replicated and the co-
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localization of the aggregates of mutant huntingtin with the centrosome is still under 
debate. 
Because the formation of mutant huntingtin aggregates is regarded as a hallmark of HD, 
many authors hypothesize that aggregation of mutant huntingtin is the trigger point that 
eventually leads to cell demise in HD. Several proteins have been shown to abnormally 
interact and be recruited into the aggregates of mutant huntingtin, causing a severe 
deregulation of several key intracellular pathways. Nevertheless, mutant huntingtin 
inclusions may only represent a side-effect of the ongoing cell dysfunction, or may even 
exert a protective role during the early stages of the disease (Kuemmerle et al., 1999). 
Indeed, it is possible that the inclusions represent a means for the cell to sequester the 
toxic N-terminal fragments and oligomers of mutant huntingtin as well as other 
misfolded proteins which in the soluble form could cause more rapid and severe damage 
(Gil and Rego, 2008). In line with this hypothesis, in vitro studies have demonstrated 
that the presence of NIIs does not correlate with huntingtin-induced death. Indeed, 
exposure of striatal neurons transfected with mutant huntingtin to conditions that 
suppress the formation of NIIs resulted in increased neuronal while the formation of 
NIIs leads to a decrease in the levels of diffuse mutant huntingtin and to an increase in 
neuronal survival (Arrasate et al., 2004).  
 
Huntingtin post-translational modifications 
Importantly, the activity of both wild-type and mutant huntingtin can be modulated by 
several post-translational modifications. Within this scenario, several studies have 
indicated that huntingtin phosphorylation at various sites is neuroprotective through 
preventing cleavage of mutant huntingtin and its consequent aggregation. Thus, 
huntingtin can be phosphorylated on serine 421 by protein kinase B or Akt and the 
closely related serum- and glucocorticoid-inducible kinase, and this attenuates mutant 
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huntingtin toxicity in vitro (Gil and Rego, 2008). Moreover, endogenous 
phosphorylation of mutant huntingtin on serine 421 is significantly reduced in the 
striatum of YAC-transgenic mice. Huntingtin can also be phosphorylated at serine 434 
by the cyclin-dependent kinase 5, and this phosphorylation reduces caspase-mediated 
huntingtin cleavage at residue 513 and attenuates aggregate formation and toxicity in 
vitro. Finally, in a recent study, the phosphorylation sites of full-length huntingtin were 
mapped by mass spectrometry. More than six novel serine phosphorylation sites were 
identified and mutation of one of these sites, which lies in the proteolytic susceptibility 
domain (serine 536), inhibited calpain-mediated cleavage and reduced toxicity of 
mutant huntingtin (Schilling et al., 2006). 
Other huntingtin post-translational modifications have also been described. Among 
them, the reversible binding of a small ubiquitin-related protein modifier 
(SUMOylation), which is thought to alter inter- and/or intra-molecular interactions of 
the modified substrate and thus modulate its subcellular localization, activity and 
stability, was shown to occur in a Drosophila model of HD. In this model, the 
SUMOylation of a pathogenic fragment of huntingtin on lysine residues exacerbated 
neurodegeneration, whereas mutation of these lysines prevented SUMOylation of the 
huntingtin fragment and reduced HD pathology in this model (Steffan et al., 2004). On 
the other hand, palmitoylation (i.e. the post-translational addition of palmitic acid) is 
believed to play a role in intracellular trafficking (including endocytosis, protein 
recycling and transport) and the association of cytosolic proteins with membranes  have 
recently demonstrated that normal huntingtin is palmitoylated at cysteine 214 by the 
palmitoyl transferase huntingtin-interacting protein 14 (HIP14), and this post-
translational modification is essential for its trafficking and function. Moreover, the HD 
mutation reduces the interaction between huntingtin and HIP14, resulting in a marked 
reduction in huntingtin palmitoylation. As the mutation of the palmitoylation site of 
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huntingtin and the down-regulation of HIP14 increases inclusion formation in vitro, it 
has been suggested that inhibition of palmitoylation might contribute to NII formation 
(Yanai et al., 2006). 
 
Huntingtin toxic gain of function 
The expanded polyglutamine is believed to confer a new function to huntingtin that is 
toxic to the cell (toxic gain of function). Indeed, the mutant protein (in either its soluble 
or its insoluble aggregate form) has been shown to disrupt several intracellular 
pathways by abnormally interacting and/or sequestering key components of these 
multiple pathways into the aggregates. On the other hand, several lines of evidence also 
suggest that a loss of function of wild-type huntingtin (due to its decreased expression 
and/or sequestration into the aggregates by interacting with the mutant protein) also 
contributes to the disruption of intracellular homeostasis, culminating in neuronal 
dysfunction and death (Gil and Rego, 2008). 
Protease cleavage sites for caspase-3 and calpain have been identified within the first 
550 amino acids of huntingtin, and proteolysis has been shown to increase in the 
presence of longer polyglutamine tails (Sun et al., 2002). It has been suggested that 
caspase-3- and calpain-mediated sequential proteolysis of mutant huntingtin produce N-
terminal fragments that are more toxic and prone to aggregate and that diffuse passively 
into the nucleus due to its smaller size (Sun et al., 2002). These fragments can in turn 
recruit more proteases into the aggregates, favoring their subsequent activation. This 
creates a positive feedback loop that results in further aggregation and proteolytic 
cleavage that may ultimately contribute to cell death. 
Furthermore, the expanded polyglutamine also reduces the ability of huntingtin to bind 
and inhibit active caspase-3 and to bind HIP1, which is then free to associate with 
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HIPPI and induce the activation of caspase-8, an initiator caspase that triggers the 
apoptotic cascade (Gil and Rego, 2008).  
Heat-shock proteins (HSPs) such as HSP40 and HSP70, which are chaperones involved 
in the refolding of misfolded proteins, are also sequestered into aggregates of mutant 
huntingtin in vitro (Wyttenbach et al., 2000). As the abnormally long polyglutamine 
tract is likely to result in an overall misfolding of huntingtin, the interaction of HSPs 
with mutant huntingtin may represent an attempt of the cell to refold the mutant protein. 
In line with this idea, it has been shown that Hsp70 and Hsp40 interfere with the 
aggregation of mutant huntingtin in vitro, preventing the aggregate-induced inhibition 
of transcription factors such as the thymidine–adenine–thymidine–adenine (TATA)-
binding protein (TBP). However, by being sequestered into the aggregates, these 
chaperones will eventually be prevented from exerting their normal protective functions 
and, over the years, this is likely to lead to an intracellular accumulation of misfolded 
proteins. 
Furthermore, several components of the proteasome, such as its regulatory and catalytic 
subunits and ubiquitin conjugation enzymes, are also sequestered in these aggregates in 
vitro and in vivo resulting in the impairment of the ubiquitin–proteasome system (Bence 
et al., 2001). On the other hand, the presence of ubiquitin residues in mutant huntingtin 
aggregates may be the result of an unsuccessful attempt of the cell to tag the mutated 
protein for the proteasome. However, the HD mutation may render the protein resistant 
to proteasomal degradation. Indeed, the mutant protein with its expanded polyglutamine 
tail may physically block the proteasome, preventing the entrance of further substrates 
into the proteasome complex.  
Importantly, studies using a conditional HD mouse model (in which silencing of mutant 
huntingtin expression leads to the disappearance of intranuclear aggregates) showed that 
aggregate formation is a balance between the rate of huntingtin synthesis and its 
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degradation by the proteasome (Martin-Aparicio et al., 2001). Therefore, over the 
course of the disease the proteasome degradation system may become overloaded with 
an increasing number of misfolded and mutated proteins in the cell. As a consequence, 
the neurons may be progressively depleted of functional proteasomes, which will lead to 
a progressive accumulation of misfolded and abnormal proteins, further increasing the 
rate of protein aggregation. Finally, an impairment of the ubiquitin–proteasome system 
can induce cell death either by apoptosis or by autophagy (a process by which 
lysosomes degrade cytoplasmic proteins and organelles), causing the recruitment of 
lysosomes and proteins involved in the formation of autophagic vacuoles into inclusion 
bodies (Iwata et al., 2005). 
Numerous transcription factors have been reported to interact with mutant huntingtin. 
Examples include CREB-binding protein (CBP), specific protein-1 (Sp1), and the TBP-
associated factor (TAF)II130, all of which directly interact with mutant huntingtin 
through the expanded polyglutamine tail. Other nuclear proteins, such as the pro-
apoptotic transcription factor p53, also interact with mutant huntingtin via its SH3 
sequences, which are distal to the polyglutamine tract (Landles and Bates, 2004). 
Under normal conditions, CBP (a co-activator of the CRE-mediated transcription 
pathway) is recruited upon phosphorylation, acting as a bridge between CREB and the 
basal transcriptional machinery. Moreover, CBP can also play a role in histone 
acetylation by acting as an acetyltransferase, which opens the chromatin structure and 
exposes the DNA to transcription factors. In the presence of mutant huntingtin, CBP is 
depleted and/or recruited into huntingtin aggregates, leading to histone hypoacetylation 
and inhibition of CBP-mediated transcription (Jiang et al., 2006). Furthermore, CRE-
mediated transcription is also regulated by TAFII130, which is part of the basal 
transcriptional machinery and can abnormally interact with mutant huntingtin, rendering 
the transcriptional complex ineffective (Dunah et al., 2002). 
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Sp1 is a regulatory protein that binds to guanine–cytosine boxes and mediates 
transcription through its glutamine-rich activation domains which target components of 
the basal transcriptional complex, such as TAFII130. Sequestration of Sp1 and TAFII130 
into NIIs leads to the inhibition of Sp1-mediated transcription (Dunah et al., 2002). 
Furthermore, it has also been shown that, despite normal protein levels and nuclear 
binding activity, the binding of Sp1 to specific promoters of susceptible genes is 
significantly decreased in transgenic HD mouse brains, striatal HD cells and human HD 
brains, suggesting that mutant huntingtin dissociates Sp1 from target promoters, 
inhibiting the transcription of specific genes (Chen-Plotkin et al., 2006). Furthermore, it 
was also shown that shorter N-terminal huntingtin fragments, which are more prone to 
misfold and aggregate, are more competent to bind and inhibit Sp1. Interestingly, this 
effect was reversed in vitro by HSP40, a molecular chaperone that reduces the 
misfolding of mutant huntingtin (Cornett et al., 2006). 
On the other hand, mutant huntingtin may also lose the ability to bind and interact with 
other transcription factors regulated by wild-type huntingtin, as is the case of the NRSE-
binding transcription factors. In this particular case, the failure of mutant huntingtin to 
interact with REST/NRSF in the cytoplasm leads to its nuclear accumulation, where it 
binds to NRSE sequences and promotes histone deacetylation, leading to the 
remodeling of the chromatin into a closed structure. As a result, there is a suppression of 
NRSE-containing genes, including the BDNF gene (Zuccato et al., 2003). This is one 
case where the loss of the normal huntingtin function can have profound effects, leading 
to decreased levels of BDNF, an important survival factor for striatal neurons. Indeed, 
BDNF-knockout models were recently shown to largely recapitulate the expression 
profiling of human HD, suggesting that striatal medium-sized spiny neurons suffer 
similar insults in HD and BDNF-deprived environments. 
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More recently, expression of mutant huntingtin has been shown to down-regulate the 
expression of the peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) 
Weydt et al., 2006), a transcriptional coactivator that regulates several metabolic 
processes, including mitochondrial biogenesis and respiration, processes that have been 
shown to be deregulated in both animal models and patients with HD. Interestingly, 
decreased expression of PGC-1α was observed in medium-sized spiny neurons, largely 
affected in HD,  whereas striatal interneurons showed increased mRNA levels for PGC-
1α which could, at least partially, explain the different vulnerability of these striatal 
neuronal populations (Weydt et al., 2006). 
The formation of neuropil aggregates of mutant huntingtin has led to the hypothesis that 
axonal transport may be impaired in HD. Indeed, it is believed that normal huntingtin 
can play a role during axonal transport, perhaps via association with HAP1, promoting 
both retrograde and anterograde transport. The expanded polyglutamine tract may 
inhibit this function, compromising the bidirectional transport of different cargoes along 
the axons, further implicating the loss of wild-type huntingtin function in HD 
(Gunawardena and Goldstein, 2005). In fact, mutant huntingtin appears to be 
responsible for altering the wild-type huntingtin/HAP1/p150 complex, causing an 
impaired association between motor proteins and microtubules, and attenuating BDNF 
transport, which results in loss of neurotrophic support. 
Alternatively, aggregates may physically block transport within narrow axonal 
terminals (Gunawardena and Goldstein, 2005). Indeed, dystrophic striatal and 
corticostriatal neurites in HD brains exhibit several characteristics of blocked axons, 
such as accumulation of vesicles and organelles in swollen axonal projections and 
multiple huntingtin aggregates. Interestingly, the appearance of striatal axonal 
inclusions are better correlated with striatal neuronal loss than the formation of NIIs 
(Gunawardena and Goldstein, 2005). 
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A direct consequence of impaired axonal transport is disruption of neuronal synaptic 
transmission. Specifically, this may occur by the depletion of synaptic vesicles and 
proteins involved in vesicle recycling and receptor endocytosis from the nerve 
terminals. 
Moreover, a number of studies suggest that mutant huntingtin can lead to synaptic 
dysfunction by altering the availability of various synaptic proteins (Smith et al., 2005). 
Examples include a progressive depletion of complexin II, a protein that regulates the 
fusion of synaptic vesicles with the presynaptic plasma membrane and a decrease in the 
SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein 
synaptobrevin-2, and the G protein rabphilin 3A in the HD striatum. A depletion of 
PACSIN 1/syndapin (a neurospecific phosphoprotein involved in receptor recycling) in 
synapses, due to its interaction with the mutant huntingtin SH3 domains, has been also 
demonstrated. These effects may result from a direct abnormal interaction between the 
mutant protein and some of the synaptic protein, which may lead to their sequestration 
in huntingtin inclusions. Alternatively, they may represent a consequence of the altered 
gene transcription, which may cause the down-regulation of some of these synaptic 
proteins. 
Furthermore, wild-type huntingtin interacts with various vesicle proteins that are 
important for endocytosis. These interactions may be impaired in the presence of the 
mutation, thus compromising the synaptic process, which emphasizes the importance of 
the loss of wild-type huntingtin function (Li et al., 2003). 
Mutant huntingtin can also induce synaptic dysfunction by disrupting the expression 
and activity of several pre- and postsynaptic neurotransmitter receptors. In agreement, it 
was found that some Huntington’ disease mice model (R6/2) striatal neurons contain 
constitutively abnormal NMDA receptors that display increased responses to NMDA 
and a decreased Mg2+ sensitivity (Starling et al., 2005). These changes were detected as 
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early as 2 weeks of age. On the other hand, a significant decrease in the percentage of 
R6/2 striatal neurons expressing the NMDA subunit NR2A was also detected at an early 
stage. This decrease was not associated with any significant change in the expression of 
NR1 or NR2B and seemed to be more pronounced in enkephalin-containing neurons. 
Furthermore, the mRNA and protein levels of the metabotropic glutamate receptors 
(mGluR)1, 2 and 3 were found to be reduced in R6/2 mice. Importantly, mGluR2 is a 
presynaptic receptor that regulates glutamate release. Therefore, a reduction in this 
receptor can lead to an increased release of glutamate due to a decreased feedback 
control, thus contributing to excitotoxicity. 
 
Mechanisms of neurodegeneration 
Over the course of HD, intracellular dysfunction induced by mutant huntingtin 
progressively leads to the degeneration of important neuronal pathways and cell loss in 
the striatum, select layers of the cerebral cortex, and other brain regions. Although not 
necessarily a direct result of the mutant protein, various mechanisms such as 
excitotoxicity, dopamine toxicity, metabolic impairment, mitochondrial dysfunction, 
oxidative stress, apoptosis and autophagy have been implicated in HD pathology. Many 
of these mechanisms may slowly develop over time, becoming increasingly pronounced 
by the late stages of the disease. Moreover, they are not mutually exclusive and are 
likely to occur in parallel and promote each other, ultimately culminating in neuronal 
loss (Gil and Rego, 2008). 
Pioneering studies have shown that intrastriatal injections of the NMDA agonist 
quinolinic acid (QA) induce selective neuronal loss both in rats and in primates 
resembling the pattern of striatal cell death observed in the human HD condition 
(Ferrante et al., 1993). However, these results have been disputed and others have 
shown that QA-induced striatal cell death does not spare medium-sized aspiny neurons, 
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as is the case in the human HD brain. With the generation of transgenic rodent models 
of the disease, a unique opportunity was established to assess the influence of expanded 
polyglutamine tracts on the susceptibility of striatal neurons to excitotoxicity in vivo. 
However, results ranging from an increased susceptibility to an excitotoxic insult to a 
complete resistance to excitotoxicity were reported (Morton and Leavens, 2000). This 
discrepancy seams to be related with the different transgenic models used in different 
studies and particularly with the size of the transgene that they express. Thus, transgenic 
mice expressing a huntingtin fragment that corresponds to 3% of the total gene (the 
R6/1 and R6/2 mice) are resistant to KA- or QA-induced excitotoxicity and transgenic 
rodents expressing 20–30% of the full-length mutant huntingtin respond normally to 
such insults, whereas transgenic mice expressing the full-length gene (the YAC mice) 
show an increased susceptibility to excitotoxicity (Gil and Rego, 2008). Although the 
mechanism responsible for the observed resistance of R6/1 and R6/2 mice to excitotoxic 
insults is not fully understood, it does not appear to be the result of a reduction in the 
number of NMDA receptors or a decreased receptor-mediated influx of Ca2+. It is 
possible that a reduction in the excitatory input to the striatum observed in older R6/2 
mice could contribute to this resistance. Moreover, the frequency of spontaneous 
GABAergic synaptic currents and the expression of the ubiquitous α1 subunit of 
GABA(A) receptors were shown to be significantly increased in medium-sized spiny 
projection neurons from symptomatic R6/2 and R6/1 mice (Cepeda et al., 2004). These 
alterations in inhibitory synaptic input can potentially provide a neuroprotective 
mechanism to counteract excitotoxicity in these transgenic mice. Alternatively, the 
resistance phenomenon may be similar to pre-conditioning, as observed with ischemia, 
where permanent exposure to low levels of excitotoxicity and to changes in intracellular 
Ca2+ homeostasis allows neurons to adapt to an even greater excitotoxic insult and 
sudden increase in intracellular Ca2+ concentration. Accordingly, while corticostriatal 
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brain slices from pre-symptomatic R6/2 mice showed an increased sensitivity to an 
ischemic insult (oxygen and glucose deprivation), slices derived from symptomatic and 
late-stage R6/2 mice were shown to be resistant to ischemia (Klapstein and Levine, 
2005). 
Despite these controversial results, the striatum receives excitatory glutamatergic inputs 
from the entire cerebral cortex and the selective vulnerability displayed by striatal 
neurons in HD may be due to the vast glutamatergic inputs they receive and/or the 
particular types of glutamate receptors expressed in these cells. Thus, striatal 
interneurons, which are less affected in HD, have fewer excitatory inputs than striatal 
projection neurons. Moreover, most medium-sized spiny GABAergic projection 
neurons express high levels of the NMDA receptor NR2B subunit, which increases the 
receptor channel permeability and determines its sensitivity to glycine and to Mg2+ 
blockage, and the channel deactivation time. Correspondingly, the spared interneurons 
express much lower levels of this subunit, which probably confers on them a higher 
threshold for activation (Sieradzan and Mann, 2001). In agreement with this hypothesis, 
in vitro studies have shown that coexpression of mutant huntingtin and the NMDA 
receptor subunits NR1A and NR2B enhances excitotoxic cell death with apoptotic 
features. Furthermore, polyglutamine expansion interferes with the ability of wild-type 
huntingtin to interact with PSD-95, resulting in the sensitization of NMDA receptors 
and promoting glutamate-mediated excitotoxicity (Sun et al., 2001). Mutant huntingtin 
can also increase tyrosine phosphorylation of NMDA receptors, further promoting their 
sensitization. Finally, mGluR5 is greatly expressed in the postsynaptic membranes of 
striatal projection neurons. The activation of these facilitatory receptors enhances the 
responses of NMDA receptors to glutamate activation, contributing to excitotoxicity 
(Vonsattel and DiFiglia, 1998). The involvement of mGluR5 and NR2B glutamate 
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receptors in mutant huntingtin-induced excitotoxicity and cell death has also been 
confirmed in striatal medium spiny neurons from YAC mice (Tang et al., 2003). 
Another factor that can contribute to the vulnerability of striatal neurons to 
excitotoxicity is the capacity of the surrounding glial cells to remove extracellular 
glutamate from the synaptic cleft. In agreement, a decrease in the mRNA levels of the 
major astroglial glutamate transporter (GLT1) and the enzyme glutamine synthetase 
were detected in the striatum and cortex of R6/1 and R6/2 mice. These changes in 
expression were accompanied by a concomitant decrease in glutamate uptake and could 
be detected before any other evidence of neurodegeneration, suggesting that a defect in 
astrocytic glutamate uptake is an early event in HD (Liévens et al., 2001). Furthermore, 
it was recently reported that mutant huntingtin accumulates in the nucleus of glial cells 
in HD brains, decreasing the expression of the glutamate transporter. Moreover, while 
wild-type glial cells protected neurons against mutant huntingtin-mediated 
neurotoxicity, glial cells expressing mutant huntingtin increased mutant huntingtin-
induced neuronal vulnerability, suggesting that a decrease in glutamate uptake by glial 
cells may indeed exacerbate neuronal excitotoxicity in HD (Shin et al., 2005). 
It is also important to note that activation of pathways that lead to the production of 
excitotoxins in the brain is likely to have an impact in HD. Indeed, recent studies have 
reported an increase in the endogenous levels of the NMDA-receptor agonist QA (a 
product of tryptophan degradation generated along the kynurenine pathway) and of its 
bioprecursor, the free radical generator 3-hydroxykynurenine (3-HK) in the striatum and 
cortex of early stage HD patients. 3-HK levels were also significantly and selectively 
elevated in the striatum, cortex and cerebellum of R6/2 mice starting at 4 weeks of age, 
while both 3-HK and QA levels were increased in the striatum and cortex of full-length 
HD mouse models (YAC128, Hdh92 and Hdh111) at later stages (Guidetti et al., 2006). 
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These results suggest that an increased generation of QA may contribute, at least in part, 
to excitotoxicity in HD and that inhibition of this pathway may have beneficial effects. 
Dysfunctional cortical glutamatergic neurons may cause a sustained glutamate 
stimulation of the vulnerable striatal neuronal populations. In agreement, striatal 
neurons from HD mice expressing one-third of the full-length huntingtin gene with 100 
CAG repeats (HD100) displayed altered responses to cortical stimulation and to 
activation by NMDA, and multiple perturbations in corticostriatal synaptic function 
were recently observed in mice expressing the full-length human huntingtin gene with 
either 72 (YAC72) or 128 (YAC128) CAG repeats (Milnerwood and Raymond, 2007). 
Under conditions of chronic activation of NMDA receptors the intracellular Ca2+ 
concentration increases, which can have deleterious consequences including 
mitochondrial dysfunction, activation of the Ca2+-dependent neuronal isoform of nitric 
oxide (NO) synthase (nNOS), generation of NO and other reactive oxygen species 
(ROS), activation of Ca2+-dependent proteases such as calpains, and apoptosis (Rego 
and Oliveira, 2003). Importantly, mutant huntingtin can also sensitize the inositol 
(1,4,5)-triphosphate receptor type 1 (InsP3R1) located in the membrane of the 
endoplasmic reticulum, promoting a further increase in intracellular Ca2+ (Tang et al., 
2003). Collectively, these events can contribute to the progressive neurodegeneration 
observed in the HD striatum. Accordingly, surgical decortication (lesion of the 
corticostriatal pathway) was recently shown to extend the survival and improve the 
behavioral, neuropathological and biochemical phenotype of R6/2 transgenic mice by 
significantly lowering striatal glutamate levels (Stack et al., 2007). 
Neuroimaging analysis of human HD brains revealed cortical sensorimotor 
degeneration early in the disease, while microarray analysis found expression changes 
in the motor cortex but almost no changes in the frontal cortex or cerebellum, further 
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suggesting that a cortical dysfunction contributes to the human condition (Hodges et al., 
2006). 
The striatum also receives dopaminergic input from the substantia nigra pars compacta, 
also implicating this pathway in the selective striatal degeneration observed in HD. In 
support of this, several studies have shown degeneration of nigrostriatal projections, an 
atrophy of dopaminergic neurons in the substantia nigra and a striking reduction in the 
dopaminergic striatal neuronal population in HD brains (Gil and Rego, 2008). 
Aggregates of mutant huntingtin were also found in this brain region. Furthermore, a 
marked loss of tyrosine hydroxylase (the rate-limiting enzyme for dopamine 
biosynthesis) and a down-regulation of the DA transporter and the D1 and D2 dopamine 
receptors occurs in HD brains  and R6/2 mice, probably due to altered gene 
transcription induced by mutant huntingtin (Gil and Rego, 2008). Interestingly, it was 
previously suggested that loss of D2 dopamine receptors is a sensitive indicator of early 
neuronal impairment in preclinical carriers of the HD mutation (van Oostrom et al., 
2005). Overall, these results suggest that both a presynaptic and a postsynaptic 
impairment may contribute to a dysfunctional nigrostriatal pathway. 
The nigrostriatal dysfunction may be involved in causing the motor and cognitive 
deficits occurring in HD. Loss of both pre- and postsynaptic markers of dopamine 
neurotransmission is positively correlated with cognitive performance in asymptomatic 
and symptomatic HD patients (Bäckman and Farde, 2001). Furthermore, late stages of 
the disease are normally characterized by bradykinesia and rigidity, symptoms that may 
be directly caused by the progressive loss of dopamine receptors in the striatum. 
In vitro and in vivo studies have also shown that dopamine itself can enhance 
polyglutamine toxicity. Using primary cultures of striatal neurons transiently expressing 
exon 1 of mutant huntingtin, it has been shown that low doses of dopamine act 
synergistically with mutant huntingtin to activate the proapoptotic transcription factor c-
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Jun through a mechanism that is thought to involve the production of ROS and the 
activation of the c-Jun N-terminal kinase pathway. Importantly, dopamine also 
increased aggregate formation in this in vitro model, which could be reversed by a 
selective D2 receptor antagonist (Charvin et al., 2005). In another recent study, double-
mutant mice (generated by crossing the dopamine transporter knockout mouse with a 
knock-in HD mouse model expressing huntingtin with 92 CAG repeats) exhibited 
increased stereotypic activity at 6 months of age, followed by a progressive decline of 
their locomotor hyperactivity. In this hyperdopaminergic mouse model of HD the 
appearance of NIIs and neuropil aggregates was shown to occur much earlier and to a 
greater extent in the striatum and other dopaminergic brain regions as compared to 
control HD mice (Cyr et al., 2006). Thus, based on the results from these studies, it is 
reasonable to conclude that dopamine exacerbates mutant huntingtin aggregation both in 
vitro and in vivo, although the relationship between dopamine-mediated aggregation and 
striatal neurodegeneration needs to be clarified. 
Importantly, dopamine itself can be a source of ROS and a trigger of oxidative stress. 
Under normal conditions, the enzyme monoamino oxidase converts dopamine into 3,4-
dihydrophenylacetic acid (DOPAC) and hydrogen peroxide (H2O2). However, 
dopamine can also undergo a nonenzymatic process of auto-oxidation producing 
dopamine quinones and H2O2, and a dopamine semiquinone and superoxide (O2−). H2O2 
and O2− can be further oxidized, respectively, through the Fenton (in the presence of 
transition metal ions) and the Haber–Weiss reactions, producing the extremely reactive 
hydroxyl radical. 
It was recently shown that glutamate and DA signaling pathways may act 
synergistically to induce elevated Ca2+ signals and to cause the degeneration of medium 
spiny neurons in YAC128 (Tang et al., 2007). 
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Thus, the intracellular dysfunction of neurons (and glia) induced by mutant huntingtin 
results in the dysfunction of neuronal interactions and circuits. These dysfunctional 
cell–cell interactions will in turn exacerbate the dysfunction of individual neurons, thus 
forming a positive feedback loop that will ultimately culminate in cell death. 
Studies in HD patients and HD post-mortem tissue have shown the following. (i) A 
significant decrease in glucose uptake (consumption) in the cortex (frontal and temporal 
lobes) and striatum (caudate and putamen) of both pre-symptomatic and symptomatic 
HD patients (Ciarmiello et al., 2006). (ii) A significant reduction in aconitase activity in 
the striatum (caudate and putamen) and cerebral cortex. Aconitase is an iron- and sulfur-
containing enzyme of the tricarboxylic acid cycle and is thought to be particularly 
sensitive to inhibition by peroxinitrate (ONOO−) and O2−. Thus, a reduction in its 
activity can be interpreted as an indirect indicator of ROS generation, mitochondrial 
dysfunction and excitotoxicity (Tabrizi et al., 1999). (iii) A significant decrease in the 
activities of mitochondrial complexes II–III and IV in the striatum. Contradictory 
results have also been published regarding the activity of mitochondrial complex I in 
HD platelets, with an initial study showing a striking reduction in the activity of this 
complex, and subsequent studies reporting no deficiencies in platelet mitochondrial 
function (Powers et al., 2007). Similarly, analysis of mitochondrial dysfunction in 
muscle from HD carriers revealed a defect of complex I, but in a more recent study no 
significant differences in the activities of complexes I and IV were found, although 
changes in the activity of complexs II–III were correlated with disease duration (Turner 
et al., 2007). (iv) An increase in lactate concentrations in the striatum and cerebral 
cortex (Koroshetz et al., 1997). (v) An increase in lactate/pyruvate ratio in the 
cerebrospinal fluid (Koroshetz et al., 1997). (vi) A reduced phosphocreatine/inorganic 
phosphate ratio in skeletal muscle and a significant delay in the recovery of 
phosphocreatine levels after exercise (a direct measure of ATP synthesis) in HD patients 
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and mutation carriers (Saft et al., 2005). (vii) Decreased mitochondrial ATP generation 
(Seong et al., 2005). (viii) Morphological and morphometric changes, as well as 
decreased membrane potential in mitochondria from lymphoblasts of both heterozygous 
and homozygous  HD patients (Squitieri et al., 2006). (ix) Depletion of mitochondrial 
DNA in leukocytes from HD patients (Liu et al., 2008). 
Interestingly, mutant huntingtin was also shown to disrupt mitochondrial-dependent 
Ca2+ handling, an effect that is ameliorated upon treatment with histone deacetylase 
inhibitors (Oliveira et al., 2006). On the other hand, mutant huntingtin can affect 
mitochondrial function by inhibiting the expression of PGC-1α (Weydt et al., 2006). 
Mutant huntingtin suppresses the activity of the promotor of the uncoupling protein-1 
(UCP-1, the effector of adaptive thermogenesis) gene, an effect that can be reversed by 
PGC-1α (Weydt et al., 2006). Moreover, reduced expression of PGC-1α target genes in 
HD is related to impaired ATP production and a reduction in intact mitochondria, 
linking transcriptional deregulation and mitochondrial dysfunction in HD (Weydt et al., 
2006). Importantly, crossbreeding of PGC-1α-knockout mice with HD knock-in mice 
exacerbates striatal neurodegeneration and motor abnormalities in the double-mutant 
mice, while lentiviral-mediated delivery of PGC-1α into the striatum of R6/2 mice has 
neuroprotective effects (Cui et al., 2006). Moreover, resveratrol, an activator of sirtuin 
Sir2 homolog 1 (SIRT1) was shown to modulate the SIRT1–PGC-1α pathway and to 
have a neuroprotective effect against mutant huntingtin-induced metabolic dysfunction 
(Parker et al., 2005). Indeed, SIRT1 functionally interacts with and deacetylates PGC-
1α in vitro and in vivo, thus regulating energy and metabolic homeostasis. This may 
have some implications in the search for new HD therapeutic targets, as molecules that 
activate PGC-1α may be valuable in promoting mitochondrial function and striatal 
survival. 
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Taken together, these reports implicate mitochondrial dysfunction and metabolic 
impairment in HD pathology. Whether these energy deficits occur early on during the 
disease progression is still uncertain. 
Systemic administration of the toxin 3-nitropropionic acid (3-NP; an irreversible 
inhibitor of mitochondrial complex II) has been largely shown to cause striatal 
neurodegeneration in rats and primates. Intrastriatal injection of this toxin  or malonate 
(a reversible mitochondrial complex II inhibitor) in rats also leads to striatal neuronal 
loss, further implicating mitochondrial dysfunction in HD. Striatal neurodegeneration 
induced by 3-NP appears to be related to the early expression and activation of matrix 
metalloproteinase-9 by ROS which can digest the endothelial basal lamina, leading to 
the disruption of the blood–brain barrier and to progressive striatal damage (Kim et al., 
2003). Excitotoxicity and dopamine toxicity were previously shown to modulate the 
striatal degeneration induced by 3-NP, supporting the idea that this mitochondrial toxin 
and mutant huntingtin may have certain degeneration mechanisms in common.  
Mitochondria are also central players in the process of caspase activation and apoptosis. 
3-NP causes mitochondrial-dependent apoptotic neuronal death through the release of 
cytochrome c and consequent activation of caspases, or the release of apoptosis-
inducing factor (Almeida et al., 2006). Experiments performed with HD lymphoblasts 
demonstrated that these HD cells show a robust mitochondrial membrane depolarization 
when exposed to weak stress conditions whereas myoblasts from presymptomatic and 
symptomatic HD subjects show mitochondrial depolarization, cytochrome c release, 
increased caspase-3, -8 and -9 activities, and defective cell differentiation (Ciammola 
et al., 2006). Furthermore, it was demonstrated that huntingtin associates with the outer 
mitochondrial membrane and that a truncated mutant huntingtin fragment can directly 
induce the opening of the mitochondrial permeability transition pore (MPTP) in isolated 
mouse liver mitochondria, an effect that was accompanied by a significant release of 
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cytochrome c (Choo et al., 2004). Cytochrome c leads to caspase activation which in 
turn can cleave mutant huntingtin and promote its translocation into the nucleus, where 
it abnormally interacts with several transcription factors. Importantly, p53, a 
transcription factor that regulates the expression of various mitochondrial proteins such 
as Bax, interacts with mutant huntingtin both in HD lymphoblasts and in neuronal cells 
expressing mutant huntingtin. In neuronal cultures, mutant huntingtin induces an 
upregulation of the nuclear levels of p53 and an increase in its activity. Interestingly, 
p53 levels are also increased both in HD transgenic mice and in HD patients, and 
genetic deletion of p53 suppresses neurodegeneration in HD transgenic flies and 
neurobehavioral abnormalities of HD transgenic mice (Bae et al., 2005). Thus, it is 
likely that mutant huntingtin-induced increase in p53 activity induces further 
mitochondrial abnormalities that contribute to HD. 
Importantly, mitochondrial dysfunction is also the major contributor to oxidative stress 
which, along with the excitotoxic activation of nNOS and the metabolism of dopamine, 
can lead to a toxic increase in the levels of ROS. Susceptible neurons, as in the case of 
HD, may not be able to handle well an increase in ROS production. High ROS levels 
may promote intracellular cascades of oxidative stress by oxidizing proteins and DNA 
and triggering lipid peroxidation. Therefore, it is reasonable to speculate that oxidative 
stress might play a crucial role in the neurodegenerative process of HD. In support of 
this hypothesis, several studies have shown an altered pattern of expression and activity 
of the enzyme nitric oxide synthase (NOS), as well as of the antioxidants superoxide 
dismutase (SOD) and ascorbate in R6/1 and R6/2 transgenic mice respectively. 
Furthermore, ROS production is increased in the striatum of R6/1 mice. Moreover, it 
has been suggested that NO generation is the underlying cause of the observed 
inhibition of aconitase in human HD brains. These authors suggest that aconitase 
inhibition is then followed by the inhibition of complex II–III and the initiation of a 
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self-amplifying cycle of ROS generation that results in severe ATP depletion and cell 
death (Tabrizi et al., 1999). Evidence of oxidative damage has been detected in 
peripheral tissues of human HD patients, including increased leukocyte levels of 8-
hydroxydeoxyguanosine (8-OHdG), increased plasma levels of malondialdehyde, 
decreased activities of the antioxidant enzymes Cu–Zn-superoxide dismutase (SOD1) 
and glutathione peroxidase (GPx) in erythrocytes, and a decreased catalase activity in 
skin fibroblasts (Chen et al., 2007). In addition, mitochondrial-dependent generation of 
ROS in HD seems to be due, at least in part, to suppression of PGC-1α in the presence 
of mutant huntingtin, as this transcription coactivator is required for the induction of 
ROS-detoxifying enzymes, namely Mn-superoxide dismutase (SOD2) and GPx, 
implicating PGC-1α as an important protector against oxidative damage in HD. 
There is strong evidence suggesting that aging is associated with poor handling of ROS 
by neuronal cells (Lu et al., 2004). Thus aging might, at least in part, increase mutant 
huntingtin toxicity through increased oxidative stress. 
 Mutant huntingtin is a substrate for several caspases and calpains, which are believed to 
mediate the formation of the toxic N-terminal fragments. Moreover, sequestration of 
pro-caspases in the aggregates is thought to promote their activation, thus promoting an 
intracellular cascade of proteolytic events. Furthermore, calpain, caspase-1 and caspase-
8 activity is increased in HD brains (Gil and Rego, 2008). These findings have led to the 
hypothesis that an apoptotic mechanism is responsible for HD neuronal loss. Indeed, 
early studies identified apoptotic-like cells in the HD striatum with terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL). However, 
some of these studies failed to detect the characteristic pattern of DNA laddering after 
DNA electrophoresis that is typically observed in cells undergoing apoptosis (Portera-
Cailliau et al., 1995). Thus, although the authors concluded that the presence of 
TUNEL-positive cells in the HD striatum strongly suggests the occurrence of apoptosis, 
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the lack of the characteristic pattern of apoptotic DNA fragmentation argues against it. 
Furthermore, the detection of activated astrocytes in HD brains suggests 
neuroinflammation, which is generally absent in apoptotic conditions. Therefore, the 
evidence for a pure apoptotic process contributing to HD cell death is controversial. 
Nevertheless, the activation of certain apoptotic pathways is likely to contribute to some 
degree to HD pathology (Hickey and Chesselet, 2003). 
Some evidence suggests that autophagy may mediate cell loss in HD. HD brains display 
endosomal and/or lysosomal organelles, multivesicular bodies and lipofuscin 
accumulation reminiscent of autophagy (Sapp et al., 1999). Moreover, several studies 
have shown that expression of mutant huntingtin induces endosomal and/or lysosomal 
activity and sequestration of the mammalian target of rapamycin (mTOR; a protein 
kinase involved in the regulation of autophagy) into the aggregates of mutant huntingtin 
with subsequent inhibition of its kinase activity. These events lead to autophagy, which 
in turn may promote huntingtin degradation and the clearance of aggregates. Within this 
scenario, it was recently shown that rapamycin and several small-molecule enhancers of 
rapamycin, which seem to act either independently or downstream of the target of 
rapamycin, are able to enhance the clearance of mutant huntingtin fragments and 
attenuate their toxicity in various HD models. Moreover, clearance of accumulated 
mutant exon 1 huntingtin is also triggered by the activation of the insulin signaling 
pathway, despite the activation of Akt, mTOR and S6 kinase, in a process requiring 
Beclin1 and hVps34, two proteins implicated in macroautophagy, the latter a class III 
phosphatidylinositol 3-kinase (Yamamoto et al., 2006). 
Hence, autophagy may represent an initial attempt of the HD cell to eliminate the 
mutant protein that over the course of the disease becomes overloaded, insufficient and 
dysfunctional, eventually resulting in cell degradation. Indeed, the lysosomal proteases 
cathepsins D, B and L were recently shown to promote the generation and accumulation 
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of mutant huntingtin fragments (Kim et al., 2006). Furthermore, sequestration of Beclin 
1 into NIIs might reduce the autophagic clearance of mutant huntingtin. Finally, some 
evidence suggests that molecular determinants of autophagic vacuole formation are 
more easily recruited to cytoplasmic than to nuclear aggregates, which could help to 
explain the toxicity of nuclear inclusions in HD (Iwata et al., 2005). 
 
TREATMENT OF HUNTINGTON’S DISEASE 
Despite the extraordinary growth of knowledge about the cellular mechanisms involved 
in HD-related neurodegeneration, no effective neuroprotective or disease-modifying 
therapy has emerged. The selection of the most appropriate symptomatic treatment 
depends on the most dominant or troublesome symptom. Patients with HD may exhibit 
a variety of movement disorders, with the most common being chorea, but also 
parkinsonism (characteristic of juvenile HD), ataxia, dystonia, bruxism, myoclonus, 
tics, and tourettism. The psychiatric, behavioral, and cognitive manifestations of the 
disease are also very debilitating, rendering the patient dependent on others. These 
include irritability, depression, lack of motivation, paranoia, hallucinations, and 
cognitive and intellectual decline. Other contributing symptoms to the overall disability 
are dysphagia, weight loss, dysarthria, and sleep disturbance. Several clinical rating 
scales have been developed and validated, and have been used extensively in clinical 
trials to ensure a uniform assessment of outcomes. The Unified Huntington’s Disease 
Rating Scale (UHDRS), developed by the Huntington Study Group (HSG), comprises 
several subscales that assess motor function, cognition, behavior, functional status, and 
independence (Huntington study group, 1996). The Abnormal Involuntary Movement 
Scale (AIMS) uses a rating of 0 (no movement) to 4 (severe) to quantify abnormal 
movements. Scores are attributed separately for abnormal movements affecting the 
muscles of facial expression, lips and perioral area, jaw, tongue, upper extremities, 
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lower extremities, and trunk. The scale also incorporates other items, related to the 
patient’s awareness of and disability caused by the abnormal movements, and the 
presence of dentures or edentia. The functional status of HD patients is commonly 
assessed using the Total Functional Capacity Scale (TFC) and the Independence Scale 
(IS), both of which are incorporated into the UHDRS.  
Because neuroprotective treatments remain elusive, improving the quality of life of HD 
patients is a priority. Traditionally, neuroleptics and dopamine depleters have been the 
cornerstone of symptomatic therapy in HD (Adam and Jankovic, 2008). The atypical 
neuroleptics tend to be used more frequently in the treatment of HD. Their advantage 
over the typical neuroleptics is a diminished incidence of the adverse effects familiar in 
movement disorders (acute dystonia, akathisia, parkinsonism, tardive dyskinesia). The 
atypical neuroleptics are not necessarily more effective, however, and they may cause 
more weight gain and other metabolic side effects (e.g., dyslipidemia, increased insulin 
resistance), resulting in a similar treatment discontinuation rate10 as with typical 
neuroleptics. Typical neuroleptics, including haloperidol, pimozide, fluphenazine, 
thioridazine, sulpiride, and tiapride, have been used for the treatment of psychotic 
symptoms as well as chorea in HD (Adam and Jankovic, 2008). These drugs have a 
high affinity for D2 dopamine receptors, however, and can potentially induce 
parkinsonism, akathisia, acute dystonias, and tardive dyskinesia. Several other classes 
of medications have been used to ameliorate the various symptoms of HD, including 
antidepressants, antiglutamatergic drugs, GABA agonists, antiepileptic medications, 
acetylcholinesterase inhibitors, and botulinum toxin. Recently, surgical approaches 
including pallidotomy, deep brain stimulation, and fetal cell transplants have been used 
for the symptomatic treatment of HD. The selected therapy must be customized to the 
needs of each patient, minimizing the potential adverse effects (Adam and Jankovic, 
2008). 
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FRIEDREICH’S ATAXIA 
Friedreich’s ataxia (FRDA) was first reported in 1863 by Nicholaus Friedreich in 
Heidelberg, Germany. He described the essential findings of the disease: degenerative 
atrophy of the posterior columns of the spinal cord leading to progressive ataxia, 
sensory loss, and muscle weakness, often associated with scoliosis, foot deformity, and 
heart disease. Although it was initially reported more than 150 years ago, the complete 
clinical spectrum of FRDA and the features that distinguished this disease from other 
ataxia syndromes have been controversial. The Québec Collaborative Group in 1976 
(Geoffreoy et al., 1976) and Harding in 1981 (Harding et al., 1981) defined the essential 
clinical criteria for diagnosis of FRDA. 
The FRDA gene was localized to chromosome 9q, and the most common mutation was 
defined as an unstable expansion of a GAA trinucleotide repeat sequence. Since this 
discovery, the molecular diagnosis of atypical cases has become possible and the 
phenotypic spectrum of FRDA has been broadened (Pandolfo M, 2002). FRDA is the 
most common hereditary ataxia. It is an autosomal-recessive neurodegenerative disorder 
with an estimated prevalence of 1:50000 (Delatycki et al., 2000). 
Progressive, unremitting ataxia is the principal feature of this disease. Most commonly, 
it begins with clumsiness in gait. The onset is usually around puberty, but it may vary 
from 2-3 years of age to later than 25 years of age (Pandolfo M, 2002). The essential 
clinical features are autosomal-recessive inheritance, onset before 25 years of age, 
progressive limb and gait ataxia, absent tendon reflexes in the lower extremities, 
electrophysiologic evidence of axonal sensory neuropathy followed by (within 5 years 
of onset), dysarthria, areflexia at all four limbs, distal loss of position and vibration 
sense, extensor plantar response, and pyramidal weakness of the legs (Alper and 
Narayanan, 2003). Loss of ambulation occurs on average 15.5 ± 7.4 years after disease 
onset (Delatycki et al., 2000). Cardiomyopathy is the most common cause of death. 
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Patients who exhibit all these clinical features listed by Harding are considered to have 
the “typical” or “classic” form of the disease. 
As with age of onset, there is a great variability in other clinical features, including the 
rate of the progression, severity, and extent of the disease involvement. Cardiac 
complications may be severe enough to cause early death or may be minimal or absent. 
Other variable neurologic findings include oculomotor abnormalities, nystagmus, optic 
atrophy, and sensorineural hearing loss (Pandolfo M, 2002). The most common 
abnormality of ocular movement is fixation instability. Ophthalmoparesis is not 
observed. More than half the patients manifest progressive scoliosis, and about half 
manifest pes cavus, pes equinovarus, and clawing of the toes (Harding et al., 1981). 
Amyotrophy of the small muscles of the hand and distal muscles of the leg and foot is 
common. About 10% of FRDA patients are diabetic, and most diabetic patients require 
insulin therapy. Cardiomyopathy is evident in around two thirds of patients with FRDA 
and is primarily symmetric concentric hypertrophic cardiomyopathy, although some 
patients exhibit asymmetric septal hypertrophy (Alper and Narayanan, 2003).  
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AIM OF THE THESIS 
 
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder 
characterized by progressively worsening chorea, psychiatric disturbances and cognitive 
impairment. The degenerative process primarily involves medium spiny striatal neurons 
and, to a lesser extent, cortical neurons. Of importance, GABAergic enkephalin neurons 
of the basal ganglia are the most vulnerable in HD and their early dysfunction is 
responsible for the development of chorea. HD is caused by the expansion of a 
polymorphic CAG trinucleotide repeat encoding a poly-glutamine tract within a protein 
named huntingtin. The mechanisms responsible for mutant huntingtin pathogenicity are 
still largely unknown. Both gain of function (in which mutant huntingtin has toxic 
properties) and loss of function of normal huntingtin have been proposed. Furthermore, 
it is unknown why the striatal medium spiny neurons are most vulnerable in HD, despite 
ubiquitous expression of mutant and normal huntingtin. 
It is noteworthy that adenosine A2A and dopamine D2 receptors are co-expressed on 
striatal GABAergic enkephalin neurons. In these cells, A2A adenosine receptors 
(A2AARs) stimulate while dopamine D2 receptors inhibit adenylyl cyclase and cAMP 
formation. Adenosine is thought to act as a trigger for development-associated apoptosis 
and, under specific conditions, activation of the A2AARs may result in cell death. 
Conversely, under certain circumstances, A2AARs may mediate trophic effects. 
Dysregulation of A2AAR physiology may thus account for striatal cell loss in HD.  
On this background, the aim of this study is to investigate the role of A2AARs in 
Huntington’s disease. In particular we have evaluated the expression and functionality 
of  the A2AARs in different in vitro and in vivo models of Huntington’s disease as well 
as of other related polyglutamine disease. 
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The aim of the chapter 1 was to investigate if the presence of mutant huntingtin may 
alter A2AAR signaling in striatal cells ST14A. For this aim, the presence and the 
functional responses of A2AAR were evaluated in parental ST14A cells and stable 
subclones expressing either 548 aminoacids N terminal to the protein huntingtin in the 
wild-type (N548wt) or mutant (N548mu) versions, or the full-length wild-type (FLwt) 
and full-length mutant (FLmu). The expression of A2AAR was investigated through 
reverse transcriptase-polymerase chain reaction (RT-PCR) and receptor binding assays. 
The A2AAR is coupled to a stimulatory protein Gs that activate adenylil cyclase with the 
conseguent production of cAMP. In order to evaluate the functionality of A2AAR in 
parental ST14A and in subclones expressing mutant huntingtin, cAMP production 
assays were performed. The basal and forskolin stimulated level of cAMP were 
evaluated in all the striatal cell clones. Furthermore, it was studied the potency of 
typical A2AAR agonists to stimulate the production of cAMP as well as the effect of 
A2AAR antagonist to counteract this stimulation in both parental and huntingtin-
expressing cells. 
The aim of the chapter 2 was to assess the presence of the aberrant A2AARs phenotype 
in the basal ganglia of transgenic R6/2 mice, an animal model of Huntington’s disease 
that express exon 1 of the human huntingtin gene with an expanded CAG repeat length 
of 141-157 under the influence of the human promoter. To study the expression of 
A2AARs, experiment of quantitative real time PCR and receptor binding assays were 
performed in striatal membranes of R6/2 mice at various presymptomatic and 
symptomatic stages. To assess the receptor activity, we performed ex-vivo 
measurements of cAMP production in homogenates from striata in the absence (basal 
activity) or presence of the selective A2AAR agonist CGS 21680, or after direct 
activation of the enzyme with forskolin. 
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The study described in chapter 3 was undertaken to assess the status of the A2AAR in 
peripheral blood cells of HD-affected and non-affected mutation carrier subjects 
compared with control healthy individuals.  
Two strategies were adopted to assess the status of the A2AAR in peripheral cells from 
HD subjects. The first one aimed at measuring the binding kinetic parameters of the 
A2AAR ligand [3H]-ZM 241385 in platelets, lymphocytes and neutrophils of patients 
with Huntington’s disease and non-affected mutation carrier subjects compared with 
control subjects. The second one aimed at assessing the ability of A2AAR agonists to 
stimulate adenylyl cyclase activity and cAMP formation in the blood cells of the three 
group of subjects. 
The aim of the chapter 4 was to extend the analysis of A2AAR activity in patients with 
Huntington’s disease including a more detailed transversal study where different disease 
stages were represented, as well as in a larger number of pre-symptomatic subjects 
enrolled from different clinical sites. In addition, we tested whether the A2AAR 
dysfunction was present in other inherited neurological diseases, such as other 
polyglutamine- (Spinocerebellar Ataxia, SCA, type 1 and 2) or not polyglutamine-
linked (Freidreich Ataxia, FRDA) neurodegenerative disorders. The identification in 
peripheral cells of a measurable significant change in a biological process might 
arguably serve as a useful endpoint to measure the efficacy of therapeutics targeting 
pathological mechanisms initiated by the mutation. 
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CHAPTER 1: 
Aberrant amplification of A2AAR signaling in striatal 
cells expressing mutant huntingtin. 
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INTRODUCTION 
Huntington’s disease (HD) is a dominantly inherited neurodegenerative disorder 
featuring progressive worsening chorea, psychiatric disturbances, and cognitive 
impairment due to brain cell loss, with basal ganglia showing the most dramatic 
morphological abnormalities and degeneration (Ross, 1995). The disease is caused by 
expansion of a polymorphic CAG trinucleotide repeat encoding of a poly-glutamine 
tract in Huntingtin (Htt), a 3154 aminoacids protein with recently described anti-
apoptotic functions. The mechanisms responsible for mutant Htt pathogenicity are still 
largely unknown, but may involve a proteolytic cleavage of the protein to generate 
fragments that aggregate into the nucleus and cytoplasm (Wellington et al., 2000). 
Much less clear is the mechanism by which, despite ubiquitous expression of mutant 
(and normal) Htt in HD patients, selective degeneration of striatal medium spiny 
neurons occurs in the disease. Adenosine agonists induce potent psychomotor 
depression and inhibit the locomotor activity induced by dopamine agonists (Ferrè et 
al., 1993). This adenosine-dopamine interaction mainly depends on a postsynaptic 
A2AAR-D2 receptor interaction in striatum (Ferrè et al., 1993). In this brain area, 
A2AARs are coexpressed with D2 receptors on GABAergic enkephalin neurons, which 
are key components of the “indirect” striatal efferent pathway involved in regulation of 
motor activity, and are highly affected in HD (Reiner et al., 1988). By activating 
A2AARs on these neurons, adenosine acts as a dopamine functional antagonist. It is 
interesting that A2AARs stimulate and D2 receptors inhibit adenylyl cyclase, which 
represents a key target in mediating the opposite effects of these two transmitters (Ferrè 
et al., 1993). Therefore, the possibility remains strong that changes in the adenosine-
dopamine system in striatum play a role in the motor dysfunction typical of HD. It has 
been suggested that adenosine triggers development-associated apoptosis; under 
specific conditions, activation of the A2AARs may result in cell death (Jacobson et al., 
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1999). It may hence be hypothesized that a dysregulation of adenosine-mediated cell 
death, likely due to an alteration of A2AAR expression or function, may contribute to 
neurodegeneration in HD. 
In this part of the study it has been tested the possibility that mutant Htt may alter 
A2AAR signaling in striatal cells expressing mutant Htt. In particular the presence and 
the functionality of A2AARs have been studied through reverse transcriptase-polymerase 
chain reaction, receptor binding assays and cyclic adenosine monophosphate (cAMP) 
assays. 
 
MATERIALS AND METHODS 
Materials 
SCH 58261 and [3H]-SCH 58261 (specific activity 68.6 Ci/mmol) were from the 
Schering-Plough Research Institute, Milan, Italy. [3H]-ZM 241385 (specific activity 17 
Ci/mmol) was from Tocris Cookson Ltd. (Bristol, England). [3H]-cAMP (specific 
activity 21 Ci/mmol) was purchased from the Radiochemical Centre (Amersham, 
Bukinghamshire, England). NECA (5'-Nethylcarboxamidoadenosine), Ro 20-1724, (4-
(3-butoxy-4-methoxybenzyl)-2-imidazolidinone), GTPγS, cAMP, and forskolin were 
from Sigma Chemicals Co. (St. Louis, Mo.). Aquassure and Atomlight were from NEN 
Research Products (Boston, Mass.). All other reagents were of analytical grade and 
obtained from commercial sources. 
 
 
Cell Culture 
Parental ST14A cells and stable subclones expressing either 548 aminoacids N terminal 
to the protein huntingtin in the wild-type (N548wt) or mutant (N548mu) versions, or the 
full-length wild-type (FLwt) and full-length mutant (FLmu) proteins were grown at 
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33°C in the presence of Dulbecco’s modified Eagle medium supplemented with 10% 
fetal bovine serum as previously described (Cattaneo and Conti, 1998). All transfected 
subclones have been previously demonstrated to express the exogenous proteins at 
comparable levels at least up to 25 passages in culture (Rigamonti et al., 2000). 
Expression levels are routinely checked by Western blot in early passaged cells. Cells 
were used when 80% confluence was reached. 
 
Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Total RNA was prepared from cells and tissue using Triazol Reagent (Gibco, BRL, 
Rockville, Md.). Retrotranscription of RNA was performed with SuperScript II (Gibco, 
BRL, Rockville, Md.) according to the instructions of the manufacturer and using 250 
ng of random primers. RNAseOUT (20 U) (Gibco, BRL) was added to each reaction. 
cDNA (0.5 µg) was amplified by PCR using DyNAzyme EXT (Finnzymes) and primers 
specific for the A2AAR (A2AAR Fw: 5’-TGTCCTGGTCCTCACGCAGAG-3’; A2AAR 
Rev: 5’CGGATCCTGTAGGCGTAGATGAAGG-3’). PCR was carried out for 40 
cycles with the following parameters: denaturation at 95°C for 30 s, annealing at 54°C 
for 30 s, extension at 72°C for 7 min. 
 
Receptor binding studies 
Cells were washed with phosphate buffered saline and scraped off T75 flasks in ice-cold 
hypotonic buffer (5 mM Tris HCl, 2 mM EDTA, pH 7.4). The cell suspension was 
homogenized with Polytron, and the homogenate was spun for 10 min at 1,000 g. The 
supernatant, collected in pools from 6 to 8 culture dishes, was then centrifuged for 30 
min at 48,000 g, and each pool was used to perform a single saturation experiment. The 
membrane pellet was resuspended in 50 mM Tris HCl, 120 mM NaCl, 5 mM KCl, 10 
mM MgCl2, and 2 mM CaCl2, pH 7.4, incubated with 2 I.U./ml of adenosine deaminase 
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for 30 min at 37°C and centrifuged for 30 min at 48,000 g. The resulting pellet was 
resuspended at a concentration of 100–150 µg protein/100 µl, and this homogenate was 
used for assaying binding of either [3H]-SCH 58261 (5-amino-7-(phenylethyl)-2- (2-
furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) (Varani et al., 1997) or [3H]-ZM 
241385 (4-(2-[7-amino-2-(2-furyl)[1,2,4] triazolo[2,3a][1,3,5] triazinyl-amino] 
ethyl)phenol). The protein concentration was determined according to a Bio Rad 
method (Bradford, 1976) with bovine serum albumin as a standard reference. Binding 
assays were carried out as previously described (Varani et al., 1997). In saturation 
studies, cell membranes were incubated for 60 min at 4°C with 8–10 different 
concentrations of either [3H]-SCH 58261 or [3H]-ZM 241385 (0.05–10 nM) in a total 
volume of 250 µl containing 50 mM Tris HCl, 120 mM NaCl, 5 mM KCl, 10 mM 
MgCl2, and 2 mM CaCl2, pH 7.4. Nonspecific binding was defined as binding in the 
presence of 10 µM NECA and was about 40% of total binding. Bound and free 
radioactivity was separated by filtering the assay mixture through Whatman GF/B glass-
fiber filters by using a Micro-Mate 196 cell harvester (Packard). The filterbound 
radioactivity was counted by using a microplate scintillation counter (Top Count) at an 
efficiency of 57% with Micro Scint 20. A weighted nonlinear least-squares curve-fitting 
program LIGAND (Munson and Rodbard, 1980) was used for computer analysis of 
saturation experiments. 
 
 
Measurement of cAMP levels 
Cells were washed in phosphate buffered saline and centrifuged for 10 min at 200 g. 
The supernatant was discarded, the pellet was resuspended in a buffer containing 120 
mM NaCl, 5 mM KCl, 0.37 mM NaH2PO4, 10 mM MgCl2, 2 mM CaCl2, 5 g/L D-
glucose, 10 mM Hepes-NaOH, pH 7.4, and centrifuged again for 10 min at 200 g. Cells 
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(4 × 105 cells/tube) were then suspended in 0.5 ml incubation mixture (120 mM NaCl, 5 
mM KCl, 0.37 mM NaH2PO4, 10 mM MgCl2, 2 mM CaCl2, 5 g/L D-glucose, 10 mM 
Hepes-NaOH, pH 7.4) containing 1.0 I.U. of adenosine deaminase/ml and 0.5 mM 4-(3-
butoxy-4-methoxybenzyl)-2-imidazolidinone (RO 201724, as phosphodiesterase 
inhibitor), and preincubated for 10 min in a shaking bath at 37°C. Then forskolin (1 
µM) or NECA (1 nM-10 µM) was added to the mixture, and the incubation continued 
for a further 5 min. The effect of several A2AAR antagonists such as CGS 15943 (1 
µM), ZM 241385 (1 µM), and SCH 58261 (1 µM) was determined by antagonism of 
NECA (100 nM)-induced stimulation of cyclic AMP levels. The reaction was 
terminated by the addition of cold 6% trichloroacetic acid (TCA). The TCA suspension 
was centrifuged at 2,000 g for 10 min at 4°C, and the supernatant was extracted four 
times with water-saturated diethyl ether. The final aqueous solution was tested for 
cyclic AMP levels by a competition protein- binding assay carried out as previously 
described (Varani et al., 1998). Samples of cyclic AMP standards (0–10 pmol) were 
added to each test tube containing trizma base 0.1 M, aminophylline 8.0 mM, 2 
mercaptoethanol 6.0 mM, pH 7.4, and [3H]-cAMP in a total volume of 0.5 ml. The 
binding protein, previously prepared from beef adrenals, was added to the samples 
previously incubated at 4° C for 150 min. The samples, after the addition of charcoal, 
were centrifuged at 2,000 g for 10 min. The clear supernatant (0.2 ml) was mixed with 4 
ml of Ultimagold XR (Hewlett-Packard) and counted in a LS-1800 Beckman 
scintillation counter. 
 
RESULTS 
Presence of the A2AARs in ST14A cells and in Htt expressing subclones.  
Striatal ST14A cells have been previously stably transfected with either normal or 
mutant full-length and truncated Htt constructs to generate a large number of stable 
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subclones (Rigamonti et al., 2000). The rationale for extending the analysis to the 
phenotype of cells expressing truncated Htts derives from well established data 
demonstrating that N-terminal fragments resulting from proteolytic cleavage of full-
length mutant Htt are more toxic than the full-length protein itself (Wellington et al., 
2000). Figure 1.1 shows A2AARs mRNA levels in parental ST14A cells and in the 
various stable subclones expressing N548wt, N548mu, FLwt, and FLmu cDNAs. As a 
positive control, mRNAs from adult rat striatum, cortex, and A2AAR stably transfected 
CHO cells were loaded. As expected, RTPCR revealed an enrichment of the A2AARs in 
striatum and in transfected CHO cells, with lower levels in rat cortex, in agreement with 
previous reports on the brain distribution of this receptor subtype (Fredholm et al., 
2001). Both parental ST14A cells, which are striatum-derived, and all stable subclones 
express the 630 bps band corresponding to the A2AAR mRNA, although to a different 
extent. Despite differences in mRNA levels, comparable A2AAR protein densities are 
found in all clones, as shown by radio-ligand binding studies performed with the highly 
selective A2AAR antagonist [3H]-SCH 58261 (Table 1.1). Scatchard plot analysis 
revealed the presence of a single class of specific, high-affinity, and saturable binding 
sites in both ST14A and in Htt-expressing cells, with comparable Bmax values, 
independently of the presence of normal or mutant Htt (Table 1.1). KD values were 
instead significantly reduced in FLmu cells with respect to parental ST14A cells, a 
change that was even more significant in N548mu cells (Table 1.1). Comparable data 
were obtained with the A2AAR ligand [3H]-ZM 241385. For the ST14A, FLwt, N548wt, 
Flmu, and N548mu, KD values were, respectively, 2.30 ± 0.10; 2.42 ± 0.08; 2.48 ± 0.05; 
1.61 ± 0.06*; 1.32 ± 0.06** nM (* P<0.05 vs. control; ** P<0.01 vs. control); 
corresponding Bmax values were 92 ± 6; 90 ± 8; 90 ± 6; 93 ± 5; 90 ± 3 fmol/mg 
protein. No changes of KD values were detected in clones expressing either FLwt or 
N548wt (Table 1.1). These data suggest a selective increase of binding affinity in the 
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presence of mutant Htt. Figure 1.2 shows an example of saturation analysis performed 
with [3H]-SCH 58261 (0.5–10 nM) in parental ST14A cells and in N548mu (A) or 
FLmu (B) cells. Consistent with the KD values reported in Table 1.1, at low radioligand 
concentrations (0.5–4.5 nM), an increase of binding values was detected in both 
N548mu and FLmu cells, as demonstrated by the shift to the left of [3H]-SCH 58261 
saturation curves (Fig. 1.2A, B). 
 
Selective alteration of forskolin-stimulated adenylyl cyclase response in cells 
expressing mutant Htt. 
The A2AARs is coupled to stimulation of adenylyl cyclase via Gs stimulatory proteins, 
which leads to increases of cAMP formation (Fredholm et al., 2001). We therefore 
analyzed the sensitivity of adenylyl cyclase to pharmacological agents that are known to 
specifically activate this effector system. Despite no changes of basal enzyme activity 
(Table 1.2), response of adenylyl cyclase to the direct activator forskolin (used in the 
presence of the cAMP-dependent phosphodiesterase inhibitor RO 201724) was notably 
increased in N548mu (and Flmu) cells with respect to parental or wild-type Htt cells. As 
shown in Table 1.2, an amplification of cAMP formation was already demonstrable 
with forskolin alone in N548mu cells. To shed light on the cyclase alteration observed 
in cells expressing mutant Htt, we performed a Michaelis-Menten analysis of adenylyl 
cyclase activity in ST14A and N548mu cells. We therefore incubated cell homogenates 
in the presence of a fixed forskolin concentration and in the presence of graded 
concentrations of substrate (0.001–1000 µM ATP, see x-axis of Fig. 1.3A). Analysis of 
the data reported in Figure 3A, according to Lineweaver-Burk (Fig. 1.3B), shows a 
statistically significant reduction of enzyme Km value in N548mu cells with respect to 
parental cells (82±3 nM vs. 180±4 nM, respectively). No changes of Vmax values were 
detected (17.2±0.6 pmol/min in N548mu compared with 16.8±0.4 pmol/min in ST14A 
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cells). This alteration in cyclase activity appears to specifically involve the catalytic 
subunit of the enzyme, because no changes in cAMP production were observed in the 
presence of GTPγS, a direct G protein activator. For example, cAMP formation in 
N548mu incubated with 10 µM GTPγS was 65 ± 2 pmoles/105 cells compared with 64 ± 
1 pmoles/105 cells in ST14A cells.  
 
Aberrant amplification of A2AAR-dependent adenylyl cyclase response in cells 
expressing mutant Htt. 
When the adenosine analog NECA was applied to the cells, an aberrant amplification of 
adenylyl cyclase response was detected selectively in cells expressing mutant Htt. In all 
clones, NECA (0.1 nM–10 µM) significantly increased cAMP production in a 
concentration-dependent manner. However, as shown in Figure 1.4, which reports the 
log dose-response curve for NECA in cells expressing either N548wt and FLwt (A) or 
N548mu and FLmu (B), cAMP formation was significantly higher in the latter two at 
almost all agonist concentrations with respect to parental ST14A cells (EC50 values: 
198±15*; 93±9** nM in FLmu and N548mu, respectively, versus 270±10 in ST14A 
cells; * P<0.05; **P<0.01 vs. control). No differences of NECA responses were 
detected in FLwt and N548wt cells with respect to ST14A cells at any of the utilized 
agonist concentrations (EC50 values: 253±11 and 236±13, respectively). These results 
suggest a selective increase of responsiveness of the A2AAR/adenylyl cyclase system in 
the presence of mutant Htt. This change is unrelated to modifications of endogenously 
produced adenosine because adenosine deaminase was present during the adenylyl 
cyclase assay. Selective A2AAR antagonists counteracted A2AAR-stimulated cAMP 
formation in both parental and Htt-expressing cells. To further confirm that the effect 
induced by NECA on cAMP formation is due to stimulation of the A2AAR subtype, we 
performed experiments in the presence of adenosine receptor antagonists characterized 
 83
by various degree of selectivity towards the A2AARs subtype. As shown in Table 1.3, in 
ST14A cells, both the relatively selective antagonists CGS15943 and ZM 241385 and 
the highly selective antagonist SCH 58261, completely prevented the increases of 
cAMP induced by NECA at an agonist concentration (100 nM), which selectively 
stimulates adenylyl cyclase via the A2AAR. Remarkably, all the tested antagonists 
retained the ability to counteract NECA-induced cAMP formation also in cells 
expressing mutant Htt, where adenylyl cyclase activity is aberrantly increased with 
respect to ST14A and to wild-type Htt cells. 
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Table 1.1 - Binding parameters of the A2AAR ligand [3H]-SCH 58261 
in membranes of ST14A, wild-type and mutant Htt cells.  
 
 
 
 ST14A FL wt N548 wt FL mu N548 mu 
KD  
(nM) 
2.20 ± 0.06 2.36 ± 0.11 2.38 ± 0.27 1.96 ± 0.06* 1.34 ± 0.08** 
Bmax 
(fmol/mg 
protein) 
 
92 ± 3 
 
89 ± 6 89 ± 4 94 ± 5 92 ± 2 
 
Analysis by Student's t test; * P <0.05 vs control; ** P <0.01 vs control. 
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Table 1.2 - Basal and forskolin-stimulated cAMP formation in 
ST14A, wild-type and mutant Htt cells. 
 
 
 
 ST14A FL wt N548 wt FL mu N548 mu 
Basal levels 18 ± 2 19 ± 2 18 ± 1 20 ± 2 20 ± 1 
Forskolin  
(1 µM) 
45 ± 5 54 ± 6 47 ± 3 55 ± 5 72 ± 4* 
Forskolin  
(1 µM) 
+ RO 201724 
(0.5 mM) 
58 ± 4 60 ± 6 63 ± 6 78 ± 7 88 ± 5* 
 
Formation of cAMP was detected in the absence of stimuli (basal levels), and upon 
stimulation with forskolin, in the absence or presence of the cAMP -phosphodiesterase 
inhibitor Ro 201 724. Data are expressed in pmol/105 cells.  
Analysis was by Student's t test; * P <0.01 vs control. 
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Table 1.3 - Effect of different A2AAR antagonists on NECA-
stimulated cAMP formation in ST14A, wild-type and mutant Htt cells. 
 
 
 
 ST14A FL wt N548 wt FL mu N548 mu 
Basal cAMP 
levels 
18 ± 2 19 ± 2 18 ± 1 20 ± 2 20 ± 1 
NECA-
stimulated 
cAMP 
formation 
38 ± 5 39 ± 5 40 ± 4 48 ± 3 55 ± 6 
NECA + 
CGS 15943  
(1 µM) 
19 ± 3* - - - 22 ± 4* 
NECA + 
ZM 241385  
(1 µM) 
20 ± 4* - - - 21 ± 3* 
NECA + 
SCH 58261  
(1 µM) 
18 ± 3* 19 ± 3* 18 ± 2* 19 ± 1* 19 ± 2* 
 
Formation of cAMP was detected in the absence of stimuli (basal levels) and upon stimulation with 
100 nM NECA, in the absence or presence of the indicated A2A receptor antagonists. Data are 
expressed as pmol/105 cells. Analysis was by Student's t test; * P <0.01 vs NECA-stimulated cAMP 
formation. 
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Figure 1.1 - RT-PCR for the A2AAR in parental ST14A cells and 
subclones expressing N548wt, N548mu, FLwt, and FLmu cDNAs.  
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Figure 1.2 - Saturation curves and Scatchard plot of [3H]-SCH 58261 
specific binding to ST14A (•), N548 mu (■) (A) and ST14A (•), FL mu 
(▲) (B). 
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Figure 1.3 - Saturation curves (A) and Lineweaver-Burk analysis (B) 
of adenylyl cyclase activity stimulated with 3 µM forskolin in ST14A 
(•) and N548 mu (■) membranes. 
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Figure 1.4 - Stimulation of cyclic AMP levels by NECA (0.1 nM – 10 
µM) in ST14A (●), in FL wt (▼), in N548 wt (♦) (A), and ST14A (●), in 
FL mu (▲), in N548 mu (■) (B). 
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DISCUSSION 
 
 
The A2AAR plays an important role in striatal function (Ferrè et al., 1993). By activating 
this receptor subtype in striatal medium spiny neurons, adenosine acts as a dopamine 
functional antagonist and inhibits the indirect efferent striatal pathway involved in 
regulation of motor activity. Hence, an intact A2AAR function is needed to preserve an 
integrated regulation of motor behavior. Besides the involvement of this receptor 
subtype in motor function, recent data have highlighted its possible role in cell survival, 
which suggests that its activation under specific pathological conditions may contribute 
to neurodegeneration in ischemic-like diseases (Abbracchio and Cattabeni, 1999). 
The role of the A2AAR in HD is still unclear. Some recent studies have focused on 
neurotransmitter receptor changes in R6/2 transgenic mice, an animal model of HD in 
which a fragment of the disease-causing variant of human Htt is expressed (Mangiarini 
et al., 1996). Reductions of dopamine D1 and D2 receptors, A2AAR mRNA,  A2AAR 
binding, and the expression of enkephalin (but not substance P) have been found in 
these animals (Jacobson et al., 1999). On the contrary, binding autoradiography for 
glutamate NMDA receptors showed no difference with respect to age-matched control 
animals, which supports the concept that specific receptor systems may be selectively 
affected in HD. Moreover, receptor down-regulation seems to appear before the onset of 
observable symptoms (Bibb et al., 2000). Yet, such changes may still be subsequent to 
or independent from earlier aberrant receptor(s) behavior. The present study describes, 
for the first time, an alteration of A2AAR signaling specifically associated with the 
expression of mutant Htt. Data have been obtained in a cellular system composed of 
immortalized striatal cells engineered to express either wild-type or mutant Htt. Using 
this system previously, it was found that Htt protects cells from the action of death 
triggers via inhibition of the caspases cascade. On the contrary, expression of an 
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expanded CAG variant of Htt in the same cells led to loss of this protective effect, 
activation of caspases and apoptosis (Rigamonti et al., 2000). 
In the present study it has been shown that both parental striatal cells and the Htt-
engineered derivatives express the A2AARs, as demonstrated by both radioligand 
binding studies and RTPCR analysis, which hence validates this cellular model as 
suitable for studying the possible changes induced by mutant Htt on A2AAR function. 
Consistent with the reduction of A2AAR mRNA in R6/2 transgenic mice (Cha, 2000) is 
our finding of decreased levels of A2AAR mRNAs in mutant Htt cells. However, the 
density of the receptor protein was demonstrated to be quite comparable in all clones as 
detected by radioligand binding studies. Despite no changes of Bmax values, binding 
studies revealed a moderate but statistically significant increase of affinity in cells 
expressing mutant Htt, which suggests that mutant, but not wild-type Htt, may interfere 
with the kinetics of A2AAR binding by endogenous adenosine and may influence the 
conformation of the ligand recognition site. These results also highlight profound 
changes of adenylyl cyclase response selectively in mutant Htt cells. Despite no changes 
of basal adenylyl cyclase activity, response to forskolin was significantly increased in 
these cells and, more remarkably, an even higher amplification of A2AAR-mediated 
cAMP formation was observed. Quite surprisingly, direct stimulation of G-protein α-
subunit with GTPγS did not result in higher adenylyl cyclase stimulation in mutant Htt 
cells, which suggests that this subunit is not apparently affected by the mutant protein. 
This finding may imply a specific effect of mutant Htt on G-protein βγ-subunits, which 
play key roles in both cyclase activity modulation and in mediating receptor 
desensitization. A dysfunction of G-protein βγ-subunits leading to reduced receptor 
desensitization may therefore contribute to the observed aberrant amplification of 
A2AAR response. From our data it is also clear that changes of A2AAR signaling are 
much more evident in cells expressing truncated mutant Htt with respect to full-length 
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mutant Htt. This finding may have intriguing functional implications, because the N548 
fragment expressed in these cells mimics one of the potential fragments suggested to be 
produced by proteolytic cleavage of Htt (Wellington et al., 2000) and which may be 
required for the expression of mutant Htt cytotoxicity and aggregate formation. 
Recent data demonstrate that the full-length mutant protein is processed gradually over-
time in vivo to generate amino terminal fragments that accumulate into the nucleus and 
also in axons and synaptic terminals. Truncated mutant Htt has been also demonstrated 
to carry significantly higher toxicity with respect to the full-length protein (Wellington 
et al., 2000). On this basis, one could speculate that N548mu cells may reflect a more 
advanced stage of the disease, where the aberrant behavior of the A2AAR is maximally 
expressed. In has been shown that wild-type Htt was protecting cells from death stimuli 
and mutant Htt was producing cell toxicity (possibly indicating a loss of Htt function by 
the expanded CAG) (Rigamonti et al., 2000). It is interesting that, in the present report, 
A2AAR signaling was not modified by wild-type Htt but was selectively altered in 
mutant Htt cells. It is possible to conclude that, besides loss of the normal protective 
function of Htt (Rigamonti et al., 2000), the CAG expansion in the mutant protein 
causes a toxic “gain-of function” activity at the level of the A2AAR signal transduction 
mechanism, which may result in selective impairment of striatal function, possibly at 
very initial stages of the disease. A possible role of this receptor in the etiopathology of 
HD is also consistent with literature suggesting that the A2AAR may contribute to cell 
death in ischemia-associated neurodegeneration and that A2AAR antagonists may indeed 
prove useful in preventing such damage (Abbracchio and Cattabeni, 1999). In this 
respect, our demonstration that selective A2AAR antagonists retain their ability to fully 
block NECA-stimulated adenylyl cyclase may disclose new avenues in the 
pharmacological manipulation of Huntington’s disease. 
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CHAPTER 2: 
Early and transient alteration of A2AAR signaling in a 
mouse model of Huntington disease. 
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INTRODUCTION 
Adenosine and dopamine receptors are co-expressed on striatal GABAergic enkephalin 
neurons. In particular, in these cells, A2AARs stimulate and D2 dopamine receptors 
inhibit adenylyl cyclase and cAMP formation (Ferrè et al., 1993). Adenosine has been 
also suggested to act as a trigger for development-associated apoptosis and, under 
specific conditions, activation of the A2AARs may result in cell death (Jacobson et al., 
1999). On this basis, another proposition to explain cell loss in HD is that a 
dysregulation of adenosine-mediated cell death, likely due to an alteration of A2AAR 
expression or function, may contribute to neurodegeneration. The role of A2AARs in cell 
viability is indeed controversial. Activation of these receptors prevented apoptosis due 
to serum deprivation in PC12 cells (Huang et al., 2001), and protected sympathetic 
neurons against nerve growth factor withdrawal, suggesting induction of trophic or 
protective pathways (Blum et al., 2003). On the other hand, activation of presynaptic 
A2AARs on cortico-striatal afferents facilitates release of the excitatory aminoacid 
glutamate (Popoli et al., 2002), whereas, in glial cells, these receptors might mediate 
induction of pro-inflammatory enzymes, thus contributing to neuroinflammation 
(Brambilla et al., 2003). Using A2AAR-/- mice and pharmacological compounds in rats, 
it was demonstrated that striatal neurodegeneration induced by the mitochondrial toxin 
3-nitropropionic acid (3NP, an experimental model of HD) is regulated by A2AARs. In 
particular, striatal outcome induced by 3NP depended on a balance between the 
deleterious activity of presynaptic A2AARs and the protective activity of post-synaptic 
A2AARs (Blum et al., 2003). In line with this dual role of A2AARs in neurodegeneration 
both A2AAR agonists and antagonists (Popoli et al., 2002) have been shown to be 
beneficial in HD. In particular, in R6/2 animals, an established model of HD, treatment 
with the selective A2A receptor agonist CGS 21680 has been recently reported to 
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attenuate symptoms (Chou et al., 2005). Interestingly, in the 3NP model of HD, an 
increase in A2AAR density has been found (Blum et al., 2002).  
One of the best characterized animal models of HD is represented by the R6/2 mice 
(Mangiarini et al., 1996). These animals express exon 1 of the human huntingtin gene 
with an expanded CAG repeat length of 141-157 under the influence of the human 
promoter. The R6/2 model has many of the temporal, behavioural and 
neuropathological features that are observed in HD patients, such as jerky movements 
and striatal atrophy. At weaning (23 days), R6/2 mice show a lower body and brain 
weight (Mangiarini et al., 1996). The life span of the affected animals is of 14-15 
weeks, with the onset of behavioural phenotype between 8 and 11 weeks. Degeneration 
within the striatum and non-apoptotic cell death have been observed after 14 weeks 
(Turmaine et al., 2000), while neuronal atrophy and neuronal intranuclear inclusions  
have been found at earlier stages (Davies et al., 1997).  
On this basis, the present study was undertaken to assess the presence of the aberrant 
A2AARs phenotype in the basal ganglia of transgenic R6/2 mice. 
 
 
MATERIALS AND METHODS 
Animals 
These studies were performed on heterozygous transgenic R6/2 mice, which express 
exon 1 of the human huntingtin gene with an expanded CAG repeat length of 141-157, 
under the influence of the human promoter (Mangiarini et al., 1996). 
A R6/2 breeding colony has been established from 15 R6/2 males founders and 35 CBA 
X C57BL/6F1 (B6CBA) females, all obtained from Jackson Laboratories (Bar Harbor, 
ME). Transgenic and wild type mice were distinguished by PCR-screening. R6/2 males 
were mated with B6CBA females to maintain the colony, while R6/2 females were 
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utilized for the experiments. Non transgenic littermates were used as controls.  
Measures were taken to minimise pain and discomfort to animals. Mice were killed by 
decapitation after treatment for 30-45 seconds with CO2. Tissues for cAMP detection 
were conserved in ice until assay, while those for RNA extraction or binding studies 
were frozen immediately after dissection and stored at -80°C. 
Experiments have been performed at asymptomatic stage, i.e., postnatal day (PND) 7-8, 
9-14, 21, at early symptomatic stages, i.e., postnatal week (PNW) 6 or 8, and at late 
symptomatic stage, i.e., 11 or 12 PNW.  
 
Genomic DNA extraction 
Genomic DNA was extracted at PND 4-5 from the tail of the animals with the 
NucleoSpin Tissue kit (Macherey Nagel, Germany).  
 
Total RNA extraction 
Total RNA was isolated from striata by extraction with Trizol (Invitrogen, US). Reverse 
transcription of 1,5 µg of RNA was performed with SuperScriptII (Invitrogen, US) 
according to the manufacturer. 
 
muHtt gene amplification 
The amplification protocol has been established on the basis of that reported in the 
literature (Mangiarini et al.,1996). The amplification of genomic and coding DNA was 
performed with Taq polymerase DyNAzime (Finnzimes, UK ) and specific primers for 
the human huntingtin gene sequence including the CAG repeat (FW: 5’-GGC GGC 
TGA GGA AGC TGA GGA-3’; RV:5’- ATG AAG GCC TTC GAG TCC CTC AAG 
TCC TTC-3’). 
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After denaturation for 3’ at 94°C, the amplification was carried out for 35 cycles as 
follow: 1’ at 94°C, 45’’ at 65°C, 1’ at 72°C. An amplified product of 580 bp 
corresponding to the expected mw of mutant Htt was detected on a agarose gel 1%. 
 
RT-PCR for A2AAR   
Qualitative RT-PCR analysis of the  A2AAR cDNA has been performed using Taq 
DyNAzyme (Finnzymes, UK) and primers specific for mouse A2AAR (FW: 5’ – TGT 
CCT GGT CCT CAC GCA GAG-3’; RV: 5’- CGG ATC CTG TAG GCG TAG ATG 
AAGG-3’). After denaturation for 3’ at 94°C, the amplification was carried out for 35 
cycles as follows: 30’’ at 94°C, 30’’ at 55°C, 1’ at 72°C. An expected product of  600 
Kb corresponding to the A2AAR gene was detected on 1% agarose gels. 
 
Quantitative Real Time PCR for A2AAR 
Real time quantitative PCR was performed using the SYBR Green kit (Biorad, USA) on 
a iQ Thermal Cycler (Biorad, USA). The PCR mixtures contain 25 ng of cDNA, 0.2 µM 
of specific primers and SYBR Green reaction MIX (Biorad, USA). Mixtures were 
incubated at 95 °C for 3’ and then 45 PCR cycles were conducted (95 °C for 30’’, 63 °C 
for 30’’  and 72°C for 30’’). The sequences of primers are listed below: for A2AAR (the 
target gene), FW: 5’-AAC CTG CAG AAC GTC AC-3’ and RV: 5’-GTC ACC AAG 
CCA TTG TAC CG-3’ and for β-Actin (the reference gene), FW: 5’-AGT GTG ACG 
TTG ACA TCC GTA-3’ and RV: 5’-GCC AGA GCA GTA ATC TCC TTC T-3’. 
Independent Real Time-PCRs were performed using the same cDNA for both the target 
gene and reference gene. A melting curve was created at the end of the PCR cycle and 
amplified products were run on 2% agarose gel to confirm that a single product was 
amplified. Data were analyzed by the iCycler operating software to determine the 
threshold cycle (CT) above the background for each reaction. The relative transcript 
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amount of the target gene was normalized to that of β-Actin of the same RNA. Four 
R6/2 and four control mice have been used at PND 9-14, while three R6/2 and three 
control mice at the other time points. Except for PNW8, animals are the same utilized 
for binding studies.  
 
Measurement of adenylyl cyclase activity  
Striata were homogenized by 30 strokes with a Teflon glass potter in cold Tris-maleate 
and DTT buffer pH 7.4, 245 mM and 20 mM respectively. 
Incubation medium contained 1 mM ATP, 0.4 mM EGTA, 4 mM MgCl2 , 20 µM GTP, 
160 mM tris-maleate, 1 I.U./ml adenosine deaminase (Sigma, MO, US), 0.1 mM 
papaverine, 237 I.U./ml creatine phosphate (Sigma, MO, US) and 310 I.U./ml creatine 
phosphokinase (Sigma, MO, US). To specifically assess A2AAR mediated stimulation of 
adenylyl cyclase, graded concentrations of the A2AAR agonist CGS 21680 (Sigma, MO, 
US) were added to tubes in absence or presence of the A2AAR antagonist ZM 241385 
(Sigma, MO, US). Forskolin was also tested at graded concentrations to assess direct 
adenylyl cyclase stimulation. cAMP levels have been measured in the presence of 
adenosine deaminase to inactivate endogenous adenosine and in the presence of the 
phosphodiesterase inhibitor papaverine to prevent cAMP degradation. Each 
experimental point was repeated at least in triplicate. Samples containing 20 µg protein 
of homogenate were incubated at 37°C for 15 minutes and then placed at 4°C to stop the 
reaction. cAMP was extracted by adding cold EtOH 70% for 10 minutes and purified by 
centrifuging; supernatant was collected and membrane pellet further incubated with 
EtOH 70%. After 10 minutes samples were centrifuged and supernatant was added to 
the previously collected one and pellet was discarded.  cAMP pellet was then obtained 
by lyophilization at  -80°C. Four transgenic mice and four age- and sex-matched 
littermates have been used at each time point. 
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Quantification of cAMP levels 
A radioenzymatic assay (Amersham, UK) has been used on cAMP pellets. The assay is 
based on the competition for a exogenously-added binding protein beetwen [3H]-cAMP 
and endogenous cAMP. After rehydrating lyophilized pellets in a reaction buffer, a 
standard amount of [3H]-cAMP was added to samples followed by incubation with the 
binding protein; unbound cAMP was removed by centrifugation with charcoal. Clear 
supernatants were then mixed with Formula 999 scintillation liquid (Sigma, MO, US) 
and counted by using a Beckman liquid scintillation counter. cAMP levels are expressed 
as pmol/ mg protein/ minutes of incubation with agonist. 
 
Receptor binding assays 
Striatal tissues derived from wild type and R6/2 mice were homogenized with a 
Polytron PTA 10 probe (setting 5, 30 s) in 25 vol of 50 mM Tris HCl buffer, pH 7.4 
(Borea et al., 1995).  The homogenate was centrifuged at 48000 g for 10 min at 4°C and 
resuspended in Tris HCl containing 2 I.U./ml adenosine deaminase. After 30 min 
incubation at 37°C membranes were centrifuged again and used for binding 
experiments. In saturation binding experiments, striatal membranes were incubated in 
50 mM Tris HCl, 10 mM MgCl2 buffer, pH 7.4 with 8 different concentrations of [3H] 
ZM 241385 ranging from 0.1 to 4 nM. Non specific binding was determined in the 
presence of 10 µM of  ZM 241385. After 60 min of incubation at 4°C, samples were 
filtered through Whatman GF/B glass fiber filters using a Brandel cell harvester. The 
filter bound radioactivity was counted on a scintillation counter Tri Carb Packard 2500 
TR (efficiency 57%). The protein concentration was determined according to a Bio-Rad 
method with bovine albumin as reference standard (Bradford, 1976). Saturation binding 
experiments were analysed with the program LIGAND (Munson and Rodbard, 1980) 
which performs weighted, non linear least squares curve fitting program. All 
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experimental data are expressed as  mean ± standard error of the mean (SEM) of three 
or four independent experiments performed in duplicate. Four R6/2 mice at PND 9-14 
and three R6/2 at the other time points have been analyzed and compared to an equal 
number of sex- and age-matched wild type littermates. Except for PNW 6, animals are 
the same utilized for Real Time PCR. 
 
Statistical analysis 
Potency values (EC50) for cAMP production were calculated by non linear regression 
analysis using the equation for a sigmoid concentration-response curve (GraphPad 
Prism version 3.03, San Diego, CA, US). Analysis of data was done by 1-way ANOVA. 
Differences between wild type and R6/2 mouses were analyzed with Student’s t test. 
Differences were considered significant at a value of p<0.01. All data are reported as 
mean ± SEM of three or four independent experiments. 
 
RESULTS  
Expression of mutated human huntingtin and A2AARs in striatum of R6/2 mice was 
confirmed by qualitative RT-PCR at every age (data not shown). 
To assess the receptor activity, we performed ex-vivo measurements of cAMP 
production in homogenates from striata in the absence (basal activity) or presence of the 
selective A2AAR agonist CGS 21680, or after direct activation of the enzyme with 
forskolin, both utilized at graded concentrations. A time course analysis of A2AAR-
dependent adenylyl cyclase activity has been performed at various presymptomatic and 
symptomatic stages. On the basis of results, 3 early presymptomatic ages (PND 7-8, 9-
14 and 21), 1 early symptomatic stage (PNW 8) and 1 late symptomatic age (PNW 11) 
are reported here. Potency values (EC50) of CGS 21680 and forskolin on cAMP 
production were calculated by non linear regression analysis using the equation for a 
 104
sigmoid concentration-response curve and by one-way ANOVA. At any age considered, 
basal cAMP values were not statistically different in R6/2 and wild type mice (e.g., at 
PND 7-8, levels in pmol/min/mg prot were 10.6 + 0.12 and 10.3 + 0.14 in wild type and 
R6/2 animals, respectively; at all other ages, highly similar levels were detected). As 
expected, at all developmental stages, CGS 21680 concentration-dependently increased 
adenylyl cyclase activity in both wild type and R6/2 mice (Fig. 2.1, Table 2.1). At PND 
7-8, a supersensitivity of A2AAR-dependent adenylyl cyclase activity was found in R6/2 
with respect to wild type mice, as demonstrated by a left-ward shift of CGS21680 
concentration-response curve and a significant reduction of agonist EC50 value (Fig. 2.1, 
Table 2.1). At PND 9-14, the increase of A2AAR-mediated adenylyl cyclase 
responsiveness in R6/2 mice was even more marked (Fig. 2.1), as demonstrated by an 
EC50 value of the A2AAR agonist CGS 21680 ten fold lower with respect to 
corresponding EC50 value in wild type mice (175+23 nM, respect to 1922+197 nM) 
(Table 2.1). A2AAR-dependent adenylyl cyclase activity in R6/2 mice was back to 
control levels at PND 21 (Fig. 2.1, Table 2.1) and remained comparable in wild type 
and R6/2 mice at PNW 8 and PNW11 (Fig. 2.1, Table 2.1). In a similar way, potency of 
forskolin in stimulating adenylyl cyclase activity was enhanced in R6/2 with respect to 
wild type mice at PND 7-8 and 9-14, as shown by significantly lower EC50 values on 
cAMP production (Table 2.2). No significant differences of forskolin-stimulated 
adenylyl cyclase activity were observed in R6/2 mice with respect to wild type animals 
at later developmental ages (i.e., PND21 and PNW11, Table 2.2). We then studied the 
effect of the selective A2AAR antagonist ZM 241385 on A2AAR-stimulated adenylyl 
cyclase in these animals. Antagonism of agonist-stimulated adenylyl cyclase in both 
wild type and R6/2 mice was found at all the stages, except for PND 9-14 (Fig. 2.2). At 
this developmental age, when the aberrant A2AAR phenotype is most evident in R6/2 
mice (Fig. 2.1), the ability of ZM 241385 to selectively counteract A2AARs-mediated 
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cAMP production was markedly impaired with respect to control mice (Fig. 2.2). In 
fact, in R6/2 mice at this developmental stage, cAMP levels measured in the presence of 
both CGS 21680 and ZM 241385 were not significantly different with respect to CGS 
21680 alone (Fig. 2.2). Conversely, at PND 21, when in transgenic mice adenylyl 
cyclase responsiveness is back to control levels (Fig. 2.1), the ability of ZM 241385 to 
counteract CGS 21680- induced cAMP production was fully restored (Fig. 2.2). 
Furthermore, in order to investigate if the increase in cAMP production observed at 
early stages is related to changes in A2AAR expression or density, quantitative Real 
Time PCR and binding studies have been performed. Real Time PCR analysis at PND 
9-14, PND 21, PNW 8 and PNW 12 revealed no changes at PND 9-14, and decreased 
expression starting from PND 21 in R6/2 mice in comparison with wild type animals 
(Fig. 2.3). 
Binding studies with the antagonist radioligand [3H] ZM 241385 at PND 9-14, PND 21, 
PNW 6 and PNW 12 revealed a significant increase in receptor density (Bmax) at PND 
9-14 with no changes in affinity (KD) (Table 2.3; Fig. 2.4); no differences in either 
receptor affinity or density were detected at later times (Table 2.3; Fig. 2.4). Except for 
PNW6 and PNW 8, the striata utilized for binding activity and Real Time PCR were 
from the same animals.  
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Table 2.1. EC50 values  of CGS 21680 on cAMP stimulation in striatal 
membranes from wild type and R6/2 mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, P<0.01 vs wild type mice. 
 Wild type mice R6/2 mice 
PND 7-8 
 
2020 ± 185 589 ± 67* 
PND 9-14 
 
1922 ± 197 175 ± 23* 
PND 21 
 
2051 ± 208 2046 ± 204 
PNW 8 
 
1983 ± 206 2180 ± 189 
PNW 11 1977 ± 178 2032 ± 215 
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Table 2.2 - EC50 values of Forskolin on cAMP stimulation in striatal 
membranes from wild type and R6/2 mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, P<0.01 vs wild type mice. 
 
 Wild type mice R6/2 mice 
PND 7-8 
 
956 ± 72 540 ± 47* 
PND 9-14 
 
1120 ± 115 267 ± 28* 
PND 21 
 
1060 ± 103 881 ± 84 
PNW 11 845 ± 90 847 ± 87 
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Table 2.3 - Binding parameters of A2AARs on striatal membranes 
from wild type and R6/2 mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*, P<0.01 vs the other wild type mice and vs R6/2 mice of PND 21 and PNW 6 and 12.  
 Wild type mice R6/2 mice 
PND 9-14 
 
KD=0.20±0.02 
Bmax=1083±19  
KD=0.19±0.02 
Bmax=1376±22* 
 
PND 21 
 
KD=0.22±0.04 
Bmax=1107±41 
KD=0.21±0.03   
Bmax=988±22 
 
PNW 6 
 
KD=0.21±0.01 
Bmax=1104±39 
KD=0.21±0.02 
Bmax=975±32 
 
PNW 12 KD=0.21±0.02 
Bmax=1125±46 
KD=0.20±0.02 
Bmax=967±38 
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Figure 2.1 - A2AAR-stimulated adenylyl cyclase activity in wild type 
(■) and R6/2 mice (•) of various ages in presence of graded 
concentrations of the A2AAR agonist CGS 21680. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
R6/2 mice
wild type mice
PND 7-8
A
log CGS 21680 Concentration (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
wild type mice
R6/2 mice
PND 9-14
log CGS 21680 Concentration (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
B
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
wild type mice
R6/2 mice
C
PND 21
log CGS 21680 Concentration (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
wild type mice
R6/2 mice
E
PNW 11
log CGS 21680 Concentration (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
-10 -9 -8 -7 -6 -5 -4
0
20
40
60
80
100
wild type mice
R6/2 mice
D
PNW 8
log CGS 21680 Concentration (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
 110
Figure 2.2 - Effect of the selective A2AAR antagonist ZM 241385 on 
A2AAR-mediated cAMP production. The ability of antagonist to 
counteract cAMP production was assessed against 0.5 µM CGS 21680 
in wild type (wt) and R6/2 mice as indicated.  
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Figure 2.3 - Real Time PCR analysis of A2AAR expression in wild 
type (open bars) and R6/2 mice (filled bars) at different ages. At each 
time point, receptor expression value in R6/2 mice is reported as % of 
correspondent value in wild type animals set as 100%. *, P < 0.01 vs 
controls. 
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Figure 2.4 - A: Saturation curves for  [3H] ZM 241385 binding to 
A2AARs in striatal membranes from wild type and R6/2 mice at PND 9-
14. B: Scatchard plot analysis of the same data reported in A. 
 
 
 
 113
DISCUSSION 
In the present study, we demonstrate that R6/2 mice exhibit a transient, but significant, 
increase of A2AAR density (Bmax) and A2AAR -stimulated adenylyl cyclase activity in 
striatum, one of the brain areas most heavily affected in HD. We speculate that the 
increased receptor number in R6/2 mice might be at the basis of the detected increase of 
A2AAR-dependent adenylyl cyclase. This aberrant A2AAR phenotype is maximally 
expressed well before the onset of motor symptoms, i.e., between PND 7 and 14, and, at 
PND 9-14, is accompanied by a transient insensitivity of adenosine A2AARs to selective 
antagonists such as ZM 241385. The reasons at the basis of this insensitivity are 
currently unknown, but it may be hypothesized that, at PND 9-14, an alteration of 
receptor conformation might impair the ability of the antagonist to counteract agonist-
induced receptor activation. The aberrant A2AAR phenotype disappears at PND 21 
(when, in R6/2 mice, sensitivity of A2AAR -dependent adenylyl cyclase to the selective 
antagonist ZM 241385 is also restored, and receptor density returns to values similar to 
wild type mice). Forskolin-stimulated adenylyl cyclase activity was also increased in 
the R6/2 animals at PND 7-8 and (more evident) at PND 9-14.  
Despite increased receptor density in radioligand binding studies, at PND 9-14, by 
employing Real Time PCR, we did not find any significant change of A2AAR mRNA in 
R6/2 mice with respect to wild-type animals. This suggests that, at this developmental 
age, receptor turn-over rather than receptor synthesis may be altered in these animals. 
Starting from PND 21, in R6/2 mice, receptor density is back to control values, as 
assessed by binding studies; instead, at this and at later ages, dramatic, time-dependent 
decreases of A2AAR mRNA are found in transgenic mice with respect to wild-type 
animals. These data are not due to variability between animals, since, with the only 
exception of PNW 6 or 8, at all other ages binding and expression data have been 
obtained on striata from the same animals. Our data indicating decreased A2AAR 
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synthesis in HD animals approaching the symptomatic stage are in line with a recent 
study showing that, in PC12 cells and primary striatal neurons, expression of mutant Htt 
with expanded poly(Q) significantly reduced the transcript levels of the endogenous 
A2AAR (Chiang et al., 2005). In our study, the apparent discrepancy between binding 
and expression data (i.e., no change of receptor density in cell membranes despite 
dramatic decreases of receptor mRNA) are indicative of a reduction of receptor turn-
over in transgenic mice. This may indeed represent a compensatory mechanism by 
which cells respond to decreased receptor synthesis.  
The increase of A2AAR mediated- and forskolin-stimulated adenylyl cyclase in the R6/2 
mice is consistent with our previous demonstration of an aberrantly-increased A2AAR 
phenotype in HD.  Importantly, this is one of the first signs of mutant huntingtin toxicity 
in R6/2 mice, which precedes of 4 weeks the previously demonstrated change in 
responsiveness to glutamate (Cepeda et al., 2001). The transitory nature of this 
dysfunction supports the hypothesis of compensatory mechanism that may mask an 
early functional abnormality, pushing symptoms recognition towards more advanced 
stages.  
The precise mechanism by which mutant huntingtin causes HD is still unknown. Both 
gain-of-function alterations in which mutant huntingtin has protein level toxicity, as 
well as loss of function of normal huntingtin have been proposed to contribute to HD 
(Beal and Ferrante, 2004). Proteolysis of mutant huntingtin with formation of toxic 
protein aggregates in the nucleus, cytoplasm and processes of neurons may represent a 
primary event contributing to early neuropathology. This also triggers cascades of both 
damaging and compensatory molecular processes and genetic programs leading to 
increasingly dysfunctional neurons that are susceptible to more generic stresses. These 
stresses include oxidative injury, transcriptional dysregulation, increased activity of 
excitotoxic glutamate receptors (Li et al., 2003), expression of inflammatory and pro-
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apoptotic signals, malfunctioning proteolysis, increased transglutaminase activity, 
mitochondrial dysfunction and energy depletion (Beal and Ferrante, 2004). These 
changes are accompanied by neurochemical alterations involving glutamate, 
dopaminergic and adenosine receptors (Pavese et al., 2003). In this respect, the aberrant 
A2AAR behaviour in cells expressing mutant huntingtin and in the striatum of HD R6/2 
mice together with the selective expression of A2AARs in the population of striatal 
neurons that degenerate early in HD (Glass et al., 2000), suggest that a dysfunction of 
A2AAR may be related to the underlying disease mechanism. Surprisingly, the early 
change of A2AAR signalling detected in this study is apparently compensated in adult 
animals; however, it is not uncommon that early insults during development seem to be 
initially compensated, but indeed accumulate with other types of damage leading to 
cytotoxicity later during life. In an electrophysiological study performed on the same 
animal model, a marked and transient increase in large-amplitude synaptic spontaneus 
events in striatal medium-spiny neurons was found at 5-7 weeks of age (Cepeda et al., 
2003). These excitatory post-synaptic currents (EPSC) primarily represent the effects of 
spontaneous excitatory neurotransmitter (e.g., glutamate) release in the striatum, and are 
taken as an indicator of corticostriatal integrity. At a later age (11 weeks), the frequency 
of these events in R6/2 mice did not statistically differ with respect to wild type 
animals. This alteration of the cortico-striatal pathway highlights a transient change of 
glutamatergic inputs that are likely to contribute to the later vulnerability of striatal 
neuron to degeneration (Cepeda et al., 2003).  
Overall, these findings seem to place the striatal A2AAR among those subtle early events 
that may be involved in the disease process, but appear temporarily compensated. If this 
is the case and considering the large degree of attention in the development of 
compounds that modulate A2AAR activities, exposure to these compounds at very early 
presymptomatic stage should not remain unexplored. 
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CHAPTER 3: 
Aberrant A2AAR expression and function in peripheral 
blood cells of patients with Huntington's disease. 
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INTRODUCTION 
Although no cure is currently available, recent advancements in the understanding of 
the molecular events underlying HD are expected to disclose novel pharmacological and 
neurosurgical approaches in the years to come. In this context and given the progressive 
manifestation of the disease, the identification of peripheral biomarkers of HD is also of 
crucial importance. Potentially, an ideal biomarker of HD should (i) be easily accessible 
and measurable in peripheral cells, (ii) show limited or no variability within the control 
population; and (iii) should reflect stages or a state (intensity) of degeneration. Various 
studies indicate that membrane receptors present in neurons of the central nervous 
system (CNS) may also be expressed in human peripheral blood cells, which, when 
studied in patients with CNS pathologies, exhibit alterations similar to those observed in 
postmortem brain tissues or in genetic animal models of the diseases (Cha et al., 1999; 
Varani et al., 1999). In this respect, a particularly interesting target to be investigated in 
HD is represented by the A2AAR. 
On this basis, the present study was undertaken to assess the status of the A2AAR in 
peripheral blood cells of HD-affected and non-affected mutation carrier subjects 
compared with control healthy individuals.  
Two strategies were adopted to assess the status of the A2AAR in peripheral cells from 
HD subjects. The first one aimed at measuring the binding kinetic parameters of the 
A2AAR receptor ligand [3H]-ZM 241385 in platelets, lymphocytes and neutrophils of 
patients with Huntington disease and non-affected mutation carrier subjects compared 
with control subjects. The second one aimed at assessing the ability of A2AAR agonists 
to stimulate adenylyl cyclase activity and cAMP formation in the blood cells of the 
three group of subjects. 
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MATERIALS AND METHODS 
Patients 
For this study, we enrolled a cohort of 48 heterozygous (22 males, 26 females) and 3 
homozygous unrelated patients (1 male, 2 females) (Table 3.1). All patients whose data 
have been collected within a databank since 1997 (Squitieri et al., 2001) were seen and 
longitudinally monitored by senior neurologists with expertise in the field. The onset of 
the disease was defined as the time when either motor clinical manifestations (i.e., 
choreic movements or other extrapyramidal symptoms) or severe psychiatric symptoms 
changing the normal life state, first became noticeable (Squitieri et al., 2003). Table 3.1 
shows the mean age of heterozygous patients and asymptomatic mutation carriers. For 
the three homozygous patients, the mean age was 60.7 ± 5.8 years. Motor symptoms 
and behavioral changes were assessed with the Unified Huntington's Disease Rating 
Scale (UHDRS; 14). Most patients were treated with low doses of neuroleptics or 
benzodiazepines. The 48 heterozygous patients enrolled were matched for similar age to 
the cohort of control subjects and were divided into three groups: 39 by age in years 
45.7 (±2.1) (Table 3.1) were analyzed for A2AAR activity (Table 3.1). The same 
parameters were measured in five additional patients who had never been treated with 
either neuroleptics or benzodiazepines. Finally, four other patients were subsequently 
enrolled for the measurement of non-A2AAR subtypes (Table 3.2). 
 
Mutation carriers at the pre-symptomatic stage 
Seven at-risk subjects (5 males and 2 females) were informed of their increased risk of 
developing HD after performing predictive testing (PT). For the study, among the at-
risk subjects who underwent the PT (15), we selected those with no evidence of even 
minor neurological signs or soft motor symptoms. To do that, we performed careful 
neurological exam by UHDRS, MRI, and additional cognitive assessments, other than 
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those included in UHDRS, specifically the Wechsler Assessment Intelligence Scale 
(WAIS) and the Mini Mental State Examination. The cognitive and behavioral 
assessments were re-evaluated after six months in an attempt to look at even subtle 
initial non-motor pathological changes of HD in these subjects. By this strategy, we 
selected mutation carrier subjects in a pre-symptomatic life stage, far enough from the 
beginning of HD. This explains why the age of at-risk subjects is younger than that of 
the already affected HD subjects (Table 3.1). 
 
Healthy control subjects  
The protocol was approved by the local Ethics Committee, and written informed 
consent was obtained from each participant in accordance with the principles outlined in 
the Declaration of Helsinki. For the controls, 58 healthy subjects (28 males and 30 
females) were included in the study (Table 3.1). In several cases, healthy controls were 
volunteers from Ferrara University Hospital Blood Bank. In other instances, subjects 
with no mutation were enrolled among either the unaffected spouses or the patients 
admitted to the hospital at Neuromed whose diagnosis was other than neurodegenerative 
disease or cardiovascular pathology (i.e., patients admitted in the Neurosurgery 
Department). After careful retrospective disease history, all the subjects with suspected 
neurological, psychiatric (i.e., behavioral disturbances), and cardiovascular pathologies 
were excluded from the study. All healthy subjects were unrelated to the mutation 
carriers. The 58 controls were matched for similar age to the cohort of HD subjects and 
were divided into three groups: 44 by age in years 46.6 (±1.8), 10 by age in years 31.1 
(1.5) (Table 3.1), and four subjects who were subsequently enrolled for the 
measurements of non-A2AAR receptor subtypes (Table 3.2). 
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Ethical approval 
For this project, we obtained a formal ethical approval by the Bioethics Committee 
according to the Helsinki Declaration and as also required by Telethon Foundation, 
before performing the study. An informed consent, specific for the study, was required 
from each subject. For PT, a different informed consent is obtained from at-risk subjects 
enrolled in the presymptomatic program at Neuromed. This program was also formally 
approved by the Bioethics Committee. After the subjects’ consent, a blood sample was 
also collected for general investigation. 
 
Mutation study 
DNA was extracted from blood lymphocytes. Polymerase chain reaction was used 
according to the published methods to study CAG trinucleotide repeats and the close 
CCG polymorphism (Squitieri et al., 1994). Reference samples and standardized 
sequence clones for sizing are used for the genetic test. All HD subjects had a CAG 
repeat number in the pathological range (mean expanded number of 44.9±5.4 CAG 
repeats, range 39–70 CAG). Normal controls showed a CAG repeat number within the 
normal range (18.4 ± 4.2, range 15–24).  
 
A2AAR receptor study: preparation of peripheral blood cells or membrane 
suspensions  
Peripheral venous blood samples were obtained from HD subjects and healthy controls. 
The isolation of the various cell fractions (platelets, lymphocytes, neutrophils) started 
no later than 6–8 hours after the samples had been taken. Membranes from human 
platelets, lymphocytes, and neutrophils were prepared as previously described (Varani 
et al., 1997;1998) and used for radioligand binding assays. Washed platelets, 
lymphocytes, and neutrophils were prepared to evaluate cAMP levels (Varani et al., 
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1997;1998). Two strategies were adopted to assess the status of the A2AAR in peripheral 
cells from HD subjects. The first one aimed at measuring the binding kinetic parameters 
of the A2AAR ligand [3H]-ZM 241385 compared with control subjects. The second one 
aimed at assessing the ability of A2AAR agonists to stimulate adenylyl cyclase activity 
and cAMP formation. Due to the larger volume of blood necessary for the cAMP assay, 
the latter has been done in a lower number of patients with respect to the radioligand 
binding study.  
 
[3H]-ZM241385 binding assay to A2AARs on membranes from peripheral blood 
cells  
Saturation binding experiments were performed by incubating membranes (50 µg of 
protein per assay) from the different cellular fractions with 8–10 concentrations of the 
A2AAR antagonist ([3H]- 4- (2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-
5-yl-amino]-ethyl)phenol) [3H]-ZM 241385 (0.01–10 nM) in a total volume of 250 µl 
containing 50 mM Tris HCl buffer and 10 mM MgCl2, pH 7.4. The incubation time was 
60 min at 4°C to allow the equilibrium to be reached. Non-specific binding was 
determined in the presence of N-ethylcarboxamido-adenosine (NECA) 10 µM and was 
about 25% of total binding. Bound and free radioactivities were separated by filtering 
the assay mixture through Whatman GF/C glass fiber filters by use of a Brandel cell 
harvester. The filter-bound radioactivity was counted by using a Beckman liquid 
scintillation counter with an efficiency of 55%. [3H] DPCPX and [3H] MRE 3008F20 
binding assays to A1ARs and A3ARs  on membranes from peripheral blood cells. 
Binding to A1ARs adenosine receptors was performed with [3H] DPCPX (0.2–20 nM) 
in membranes obtained from human lymphocytes in a 50 mM Tris HCl buffer, pH 7.4, 
for 120 min at 4°C, following the same technical procedure used for A2AAR binding. 
Non-specific binding was determined with 100 µM of NECA (Varani et al., 2000). 
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Binding to A3ARs was performed by incubating membranes obtained from human 
neutrophils with [3H] MRE 3008F20 (0.2–20 nM) in a 50 mM Tris HCl buffer, pH 7.4, 
containing 10 mM MgCl2 and 1 mM EDTA for 120 min at 4°C. Non-specific binding 
was determined with 1 µM of MRE 3008F20 (Varani et al., 2000). [3H] UK 14304 
binding assays to α2-adrenergic receptors on membranes from blood platelets. Binding 
to α2-adrenergic receptors on human platelets was performed with [3H] UK 14304 (0.2–
20 nM) in a 50 mM Tris HCl buffer, pH 7.4, containing MgCl2 10 mM for 60 min at 
25°C, and following the same technical procedure used for A2AAR binding. Non-
specific binding was determined with 10 µM of UK 14304 (Varani et al., 1999). 
 
Measurement of cyclic AMP levels in peripheral blood cells 
Adenylyl cyclase activity was evaluated by incubating washed peripheral blood cells 
(either platelets or lymphocytes or neutrophils) in the absence or presence of 6–8 
different concentrations of the A2AAR agonist NECA. Cells were suspended in 0.5 ml 
of buffer containing 2 I.U. of adenosine deaminase and 0.5 mM 4-3-butoxy-4-
methoxybenzyl-2-imidazolidinone (Ro 20-1724) as a phosphodiesterase inhibitor and 
were preincubated in a shaking bath at 37°C. NECA was added to the mixture and the 
incubation continued for another 10 min. The reaction was terminated by addition of 
cold 6% trichloroacetic acid (TCA). The TCA suspension was centrifuged at 2000 x g 
for 10 min at 4°C, and the supernatant was extracted four times with water-saturated 
diethyl ether. The final aqueous solution was tested for cAMP levels by a competition 
protein-binding assay. Samples of cAMP standards (0–10 pmol) were added to each test 
tube containing the binding protein (previously prepared from beef adrenals and 
incubated at 4°C for 150 min). After addition of charcoal, the samples were centrifuged 
at 2000 x g for 10 min. The clear supernatant was mixed with Atomlight (Perkin-Elmer, 
Beltsville, MD) and counted by using a Beckman liquid scintillation counter. 
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Statistical analysis 
A weighted nonlinear least-squares curve-fitting program LIGAND (Munson and 
Rodbard, 1980) was used for computer analysis of the data from the binding saturation 
experiments, as previously described. EC50 values in the cAMP assay were calculated 
with the non-linear least-squares curve-fitting program Prism (Graph PAD, San Diego, 
CA). Nonparametric tests (Mann Whitney U) were used to compare each class of HD 
subjects (affected heterozygotes, presymptomatic heterozygotes, and homozygous 
patients) and healthy controls. Differences were considered significant at a value of P < 
0.01. All data are reported as mean ± SEM. 
 
RESULTS 
Figure 3.1 shows [3H]-ZM 241385 saturation curve in membranes prepared from 
platelets, lymphocytes, and neutrophils from control and HD heterozygous subjects. In 
all cell preparations from control subjects, A2AAR binding was saturable and indicated 
the presence of a single receptor population characterized by affinity (expressed as 
ligand dissociation constant, KD) and density (expressed as femtomoles of bound ligand 
per milligram of protein, Bmax) values that are in agreement with those previously 
reported in the literature for these human cell populations (Table 3.1; Varani et al., 
2003). In particular, and as expected, this analysis in control healthy subjects revealed a 
uniform level of A2AARs in the peripheral blood cells of all the subjects. In only two 
cases, which have been nevertheless included in the data analysis of the control group, 
increased A2AAR values were present (the reasons at the basis of this deviance from the 
other control values are presently unknown). Analysis of the same parameters in HD 
subjects revealed a statistically significant increase in A2AARs density (Bmax) in all cell 
populations with respect to controls (P=0.0001 versus control, Table 3.1, Fig. 3.1). A 
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statistically significant difference was obtained by considering either the HD subjects as 
a whole (HD patients and at risk mutation carriers) or each cohort of mutation carriers 
compared to healthy controls (heterozygotes P<0.01, asymptomatic at risk P<0.0001, 
Table 3.1). The increase in Bmax was accompanied by an increase in KD values 
(P<0.0001 vs. control, Table 3.1). Also in this case the difference was highly significant 
when considering either the whole cohort of mutation carriers (P<0.01) or each cohort 
of HD subjects (P<0.01, Table 3.1). Given that the mean age of asymptomatic mutation 
carriers is lower than that of symptomatic patients, 10 additional age-matched healthy 
subjects (5 males and 5 females) were included in the protocol and subsequently 
analyzed (Table 3.1). As shown in Table 3.1, this analysis revealed A2AAR parameters 
that were in agreement with those obtained from the samples from the other control 
subjects. This indicates that receptor changes in the at-risk mutation carriers are related 
to their genetic status (Table 3.1). 
Subsequent analysis of A2AAR KD and Bmax values in three subjects homozygous for 
the HD mutation also revealed highly increased A2AAR parameters in all three blood 
cell types compared with controls (Table 3.1). In spite of the limited number of blood 
samples from homozygous patients available, neutrophil cells from these subjects 
showed even significantly higher ligand dissociation constant (KD) and Bmax with 
respect to heterozygotes (Table 3.1). Finally, in all groups considered, the values of KD 
and Bmax did not seem to correlate to the triplet number and age at onset, and neither 
seemed to depend on the number of HD years. Because both the density and the 
functional response of A2AARs may be influenced by drugs, such as neuroleptics and/or 
benzodiazepines that are generally administered to these patients (Parson et al., 1995), 
we have performed a study where we measured A2AAR -binding parameters in the 
lymphocytes of a small cohort of 5 HD affected patients who had never been treated 
with these drugs. In these patients, a KD value of 3.54 ± 0.35 nM and a Bmax value of 
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223 ± 9 fmol/mg protein were found, which were highly statistically different with 
respect to the corresponding values in control subjects (P<0.01). Furthermore they did 
not differ from the binding parameters obtained in the other HD patients included in the 
present study. These results suggest that the detected A2AAR phenotype correlates with 
the genetic status of the patients and is unlikely to be affected by pharmacological 
treatments generally administered to these patients. Moreover, to verify whether the 
observed changes in A2AAR activities are specific for this receptor subtype or also 
involve other types of membrane GPCRs, we have evaluated the binding parameters 
(KD and Bmax) of two additional adenosine receptors (the A1AR and A3AR subtypes), 
and of another GPCR unrelated to this receptor family (i.e., the α2-adrenergic receptor) 
in the circulating blood cells of four control subjects and four HD-affected patients 
(Table 3.2). Saturation binding experiments have been performed by using [3H] 
DPCPX, [3H] MRE 3008F20 and [3H] UK 14304 to label A1ARs, A3ARs, and α2-
adrenergic receptors in lymphocytes, neutrophils, and platelets, respectively. A single, 
saturable binding site was detected for all types of receptors examined. Saturation of 
[3H] DPCPX binding to A1ARs in lymphocytes showed a KD value of 1.89 ± 0.11 nM 
and a Bmax value of 45 ± 3 fmol/mg protein in control subjects, which were very 
similar to those obtained in HD patients (Table 3.2). Similarly, saturation of [3H] MRE 
3008F20 binding to A3AR adenosine receptors in neutrophils revealed overlapping KD 
and Bmax values between controls and HD patients (Table 3.2). Finally, saturation of 
[3H] UK 14304 binding to α2 adrenergic receptors in the platelets of controls and HD 
subjects also showed similar KD and Bmax values. Hence, we concluded that the 
A2AAR changes detected in HD patients are highly specific for this receptor subtype. In 
a parallel study performed on a selected number of heterozygous subjects, the coupling 
of A2AARs to adenylyl cyclase stimulation and cAMP accumulation in the blood 
peripheral cells has been determined compared with control subjects. Figure 3.2 shows 
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typical concentration-response curves to the A2AAR agonist NECA in platelets, 
lymphocytes, and neutrophils obtained from control and HD heterozygous subjects. A 
concentration-dependent stimulation of cAMP formation was obtained in the presence 
of NECA in all cell preparations from control subjects, as shown by EC50 values (the 
agonist concentration eliciting the 50% of maximal cAMP formation) in accordance 
with literature data (Figure 3.2; Varani et al., 1998). Significantly, NECA EC50 values 
in the peripheral cells from controls (platelets: 308±7 nM, lymphocytes: 199±4 nM, 
neutrophils: 168±5 nM, n=10) were higher than HD subjects (platelets, 119±13* nM; 
lymphocytes, 79±10* nM; neutrophils, 85±9* nM; n=10, *P=0.0001), indicating an 
increased potency of NECA in stimulating cAMP accumulation in HD subjects. 
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Table 3.1 - Binding parameters of the A2AAR in human circulating 
blood cells of control and HD subjects. *, P < 0.01 vs age-matched 
controls. 
 
 
 
  Platelets (P) Lymphocytes (L)      Neutrophils (N) 
Subjects 
(males/females) 
Age 
in 
years 
KD (nM) Bmax 
(fmol/mg 
protein) 
KD (nM) Bmax 
(fmol/mg 
protein) 
KD (nM) Bmax 
(fmol/mg 
protein) 
Controls 
44 (21/23) 
46.6 
 ± 1.8  
 
1.04 ± 0.03 115 ± 3 1.08 ± 0.04 67 ± 6 1.14 ± 0.03 86 ± 5 
Heterozygous 
patients 
39 (18/21) 
45.7 
± 2.1 
2.82 ± 0.21* 212 ± 9* 2.92 ± 0.13* 218 ± 5* 3.43 ±1.67* 230 ± 6* 
Homozygous 
patients 
3 (2/1) 
60.7 
± 5.8 
3.12 ± 1.14* 220 ± 11* 3.24 ± 0.24* 219 ± 18* 7.31 ± 0.72* 304 ± 14* 
Controls 
10 (5/5) 
31.1 
± 1.5 
1.06 ± 0.05 119 ± 2 1.09 ± 0.06 70 ± 4 1.17 ± 0.02 84 ± 2 
Asymptomatic 
mutation 
carriers 
7 (5/2) 
32.9 
± 2.3 
3.02 ± 0.53* 211 ± 16* 3.43 ± 0.35* 234 ± 15* 4.14 ± 0.72* 243 ± 10* 
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Table 3.2 - Binding parameters of the α2-adrenergic receptor, the 
A1ARs and A3ARs in human circulating blood cells from control and 
HD subjects. 
 
 
Subjects Platelets 
α2 receptors 
Lymphocytes 
A1ARs  
Neutrophils 
A3ARs  
 
Controls 
n=4 
KD = 3.29 ± 0.14 
Bmax = 337 ± 15 
KD =1.89 ± 0.11 
Bmax = 45 ± 3 
KD = 2.24 ± 0.37 
Bmax = 451 ± 20 
HD 
n=4 
KD = 3.42 ± 0.16 
Bmax = 358 ± 17 
KD = 1.85 ± 0.11 
Bmax = 43 ± 3 
KD = 2.07 ± 0.26 
Bmax = 461 ± 27 
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Figure 3.1 - Specific binding of [3H]ZM 241385 to platelet, 
lymphocyte and neutrophil membranes obtained from control (■) and 
HD heterozygous subjects (●). In inset, the Scatchard plot analysis of 
specific binding. B and F denote bound radioactivity and free ligand, 
respectively. 
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Figure 3.2 - NECA concentration-response curves on cAMP 
accumulation in platelets, lymphocytes, and neutrophils obtained from 
control (■) (platelets: EC50 = 308 ± 7 nM, lymphocytes: EC50=199±4 
nM, neutrophils: EC50=168±5 nM, n=10) and HD heterozygous 
subjects (●) (platelets: EC50=119±13* nM, lymphocytes: EC50=79±10* 
nM, neutrophils: EC50=85±9* nM, n=10, *P<0.01). 
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DISCUSSION 
In this study we show, for the first time, that peripheral blood cells from HD subjects 
exhibit an aberrant increase in A2AAR number, as demonstrated by Bmax values 
significantly higher in these subjects than age-matched healthy controls. This effect was 
accompanied by an increase of KD, indicating a decrease in binding affinity. However, 
the detected increase of KD is unlike to have any biological significance. In fact, due to 
the mathematical relationship between Bmax and KD values and to the method used for 
the analysis of the results of antagonist ligand binding studies, an increase of receptor 
density (Bmax) may be accompanied by an increase of the corresponding KD value 
(Rovati, 1998). In HD patients, the increase of Bmax was associated with an over-
stimulation of A2AAR-mediated cAMP production, which is in line with the currently 
accepted receptor theory. In fact, due to the ratio between extracellular receptors and 
transductional G-proteins in cellular membranes, an increase of Bmax is expected to 
result in increased coupling with G-proteins, which, in turn, would result in an increase 
in function (Kenakin, 1997). No changes of either the A1ARs or A3ARs, and of another 
unrelated GPCR (the α2-adrenergic receptor), have been detected in the circulating cells 
of HD patients compared with healthy subjects, suggesting that the aberrant A2AAR 
phenotype in HD is a highly specific receptor change not only within the P1/adenosine 
receptor family, but also in general within the GPCR superfamily. Globally, these 
findings recapitulate results obtained in striatal cells expressing human mutant Htt and 
suggests that the status of the A2AAR in human peripheral cells may reflect a 
dysfunction present in HD brain. The aberrant A2AAR phenotype was also found in the 
circulating cells of pre-symptomatic individuals carrying the CAG mutation. These 
individuals were selected after careful neurological, behavioral, and cognitive 
assessment and demonstrated to be far away from first HD clinical symptoms. This 
finding suggests that the aberrant A2AAR behavior may be present at birth or may 
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accumulate in the pre-symptomatic years. Of note, in spite of the difficulties in directly 
comparing KD and Bmax values from HD heterozygotes with those observed in the 
three homozygous patients available, the latter appeared to express a more severe 
A2AAR phenotype in neutrophils that reached statistical significance (Table 3.1). As 
these three homozygotes showed a particularly accelerated disease progression towards 
disability and no difference in age at onset with respect to the heterozygotes (Squitieri et 
al., 2003), the biochemical findings herein reported may potentially reflect the clinical 
and genetic differences between these two groups of patients. A dosage effect of 
expanded proteins has been demonstrated in other polyglutamine diseases (Gusella and 
MacDonald, 2000). Further studies are required to evaluate the impact of different 
disease stages and progression rates on this biochemical parameter and its potential 
exploitation as a peripheral biomarker of HD. Various reports now indicate that 
neuronal dysfunction does occur in the pre-symptomatic life stages in HD animal 
models (Lin et al., 2001) and humans (Lawrence et al., 1998). The findings reported 
herein that an aberrant A2AAR activity can be measured in the peripheral cells of HD 
subjects and is already present in pre-symptomatic CAG mutation carriers strengthen 
the hypothesis that changes of this receptor subtype may occur early in HD 
pathogenesis and contribute to its progression (Blum et al., 2003). In the brain, A2AAR 
stimulation of adenylyl cyclase is almost exclusively expressed by striatal medium 
spiny neurons, where it regulates motor behaviour in cooperation with D2 dopamine 
receptors (Ferrè et al., 1993). Consistent with the possible involvement of the A2AAR in 
HD pathogenesis, selective A2AAR antagonists could reduce the loss of striatal neurons 
in a pathophysiological animal model of HD and could revert aberrantly increased 
A2AAR stimulation of adenylyl cyclase in mutant-Htt expressing striatal cells. This 
evidence highlights the A2AAR as an interesting target for HD therapy. Although further 
studies are needed to evaluate the actual impact of selective A2AAR antagonists on the 
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survival of striatal neurons, we speculate that an early treatment with such compounds 
may be able to reduce or retard HD-associated neuronal loss. Although this study 
demonstrates that an aberrant A2AAR behavior is present in peripheral, circulating cells 
of HD subjects, it remains to be established whether this measurable receptor activity 
can be taken as a marker of disease severity and/or progression. For other CNS 
disorders, alterations of proteins specifically involved in the disease, such as dopamine 
receptors in migraine (Barbanti et al., 2000) and schizophrenia (Ilani et al., 2001) and 
amyloid precursor protein (APP) in Alzheimer's disease (Di Luca et al., 1998), have 
been found to be reproduced in the peripheral blood cells of patients.  
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CHAPTER 4: 
Biological abnormalities of peripheral A2AARs in a 
large representation of polyglutamine disorders and 
Huntington's disease stages. 
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INTRODUCTION 
HD is a dominantly inherited neurodegenerative disease featuring progressive 
worsening motor dysfunctions, psychiatric disturbances and cognitive impairment due 
to brain cell loss. Although the GABAergic enkephalin neurons of the basal ganglia and 
neurons in the cerebral cortex are primarily affected, a number of reports now indicate 
that mutant huntingtin, which is ubiquitously expressed, evokes profound molecular 
alterations in a variety of extraneural tissues. This evidence has led to the intense search 
in patients of peripheral changes that may be directly linked to the clinical 
manifestations and outcome of the disease, as to improve early detection of disease 
progression and efficacy of future therapeutic interventions. The ultimate goal will be 
the availability of diagnostic biomarkers that reflect pathophysiological mechanisms to 
be targeted in peripheral cells and that are linked to disease status. 
Toward this aim we reported the first evidence of a peripheral dysfunction in human 
HD subjects consisting of an aberrant A2AAR receptor function in freshly isolated 
peripheral blood cells. The A2AAR is a membrane receptor with a main locus on the 
GABAergic-striatal neurons which degenerate in HD. Its role is related to the control of 
movement and in particular to the inhibition of involuntary movements. We originally 
reported that an aberrant amplification of A2AAR-stimulated adenylyl cyclase is present 
in a cellular model of HD while data in HD mice showed an increase of A2AAR receptor 
density (Bmax) and A2AAR-stimulated adenylyl cyclase activity in the striatum.   
On these grounds we assessed whether the aberrant peripheral A2AAR phenotype could 
be detected also in human peripheral cells and may possibly represent a biomarker for 
the disease. We reported that, likewise in the mice, the A2AAR density was substantially 
increased in all tested cells (lymphocytes, neutrophils and platelets) from 51 HD 
patients and seven subjects at pre-symptomatic stage versus 58 controls that remained 
remarkably similar in their A2AAR receptor Bmax value. 
 140
Here we aimed at extending the analyses of A2AAR receptor activity to include a more 
detailed transversal study where different disease stages were represented, as well as at 
testing HD patients and larger number of pre-symptomatic subjects enrolled from 
different clinical sites. In addition, we tested whether the A2AAR dysfunction was 
present in other inherited neurological diseases, such as other polyQ- (Spinocerebellar 
Ataxia, SCA, type 1 and 2) or not polyQ-linked (Freidreich Ataxia, FRDA) 
neurodegenerative disorders. Our assumption was that diseases with a common 
pathogenic mechanism (for example an expanded CAG repeat) could exhibit the same 
dysfunction, a finding that may have implications in the development of future 
therapeutic interventions. Though it is often unpredictable whether or not a peripheral 
abnormality could be of clinical utility, the identification in peripheral cells of a 
measurable significant change in a biological process might arguably serve as a useful 
endpoint to measure the efficacy of therapeutics targeting pathological mechanisms 
initiated by the mutation. 
 
MATHERIALS AND METHODS 
Patients 
Individuals were recruited for study and clinically assessed at the Henri Mondor 
Hospital, Créteil (France), at the National Neurological Institute Carlo Besta, Milan 
(Italy), at the Ferrara University Hospital Blood Bank (Italy) and at the University 
Hospital of Wales (UK). During the visit, 30 ml of blood was withdrawn. All eligible 
participants received verbal and written information about the study and signed an 
informed consent form. For symptomatic HD patients with severe cognitive 
impairment, the informed consent was obtained from their relatives. The study protocol 
was approved by the Ethics Committee of each participating centre. 
 141
A total of 252 individuals were recruited in the study period. Of these, 94 were HD 
patients (73 from Henri Mondor Hospital, 21 from Neurological Institute Besta); 32 
were pre-HD (4 from Henri Mondor Hospital, 17 from Neurological Institute Besta, 11 
from University of Wales); 12 were SCA1, 27 SCA2, 24 FRDA (all from Neurological 
Institute Besta); and 63 control individuals (58 from Ferrara University Hospital Blood 
Bank University of Ferrara and 5 from Neurological Institute Besta). Clinical and 
genetic characteristics of participants are illustrated in Table 4.1. Patients from the 
different disease groups were representative of the disease spectrum in terms of gender, 
disease duration and clinical compromise. As expected, pre-HD had a median age lower 
than HD. Also FRDA age was younger, as expected in an infantile-juvenile disease. 
Due to the similar characteristics and limited numbers, SCA1 and SCA2 patients have 
been combined in subsequent analyses. Disease-specific inclusion criteria were as 
follows: 
(a) Symptomatic HD patients (HD). Patients with manifest clinical signs and symptoms 
of the disease, with UHDRS motor score ≥ 5 and positive at molecular test for the 
presence of a CAG triplet repeat number ≥ 35 in the Huntington gene. 
(b) Pre-symptomatic HD individuals (Pre-HD). These individuals were selected among 
those who decided to undergo the program for pre-symptomatic genetic testing 
according to the International Huntington’s Association (IHA) and World Federation of 
Neurology (WFN) guidelines (IHA and WFN Research Group for HD, 1994). People 
with more that 35 CAG triplet repeats, no clinical signs/symptoms of the disease, 
UHDRS motor score < 5 were recruited for the study. 
(c) Patients with spinocerebellar ataxia type 1 (SCA1) and type 2 (SCA2). Patients with 
clinical signs of cerebellar ataxia, ICARS score ≥ 2 and positive molecular test, showing 
CAG triplet repeats ≥ 38 in SCA1 gene, or ≥ 32 in SCA2 gene. 
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(d) Patients with Friedreich ataxia (FRDA). Patients with clinical signs of cerebellar 
ataxia (ICARS score ≥ 2) and with GAA triplet repeat ≥ 66 on both FRDA gene alleles. 
(e) Control individuals. Volunteers with no neurodegenerative disorders were enrolled 
from Ferrara University Hospital Blood Bank and Neurological Institute Besta. 
Patients and controls aged less than 18 years or/and having known major medical 
conditions, in addition to the primary genetic disorder, were excluded. 
All the patients were evaluated by a standard neurological examination. Detailed family 
history, age of onset of symptoms, medications and other relevant clinical information 
were collected. Clinical status was determined using the Unified Huntington Disease 
Rating Scale (UHDRS) in HD patients (Marder et al., 2000) and the International 
Cooperative Ataxia Rating Scale (ICARS) in SCA1, SCA2 and FRDA patients 
(Trouillas et al., 1997). 
 
Genetic assessment 
DNA for genetic diagnosis was extracted from venous lymphocytes. Genetic tests for 
HD, SCA1, SCA2 and FRDA were performed in the laboratory of molecular genetic of 
the division of Biochemistry and Genetics of the Neurological Institute Carlo Besta 
according to the published methods to study trinucleotide repeat diseases (Gellera et al., 
1996). HD tests were carried out in the laboratory of Medical Genetics, University 
Hospital of Wales and in different approved centers for genetic testing in HD included 
in the Huntington French Speaking Group for the Henri Mondor Hospital subjects 
(Créteil). 
 
A2AAR receptor study: preparation of peripheral blood cells or membrane 
suspensions  
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Peripheral venous blood samples were obtained from patients and healthy controls. The 
isolation of the various cell fractions (platelets, lymphocytes, neutrophils) started no 
later than 6–8 hours after the samples had been taken. Membranes from human 
platelets, lymphocytes, and neutrophils were prepared as previously described (Varani 
et al., 1997;1998) and used for radioligand binding assays. Washed platelets, 
lymphocytes, and neutrophils were prepared to evaluate cAMP levels (Varani et al., 
1997;1998). 
 
[3H]-ZM 241385 binding assay to A2AARs 
A2AAR parameters were evaluated by means of receptor binding with A2AAR 
radioligand antagonist [3H] ZM 241385 (Tocris Cookson Ltd., Bristol, UK). The 
binding parameters of the human A2AARs were determined in lymphocytes by a 
standard procedure (Varani et al., 1998). 
Briefly, membranes were incubated with 8–10 different concentrations of the A2AAR 
antagonist radioligand [3H] ZM 241385 for 60 min at 4 °C. Non-specific binding was 
determined in the presence of NECA 10 µM. Bound and free radioactivity were 
separated by filtering the assay mixture on Whatman GF/B glass fiber filters with a 
Micro Mate 196 Cell harvester (Packard Instrument Co.). The filter bound radioactivity 
was measured using a microplate scintillation counter (Top Count, Meriden, CT) at an 
efficiency of 57% with Micro Scint 20. Binding parameters such as affinity (KD) and 
receptor density (Bmax) were calculated by computer-assisted analysis. 
 
Measurement of cyclic AMP levels in peripheral blood cells 
Adenylyl cyclase activity was evaluated by incubating washed peripheral blood cells 
(either platelets or lymphocytes or neutrophils) in the absence or presence of 6–8 
different concentrations of the A2AAR agonist NECA. Cells were suspended in 0.5 ml 
 144
of buffer containing 2 I.U. of adenosine deaminase and 0.5 mM 4-3-butoxy-4-
methoxybenzyl-2-imidazolidinone (Ro 20-1724) as a phosphodiesterase inhibitor and 
were preincubated in a shaking bath at 37°C. NECA was added to the mixture and the 
incubation continued for another 10 min. The reaction was terminated by addition of 
cold 6% trichloroacetic acid (TCA). The TCA suspension was centrifuged at 2000 x g 
for 10 min at 4°C, and the supernatant was extracted four times with water-saturated 
diethyl ether. The final aqueous solution was tested for cAMP levels by a competition 
protein-binding assay. Samples of cAMP standards (0–10 pmol) were added to each test 
tube containing the binding protein (previously prepared from beef adrenals and 
incubated at 4°C for 150 min). After addition of charcoal, the samples were centrifuged 
at 2000 x g for 10 min. The clear supernatant was mixed with Atomlight (Perkin-Elmer, 
Beltsville, MD) and counted by using a Beckman liquid scintillation counter. 
 
Statistical analysis 
A weighted nonlinear least-squares curve-fitting program LIGAND (Munson and 
Rodbard, 1980) was used for computer analysis of the data from the binding saturation 
experiments, as previously described. EC50 values in the cAMP assay were calculated 
with the non-linear least-squares curve-fitting program Prism (Graph PAD, San Diego, 
CA). Nonparametric tests (Mann Whitney U) were used to compare each class of 
patients and healthy controls. Differences were considered significant at a value of P < 
0.01. All data are reported as mean ± SEM. 
 
RESULTS 
Binding characterization of A2AARs  
Figure 4.1 shows [3H]-ZM 241385 saturation curves in membranes prepared from 
platelets from HD, pre-HD, SCA (1 and 2) and FRDA compared with control subjects.  
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Figures 4.2 and 4.3 show [3H]-ZM 241385 saturation curves in membranes of 
lymphocytes and neutrophils of the same subjects, respectively. In all the blood cells 
studied, A2AAR binding was saturable and indicated the presence of a single receptor 
population characterized by affinity  and density values that are in agreement with those 
previously reported in the literature for these human cell populations (Table 4.2; Varani 
et al., 2003). In particular, as expected, this analysis in control healthy subjects revealed 
a uniform level of A2AARs in the peripheral blood cells. Analysis of the same 
parameters in HD subjects revealed a statistically significant increase in A2AARs 
density (Bmax) in all cell populations when compared to controls (P<0.01 versus 
control, Table 4.1). The increase in Bmax was accompanied by an increase in KD values 
(P<0.01 vs. control, Table 4.2).  
Interestingly, analysis of A2AAR KD and Bmax values in pre-symptomatic HD mutation 
carrier revealed highly increased A2AAR parameters in all three blood cell types when 
compared to controls (Table 4.2). In addition, also in the membranes obtained from the 
patients affected by SCA1 and SCA2, Bmax values for the A2AARs were significantly 
higehr than in control subjects and strictly similar to those obtained from HD patients. 
On the contrary, analysis of the A2AAR parameters in the blood cells of patients affected 
by FRDA revealed KD and Bmax values similar to those obtained from control subjects 
and consequently different from HD and SCA subjects (Table 4.2). 
 
cAMP assays in peripheral blood cells 
In platelet, lymphocytes and neutrophils obtained from HD, pre HD, SCA (1 and 2) and 
FRDA patients, the coupling of A2AARs to adenylyl cyclase stimulation and cAMP 
accumulation has been determined compared with control subjects. Figure 4.4 shows 
typical concentration-response curves of the A2AAR agonist NECA in platelets, 
lymphocytes, and neutrophils obtained from examined controls and patients. A 
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concentration-dependent stimulation of cAMP formation was obtained in the presence 
of NECA in all cell preparations from control subjects, as shown by EC50 values (the 
agonist concentration eliciting the 50% of maximal cAMP formation) in accordance 
with literature data (Table 4.3; Varani et al., 1998). 
Interestingly, NECA EC50 values in the peripheral cells from controls were higher than 
all HD subjects (symptomatic or pre- symptomatic), indicating an increased potency of 
NECA in stimulating cAMP accumulation in HD subjects (Table 4.3). Interestingly, the 
potency of NECA was increased also in the peripheral blood cells of SCA subject when 
compared to controls. On the contrary, in platelets, lymphocytes and neutrophils from 
FRDA subjects, the potency of NECA was strictly similar to that obtaine in control 
healthy subjects. 
 
Effect of pharmacological treatments 
Many of the patients examined in this study were treated with one or more drugs which 
included selective serotoninergic reuptake inhibitors (SSRI), tricyclic compounds, 
neuroleptic, benzodiazepine and antiepileptics for the neurological phenotype and 
antioxidant, anti-hypertensive and other non-specific drugs as anti-inflammatory drugs 
or hormones (Table 4.4). The comparison of the A2AAR binding parameter in 
differently treated patients revealed that the status of A2AAR is not affected by different 
pharmacological treatments. 
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Table 4.1 – Clinical and genetic characteristics of patients and 
healthy controls.  
 
 
 
Characteristic HD  
(n=94) 
Pre-HD  
(n=32) 
SCA 1  
(n=12) 
SCA 2  
(n=27) 
FRDA  
(n=24) 
Controls  
(n=63) 
 
Male/Female  50/44  16/16  5/7  13/14  12/12  29/34  
Age (yrs) 49 (25–76) 36 (22–55) 44 (29–63) 41 (24–66) 30 (18–55) 45 (24–64) 
Disease 
duration (yrs) 5 (1–22) 0 8 (3–15) 7 (0–25) 19 (6–41) -- 
CAG/GAAa 
 repeats  
normal allele 
17 (10-33) 18 (10-21) 29 (22-33) 22 (22-28) 605 (330-930)a -- 
CAG/GAAa 
 repeats                         
expanded 
44 (39-54) 43 (38-52) 48 (38-62) 40 (35-48) 803 (560-1200)a -- 
Modified 
Rankin 2 (0-4) -- 3 (1-5) 1 (1-2) 4 (2-4) -- 
UHDRS 
Motor Score 33 (5-96) 0 (0-4) -- -- -- -- 
TFC 11 (0-13) 13 (12-13) -- -- -- -- 
ICARS 
-- -- 36 (8-84) 27 (2-73) 65 (22-94) -- 
 
Data are expressed as median (min-max) 
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Table 4.2 - Binding parameters of A2AARs in platelets, lymphocytes 
and neutrophils of examined subjects. *, P < 0.01 vs control subjects. 
 
 
 
 
 Platelets Lymphocytes Neutrophils 
 
 
KD 
 
(nM) 
Bmax 
(fmol/mg 
protein) 
 
KD 
 
(nM) 
Bmax 
(fmol/mg 
protein) 
 
KD 
 
(nM) 
Bmax 
(fmol/mg 
protein) 
 
Controls 
(n=63) 
1.15 ± 0.10 
 
62 ± 6 
 
1.10 ± 0.10 
 
65 ± 6 
 
1.40 ± 0.15 
 
89 ± 8 
 
HD 
(n=94) 
2.21 ± 0.20* 
 
173 ± 18* 
 
2.85 ± 0.29* 
 
253 ± 22* 
 
3.10 ± 0.30* 
 
267 ± 25* 
 
Pre-HD 
(n=32) 
2.32 ± 0.24* 
 
178 ± 16* 
 
2.78 ± 0.25* 
 
201 ± 16* 
 
3.04 ± 0.30* 
 
240 ± 20* 
 
SCA 
(n=39) 
2.40 ± 0.22* 
 
187 ± 20* 
 
2.92 ± 0.30* 
 
236 ± 20* 
 
2.98 ± 0.30* 
 
249 ± 23* 
 
FRDA 
(n=24) 
1.05 ± 0.10 
 
66 ± 5 
 
1.20 ± 0.11 
 
62 ± 6 
 
1.20 ± 0.10 
 
82 ± 8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149
Table 4.3 - EC50 values  of NECA on cAMP stimulation in platelets, 
lymphocytes and neutrophils of examined subjects. *, P < 0.01 vs 
control subjects. 
 
 
 
 
 Platelets 
(EC50, nM) 
Lymphocytes 
(EC50, nM) 
Neutrophils 
(EC50, nM) 
 
Controls 
(n=63) 
300 ± 28 
 
205 ± 20 
 
246 ± 22 
 
HD 
(n=94) 
80 ± 8* 
 
60 ± 6* 
 
70 ± 7* 
 
Pre-HD 
(n=32) 
84 ± 7* 
 
65 ± 6* 
 
78 ± 8* 
 
SCA 
(n=39) 
76 ± 7* 
 
55 ± 6* 
 
68 ± 7* 
 
FRDA 
(n=24) 
320 ± 30 
 
210 ± 0.22 
 
230 ± 25 
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Table 4.4 - Pharmacological therapies of patients involved in the 
study. 
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HD (94) 11 29 25 29 34 4 3 3 17 27 
Pre-HD (32) 25 1   1     5 
SCA (39) 17 7 1 4 5 4 8 2 2 16 
FRDA (24) 2 3   5 1 16 1 4 4 
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Figure 4.1 - Saturation curves (A) and Scatchard Plot (B) of  [3H]-
ZM241385 in platelets from the examined subjects.  
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Figure 4.2 – Saturation curves (A) and Scatchard Plot (B) of  [3H] - 
ZM241385 in lymphocytes from the examined subjects. 
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Figure 4.3 - Saturation curves (A) and Scatchard Plot (B) of  [3H] - 
ZM241385 in neutrophils from the examined subjects. 
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Figure 4.4 – Dose response curves of NECA in plateles (A), 
lymphocytes (B) and neutrophils (C) from the examined subjects. 
 
 
-10 -9 -8 -7 -6 -5
0
25
50
75
100
Control
HD
pre-HD
SCA
FRDA
A
    Platelets
log NECA (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
 
-10 -9 -8 -7 -6 -5
0
25
50
75
100
Control
HD
pre-HD
SCA
FRDA
B
   Lymphocytes
log NECA (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
 
-10 -9 -8 -7 -6 -5
0
25
50
75
100
Control
HD
pre-HD
SCA
FRDA
C
   Neutrophils
log NECA (M)
%
 
cA
M
P 
ac
cu
m
u
la
tio
n
 
 155
DISCUSSION 
In neurology, the search for objectively measurable tests of disease progression is 
playing an increasing role. In Huntington’s disease, the evidence that the mutant protein 
is widely distributed and present in peripheral cells has fueled a large number of 
attempts aimed at identifying disease-specific changes in biological processes that could 
be detected in easily accessible cells. The hope is that these could then be included in 
therapeutic trials as molecular markers of the action of the mutant protein and, as a 
consequence exploited to evaluate the effectiveness of novel potential therapeutic 
agents. In addition, a change in a peripheral parameter that is embedded into a 
pathophysiological mechanism may be indicative of a pathway of clinical and biological 
relevance and possibly represent itself a target of therapeutic interest. 
So far, there are limited reports of peripheral changes in human HD samples and far less 
that correlate with disease status. The most promising results likely derive from a non-
hypothesis-driven study of global changes in gene expression in blood samples from 17 
HD subjects (late pre-symptomatic and symptomatic) and 14 gender-matched controls 
(Borovecki et al., 2005). Among the critical outcomes of this study is the evidence that 
a set of 12 genes distinguishes normal controls from HD subjects and that early pre-
symptomatic HD subjects disclose an expression pattern similar to controls, whereas the 
late pre-symptomatic subjects had patterns similar to symptomatic HD patients 
(Borovecki et al., 2005). These findings suggested that a subset of mRNAs isolated 
from whole blood could help in monitoring clinical onset of this neurodegenerative 
disease. 
We have previously assessed that an alteration in A2AAR binding activity is present in 
peripheral blood cells from HD patients and a small number of pre-HD, but that study 
was not addressing the issue of whether the detected A2AAR alteration is specific to HD, 
and possibly correlates to disease stage and/or to other HD clinical and genetic 
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parameters. The results obtained in this new study show three new findings: (i) all HD 
patients who tested positively for the polyQ expansion also presented an altered Bmax 
value with respect to control subjects with no significant differences in Bmax across 
patients with different disease stages; (ii) the 32 HD-positive pre-manifesting subjects 
did not differ from symptomatic HD patients with respect to Bmax values; (iii) patients 
with other polyQ diseases as SCA1 and SCA2 showed the very same change in A2AAR 
Bmax values as HD patients and differed from controls and patients with other 
neurodegenerative disorders such as Friedreich’s ataxia. 
The fact that the Bmax values are similarly altered in HD patients at different stages and 
in pre-HD subjects indicates that this change is directly related to the immediate cellular 
effects of the mutation and not to the pathological state of the patients or disease 
progression. The presence of the very same change in the A2AAR in SCA1 and SCA2 
patients reinforces the assumption that our findings substantially represent a cellular 
toxic effect of the polyQ proteins.  
Similar A2AAR alteration was found evaluating the functionality of the receptor through 
cAMP accumulation assay. Indeed, increased potency of NECA was found in peripheral 
blood cells of HD, pre-HD and SCA subject, but not in FRDA subjects, when compared 
to control healthy subjects 
We can conclude that the observed alteration of A2AAR in platelets, lymphocytes and 
neutrophils links with the presence of the poliglutamine proteins and may be of 
potential interest in the search of novel drugs aimed to counteract the toxic effect of the 
mutation. 
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GENERAL CONCLUSIONS 
 
Huntington's disease (HD) is a devastating autosomal dominant neurodegenerative 
disease caused by a CAG trinucleotide repeat expansion encoding an abnormally long 
polyglutamine tract in the huntingtin protein. Expression of mutant huntingtin leads to 
the selective death of the medium spiny neurons in the neostriatum, resulting in the 
appearance of generalized involuntary movements, the main phenotypic alteration of 
HD. A2AARs are largely expressed in these neurons and modulate different processes in 
the cental nervous system, suggesting a possible involvement of these receptors in 
Huntington’s disease. 
In the first part of this study we have investigated the presence and functionality of 
A2AARs in striatal cells expressing different form of mutant huntingtin. We found an 
aberrant amplification of A2AARs-stimulated adenylyl cyclase specifically associated 
with the expression of mutant huntingtin. Despite no changes of Bmax values, binding 
studies revealed a moderate but statistically significant increase of ligand binding 
affinity in cells expressing mutant huntingtin, which suggests that mutant, but not wild-
type huntingtin, may interfere with the kinetics of A2AAR binding by endogenous 
adenosine and may influence the conformation of the ligand recognition site. From our 
data it is also clear that changes of A2AAR signaling are much more evident in cells 
expressing truncated than full-length mutant huntingtin. This finding may have 
intriguing functional implications, because the N548 fragment expressed in these cells 
mimics one of the potential fragments suggested to be produced by proteolytic cleavage 
of huntingtin and which may be required for the expression of mutant huntingtin 
cytotoxicity and aggregate formation. 
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In the second part of the study we investigated if the aberrant phenotype of A2AAR was 
also present in R6/2 mice. These animals express exon 1 of the human Huntingtin gene 
with an expanded CAG repeat length of 141–157 under the influence of the human 
promoter. The R6/2 model has many of the temporal, behavioral and neuropathological 
features observed in HD patients, such as jerky movements and striatal atrophy. 
Analysis of striatal A2AAR binding and adenylyl cyclase activity in R6/2 mice of 
different developmental ages in comparison with age-matched wild-type animals 
showed a transient increase in A2AAR density (Bmax) and A2AAR -dependent cAMP 
production at early presymptomatic ages (7–14 postnatal days, PND) that is, well before 
the onset of motor symptoms. Despite the increased receptor density observed in 
radioligand binding studies in R6/2 versus wild-type mice (PND 9–14), we did not find 
any significant change of A2AAR mRNA by employing real time PCR. This suggests 
that, at this developmental age, receptor turnover rather than receptor synthesis may be 
altered in these animals.  
In the subsequent  study we have shown, for the first time, that peripheral blood cells 
from HD subjects exhibit an aberrant increase in A2AAR number, as demonstrated by 
Bmax values significantly higher than age-matched healthy controls. In platelets, 
lymphocytes and neutrophils of HD patients, the increase of Bmax was associated with 
an over-stimulation of A2AAR-mediated cAMP production. The aberrant A2AAR 
phenotype was also found in the circulating cells of pre-symptomatic individuals 
carrying the CAG mutation. This opened the possibility that A2AAR may represent a 
novel potential biomarker of HD, useful for monitoring disease progression and 
assessing the efficacy of novel neuroprotective approaches. 
The last part of the study was performed in a larger number of  HD patients at different 
stages of the disease, in pre-symptomatic carrier of the mutation, in patients affected by 
other polyglutamine disease such as Spinocerebellar Ataxia 1 (SCA1), Spinocerebellar 
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Ataxia 2 (SCA2) and in patients affected by a non-polyglutamine disease, i.e. Friedreich 
ataxia. 
We found that all HD patients who tested positively for the polyglutamine expansion 
also presented an altered Bmax value when compared to control subjects with no 
significant differences in Bmax across patients with different disease stages. 
Furthermore, A2AAR density of pre-symptomatic carrier of the mutation did not differ 
from symptomatic HD patients. In addition, patients with other polyglutamine diseases 
such as SCA1 and SCA2 showed a strictly similar change in A2AAR Bmax values as 
HD patients and differed from controls and patients with other neurodegenerative 
disorders such as Friedreich’s ataxia. 
Overall these data demonstrate that an aberrant A2AAR phenotype is present in 
Huntington’s disease and this seems to be related with the presence of the expanded 
GCA triplet. The amplification of the signal transduction system of A2AARs suggests 
that the use of selective A2AAR antagonists could be beneficial in the treatment of 
Huntington’s disease as well as in other related polyglutamine diseases. In addition, the 
alteration of A2AARs in peripheral blood cells of patient with polyglutamine diseases 
suggests that this receptor could be an easily accessible biomarker for the evaluation of 
the efficacy of potential new therapies. 
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